

## **16.2.5 Compliance and/or Drug Concentration Data**

**Listing 16.2.5-1 Product Dispensation by Subject**

(Page 1 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R1001	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	4
R1002	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R1003	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4

Listing 16.2.5-1 Product Dispensation by Subject

(Page 2 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R1004	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	3
	Week 10	0.5 g of snus or placebo logs dispensed	6
		1.0 g of snus or placebo logs dispensed	0
R1005	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	2
R1006	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4

Listing 16.2.5-1 Product Dispensation by Subject

(Page 3 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R1006	Week 6	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R1007	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
R1008	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 4 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R1009	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R1010	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	4
R1011	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 5 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R1011	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R1012	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	3
	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	5
R1013	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 6 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R1014	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
R1015	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R1016	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2

Listing 16.2.5-1 Product Dispensation by Subject

(Page 7 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R1017	Week 0	0.5 g of snus or placebo logs dispensed	08
		1.0 g of snus or placebo logs dispensed	04
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R1018	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	06
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R1019	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	3

Listing 16.2.5-1 Product Dispensation by Subject

(Page 8 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R1019	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	3
R1020	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R1021	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	3

Listing 16.2.5-1 Product Dispensation by Subject

(Page 9 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R1022	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	1
	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	3
R1023	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
R1024	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	1

Listing 16.2.5-1 Product Dispensation by Subject

(Page 10 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R1025	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R1026	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R1027	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	3

Listing 16.2.5-1 Product Dispensation by Subject

(Page 11 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R1028	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	3
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	1
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	1
R1029	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	3
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R1030	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 12 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R1030	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R1031	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R1032	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R1033	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2

Listing 16.2.5-1 Product Dispensation by Subject

(Page 13 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R1034	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R1035	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R1036	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3

Listing 16.2.5-1 Product Dispensation by Subject

(Page 14 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R1036	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	1
	Week 10	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
R1037	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R2001	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
R2002	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 15 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R2002	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R2003	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R2004	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
R2005	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	1

Listing 16.2.5-1 Product Dispensation by Subject

(Page 16 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R2005	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R2006	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R2007	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 17 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R2008	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	1
R2009	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R2010	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 18 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R2010	Week 10	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	0
R2011	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R2012	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 19 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R2013	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	25
		1.0 g of snus or placebo logs dispensed	4.6
R2014	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R2015	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4

Listing 16.2.5-1 Product Dispensation by Subject

(Page 20 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R2015	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
R2016	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	3
R2017	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 21 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R2017	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R2018	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R2019	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	3
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	4
R2020	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4

Listing 16.2.5-1 Product Dispensation by Subject

(Page 22 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R2020	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R2021	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R2022	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	4
	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
R2022	Week 6	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
R2023	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4

Listing 16.2.5-1 Product Dispensation by Subject

(Page 23 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R2023	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R2024	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R2025	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2

Listing 16.2.5-1 Product Dispensation by Subject

(Page 24 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R2025	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	3
R2026	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R2027	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 25 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R2028	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	3
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	5
R2029	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	11
		1.0 g of snus or placebo logs dispensed	2.3
R2030	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4

Listing 16.2.5-1 Product Dispensation by Subject

(Page 26 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R2031	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	1
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	1
R2032	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R3001	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4

Listing 16.2.5-1 Product Dispensation by Subject

(Page 27 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R3001	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	0
R3002	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	1
R3003	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 28 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R3004	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	5
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	6
R3005	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
R3006	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4

Listing 16.2.5-1 Product Dispensation by Subject

(Page 29 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R3006	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	1
	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	1
R3007	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	4
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R3008	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 30 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R3008	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R3009	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	0
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	0
R3010	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R3011	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4

Listing 16.2.5-1 Product Dispensation by Subject

(Page 31 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R3011	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	1
	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R3012	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
R3013	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R3014	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6

Listing 16.2.5-1 Product Dispensation by Subject

(Page 32 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R3014	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	0
R3015	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
R3016	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	2
R3017	Week 0	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	2
R3018	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4

Listing 16.2.5-1 Product Dispensation by Subject

(Page 33 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R3018	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	0
R3019	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R3020	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	3
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	1
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	2

Listing 16.2.5-1 Product Dispensation by Subject

(Page 34 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R3021	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
R3022	Week 0	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	1
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	2
R3023	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
R3024	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
R3025	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2

Listing 16.2.5-1 Product Dispensation by Subject

(Page 35 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R3026	Week 0	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	3
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	3
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	4
R3027	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
R3028	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2

Listing 16.2.5-1 Product Dispensation by Subject

(Page 36 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R3028	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	3
R3029	Week 0	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	1
R3030	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
R3031	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
R3032	Week 0	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	2

Listing 16.2.5-1 Product Dispensation by Subject

(Page 37 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4001	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	4
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	4
R4002	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R4003	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6

Listing 16.2.5-1 Product Dispensation by Subject

(Page 38 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4003	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R4004	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
R4005	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R4006	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4

Listing 16.2.5-1 Product Dispensation by Subject

(Page 39 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4007	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
R4008	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	3
	Week 10	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
R4009	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4

Listing 16.2.5-1 Product Dispensation by Subject

(Page 40 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4009	Week 6	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	0
R4010	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R4011	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	3

Listing 16.2.5-1 Product Dispensation by Subject

(Page 41 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4011	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	1
R4012	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R4013	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
R4014	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	4

Listing 16.2.5-1 Product Dispensation by Subject

(Page 42 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4014	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	4
R4015	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	4
Week 10	0.5 g of snus or placebo logs dispensed	5	
	1.0 g of snus or placebo logs dispensed	0	
R4016	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
Week 10	0.5 g of snus or placebo logs dispensed	0	
	1.0 g of snus or placebo logs dispensed	2	

Listing 16.2.5-1 Product Dispensation by Subject

(Page 43 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4017	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R4018	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	1
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R4019	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6

Listing 16.2.5-1 Product Dispensation by Subject

(Page 44 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4019	Week 6	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R4020	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	0
R4021	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 45 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4021	Week 10	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	0
R4022	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R4023	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 46 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4024	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
R4025	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
R4026	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
R4027	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 47 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4027	Week 10	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	0
R4028	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	1
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	1
R4029	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 48 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4030	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	0
R4031	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
R4032	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R4033	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6

Listing 16.2.5-1 Product Dispensation by Subject

(Page 49 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4033	Week 10	0.5 g of snus or placebo logs dispensed	6
		1.0 g of snus or placebo logs dispensed	0
R4034	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
R4035	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R4036	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	1
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2

Listing 16.2.5-1 Product Dispensation by Subject

(Page 50 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4037	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R4038	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	3
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R4039	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6

Listing 16.2.5-1 Product Dispensation by Subject

(Page 51 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4039	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R4040	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R4041	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	1

Listing 16.2.5-1 Product Dispensation by Subject

(Page 52 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4041	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R4042	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	3
R4042	Week 10	1.0 g of snus or placebo logs dispensed	0
		0.5 g of snus or placebo logs dispensed	5
	Week 0	0.5 g of snus or placebo logs dispensed	8
R4043	Week 0	1.0 g of snus or placebo logs dispensed	4
		0.5 g of snus or placebo logs dispensed	8
R4044	Week 0	1.0 g of snus or placebo logs dispensed	4
		0.5 g of snus or placebo logs dispensed	8
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	3

Listing 16.2.5-1 Product Dispensation by Subject

(Page 53 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4045	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R4046	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R4047	Week 0	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	5
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2

Listing 16.2.5-1 Product Dispensation by Subject

(Page 54 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4047	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	3
R4048	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R4049	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R4050	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3

Listing 16.2.5-1 Product Dispensation by Subject

(Page 55 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4050	Week 6	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	0
R4051	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	0
R4052	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2

Listing 16.2.5-1 Product Dispensation by Subject

(Page 56 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4052	Week 10	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
R4053	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
R4054	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	4
R4055	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	1
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 57 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4056	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	0
R4057	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
R4058	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	3

Listing 16.2.5-1 Product Dispensation by Subject

(Page 58 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4058	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	4
R4059	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
R4059	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	0
R4060	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3
R4060	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R4061	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3
R4062	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2

Listing 16.2.5-1 Product Dispensation by Subject

(Page 59 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4062	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	3
R4063	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R4064	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 60 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4065	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R4066	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
R4067	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3
R4068	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	5

Listing 16.2.5-1 Product Dispensation by Subject

(Page 61 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4068	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	4
R4069	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	0
R4070	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	5
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	4
R4071	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3

Listing 16.2.5-1 Product Dispensation by Subject

(Page 62 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4071	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R4072	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
R4073	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3
R4074	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2

Listing 16.2.5-1 Product Dispensation by Subject

(Page 63 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4075	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	4
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R4076	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3
R4077	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R4078	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3

Listing 16.2.5-1 Product Dispensation by Subject

(Page 64 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4078	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	7
R4079	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	1
R4080	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	1
	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
R4081	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
R4082	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3

Listing 16.2.5-1 Product Dispensation by Subject

(Page 65 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4083	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	3
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	4
R4084	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	3
R4085	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
R4086	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2

Listing 16.2.5-1 Product Dispensation by Subject

(Page 66 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4086	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R4087	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3
R4088	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R4089	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	1
R4090	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2

Listing 16.2.5-1 Product Dispensation by Subject

(Page 67 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4090	Week 6	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	0
R4091	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R4092	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 68 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4092	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R4093	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R4094	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	1

Listing 16.2.5-1 Product Dispensation by Subject

(Page 69 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4095	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3
R4096	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	1
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	1
R4097	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 70 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4098	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
R4099	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R4100	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 71 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4101	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
R4102	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
R4103	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R4104	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
R4105	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 72 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4105	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R4106	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R4107	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 73 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4108	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
R4109	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
R4110	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
R4111	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
R4112	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
R4113	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	1

Listing 16.2.5-1 Product Dispensation by Subject

(Page 74 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4113	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R4114	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R4115	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R4116	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2

Listing 16.2.5-1 Product Dispensation by Subject

(Page 75 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4116	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	1
R4117	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R4118	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 76 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4118	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R4119	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3
	Week 6	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0
R4120	Week 0	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	2
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 77 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R4121	Week 0	0.5 g of snus or placebo logs dispensed	5
		1.0 g of snus or placebo logs dispensed	3
R5001	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	1
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R5002	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 78 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R5003	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
R5004	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	20
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
R5005	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4

Listing 16.2.5-1 Product Dispensation by Subject

(Page 79 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R5005	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R5006	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed 1.0 g of snus or placebo logs dispensed	0 2
R5007	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 10	0.5 g of snus or placebo logs dispensed 1.0 g of snus or placebo logs dispensed	0 6
R5008	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	2

Listing 16.2.5-1 Product Dispensation by Subject

(Page 80 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R5008	Week 10	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
R5009	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
R5010	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
R5011	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	2
	Week 10	1.0 g of snus or placebo logs dispensed	0
R5012	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6

Listing 16.2.5-1 Product Dispensation by Subject

(Page 81 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R5013	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	1
		1.0 g of snus or placebo logs dispensed	0
R5014	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	1
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	3
R5015	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4

Listing 16.2.5-1 Product Dispensation by Subject

(Page 82 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R5015	Week 6	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	6
		1.0 g of snus or placebo logs dispensed	0
R5016	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
R5017	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
R5018	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2

Listing 16.2.5-1 Product Dispensation by Subject

(Page 83 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R5019	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	5
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	0
R5020	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	2
R5021	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4

Listing 16.2.5-1 Product Dispensation by Subject

(Page 84 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R5021	Week 6	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	1
	Week 10	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
R5022	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed	3
		1.0 g of snus or placebo logs dispensed	0
	Week 10	0.5 g of snus or placebo logs dispensed	4
		1.0 g of snus or placebo logs dispensed	0
R5023	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 85 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R5024	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
R5025	Week 0	0.5 g of snus or placebo logs dispensed	10
		1.0 g of snus or placebo logs dispensed	6
	Week 6	0.5 g of snus or placebo logs dispensed 1.0 g of snus or placebo logs dispensed	3 0
R5026	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 6	0.5 g of snus or placebo logs dispensed 1.0 g of snus or placebo logs dispensed	0 0
R5027	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
R5027	Week 6	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	0

Listing 16.2.5-1 Product Dispensation by Subject

(Page 86 of 86)

Study Population: ITT

Subject Number	Timepoint	Study product	Amount Dispensed (logs)
R5027	Week 10	0.5 g of snus or placebo logs dispensed	0
		1.0 g of snus or placebo logs dispensed	0
R5028	Week 0	0.5 g of snus or placebo logs dispensed	8
		1.0 g of snus or placebo logs dispensed	4
	Week 10	0.5 g of snus or placebo logs dispensed	2
		1.0 g of snus or placebo logs dispensed	2

**Listing 16.2.5-2 Previous and Concomitant Medications by Subject**

(Page 1 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1001	"SYNTHROID" LEVOTHYROXINE SODIUM	HYPOTHYROIDISM	11.2	ug	QD	1999	ONGOING
R1002	"CALCIUM" CALCIUM	SUPPLEMENT	1000	mg	QD	1991-01	ONGOING
	"MULTI VITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	1991-01	ONGOING
	"LORATADINE" LORATADINE	ALLERGIES	10	mg	PRN	2002-01	ONGOING
	"TRIAM/HYDROCHLOROTHIAZIDE" DIAZIDE	HYPERTENSION	1	tablet	QD	2007-01	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 2 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1002	"FLAXSEED" LINUM USITATISSIMUM SEED OIL	SUPPLEMENT	1000	mg	TID	2008-01	ONGOING
	"ADVIL" IBUPROFEN	ACHES/PAINS	400	mg	PRN	2009-01	ONGOING
R1003	"ATENOLOL" ATENOLOL	HYPERTENSION	25	mg	QD	1994	ONGOING
	"TRIAM/HCTZ" DYAZIDE	HYPERTENSION	1	tablet	QD	1994	ONGOING
	"FOLIC ACID" FOLIC ACID	SUPPLEMENT	1	mg	QD	2004	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 3 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1003	"LISINOPRIL" LISINOPRIL	HYPERTENSION	10	mg	QD	2004	ONGOING
	"CLARITIN" LORATADINE	SEASONAL ALLERGIES	10	mg	PRN	2006	ONGOING
	"VITAMIN D" VITAMIN D AND ANALOGUES	SUPPLEMENT	1000	other, specify: i.u.	QD	2006	ONGOING
	"ASPIRIN" ACETYLSALICYLIC ACID	PROPHYLAXIS	81	mg	QD	2007	ONGOING
	"NAPROXEN" NAPROXEN	BACK PAIN	200	mg	PRN	2008	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 4 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1003	"BIOTIN" BIOTIN	SUPPLEMENT	1000	ug	QD	2008-12	ONGOING
R1004	"MULTIVITAMINS" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	1999	ONGOING
	"GLUCOSAMINE" GLUCOSAMINE	SUPPLEMENT	1	tablet	QD	2008-08	ONGOING
	"OMEGA-3 FISH OIL" FISH OIL	SUPPLEMENT	1000	mg	QD	2008-08	ONGOING
R1005	"ALLEGRA D" GALENIC /FEXOFENADINE HCL/PSEUDOEPHEDRINE/	SEASONAL ALLERGIES	30	mg	PRN	2000	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 5 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1005	"THERAGRAN M" THERAGRAN /00554301/	SUPPLEMENT	1	tablet	QD	2000	ONGOING
	"CRESTOR" ROSUVASTATIN CALCIUM	HYPERCHOLESTER OLEMIA	10	mg	QD	2008	ONGOING
	"PEPTO-BISMOL" BISMUTH SUBSALICYLATE	DIARRHEA	30	milliliters	TID	2009-05-18	2009-05-18
	"ANTI DIARRHEAL" ANTIDIARR., INTEST.ANTIINFL./ ANTIINFECT.AGEN.	DIARRHEA	2	mg	BID	2009-05-19	2009-05-19
R1006	"NONE"						

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 6 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1007	"NAPROXEN" NAPROXEN	BACK PAIN	880	mg	Once	2009-04-08	2009-04-08
R1008	"FLUOXETINE" FLUOXETINE	DEPRESSION	20	mg	QD	1999	ONGOING
	"ADVAIR" SERETIDE /01420901/	ASTHMA	1	other, specify: puff	BID	2004	ONGOING
	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	2006	ONGOING
	"ASPIRIN" ACETYLSALICYLIC ACID	PROPHYLACTIC	81	mg	QD	2007	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 7 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1008	"TRAZODONE" TRAZODONE	INSOMNIA	75	mg	QD	2007	ONGOING
	"PRILOSEC" OMEPRAZOLE MAGNESIUM	HEARTBURN	20	mg	QD	2008	ONGOING
	"FISH OIL" FISH OIL	SUPPLEMENT	1200	mg	QD	2008-01	ONGOING
	"ENALAPRIL" ENALAPRIL	HYPERTENSION	5	mg	QD	2008-12-04	ONGOING
	"HALLS COUGH DROPS" HALL'S MENTHO-LYPTUS	SORE THROAT	1	other, specify: coughdrop	QD	2009-03-25	2009-03-27

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 8 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1008	"SALT WATER GARGLE" SODIUM CHLORIDE	SORE THROAT	NA	other, specify: mouth wash	QD	2009-03-25	2009-03-27
	"CELEBREX" CELECOXIB	SHOULDER PAIN	200	mg	BID	2009-04-16	2009-04-21
	"MEDROL" METHYLPREDNISOLONE	SHOULDER PAIN	1	other, specify: dose pack	QD	2009-04-16	2009-04-21
R1009	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	2005	ONGOING
	"CO-Q 10" UBIDECARENONE	SUPPLEMENT	300	mg	QD	2008-09	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 9 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1009	"OMEGA 3,6,9" PELAGO	SUPPLEMENT	1200	mg	QD	2008-09	ONGOING
	"AMLODIPINE BESYLATE" AMLODIPINE BESILATE	HYPERTENSION	5	mg	QD	2009-01	ONGOING
	"ALEVE" NAPROXEN SODIUM	ROOT CANAL	220	mg	BID	2009-03-05	2009-03-11
	"NOVOCAINE" PROCAINE HYDROCHLORIDE	ROOT CANAL	UNK	other, specify: unk	Once	2009-03-05	2009-03-05
	"PENICILLIN VK" PHENOXYMETHYLPENICILLIN POTASSIUM	ROOT CANAL TOOTH #19	500	mg	QID	2009-03-05	2009-03-11

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 10 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1009	"AZITHROMYCIN" AZITHROMYCIN	OTITIS EXTERNA	500	mg	Once	2009-05-21	2009-05-21
	"NEO/POLY/HC" NEOMYCIN SULFATE W/ POLYMYCIN B/HYDROCORTISO.	OTITIS EXTERNA	10	milliliters	QID	2009-05-21	2009-05-30
	"AZITHROMYCIN" AZITHROMYCIN	OTITIS EXTERNA	250	mg	QD	2009-05-22	2009-05-25
R1010	"NONE"						
R1011	"ASPIRIN" ACETYLSALICYLIC ACID	HEADACHE	325	mg	PRN	1964	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 11 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1011	"DIOVAN" VALSARTAN	HYPERTENSION	80	mg	QD	2006	2009-10-15
	"RANITIDINE" RANITIDINE	ACID REFLUX	150	mg	PRN	2006	ONGOING
	"VITAMIN E" TOCOPHEROL	SUPPLEMENT	1	tablet	QD	2009-07-15	ONGOING
	"BENZAEPRIIL" BENZAEPRIIL	HYPERTENSION	10	mg	QD	2009-10-16	ONGOING
R1012	"IBUPROFEN" IBUPROFEN	ACHES	200	mg	PRN	2004	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 12 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1012	"CALCIUM D" CALCIUM D3 /01483701/	SUPPLEMENT	1	tablet	OTHER, SPECIFY, TWO PER WEEK	2007	ONGOING
	"B12" CYANOCOBALAMIN-TANNIN COMPLEX	SUPPLEMENT	500	ug	OTHER, SPECIFY, 2 PER WEEK	2008	ONGOING
	"MULTIVITAMINS" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	2008	ONGOING
	"IBUPROFEN" IBUPROFEN	HEADACHE	200	mg	Once	2009-03-29	2009-03-29
R1013	"AZITHROMYCIN" AZITHROMYCIN	SINUSITIS	500	mg	Once	2009-06-15	2009-06-15

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 13 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1013	"AZITHROMYCIN" AZITHROMYCIN	SINUSITIS	250	mg	QD	2009-06-16	2009-06-20
	"PRIMATENE MIST" EPINEPHRINE	CHEST CONGESTION	2	other, specify: puffs	TID	2009-11-03	2009-11-09
R1014	"LORTAB" VICODIN	LOWER BACK PAIN	7.5	mg	PRN	2008-01	ONGOING
R1015	"TORADOL" KETOROLAC TROMETHAMINE	HEADACHE	1	other, specify: injection	Once	2009-05-18	2009-05-18
R1016	"NONE"						

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 14 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1017	"NONE"						
R1018	"NONE"						
R1019	"IBUPROFEN" IBUPROFEN	BACK PAIN	750	mg	Once	2009-09-17	2009-09-17
	"COPENHAGEN SNUFF" NICOTINE	SMOKING CESSATION	UNK	other, specify: unk	PRN	2009-09-23	2009-10-27
	"LEVI GARRETT CHEWING TOBACCO" NICOTINE	SMOKING CESSATION	UNK	other, specify: unk	PRN	2009-10-28	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 15 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1019	"IBUPROFEN" IBUPROFEN	SINUS HEADACHE	750	mg	Once	2009-11-29	2009-11-29
R1020	"IBUPROFEN" IBUPROFEN	KNEE/BACK PAIN	1000	mg	PRN	2002	ONGOING
	"MULTIVITAMINS" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	2007	ONGOING
	"VITAMIN C" ASCORBIC ACID	SUPPLEMENT	1	tablet	QD	2008	2009-05-23
	"GOODYS" THOMAPYRIN N	KNEE/BACK PAIN	2	other, specify: packets	PRN	2009-02	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 16 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1020	"JOINT MD" JOINT /03092101/	SUPPLEMENT	2	tablet	BID	2009-04-20	2009-06-02
	"TORADOL" KETOROLAC TROMETHAMINE	BACK STRAIN	1	other, specify: injection	Once	2009-08-12	2009-08-12
	"FLEXERIL" CYCLOBENZAPRINE HYDROCHLORIDE	BACK STRAIN	15	mg	TID	2009-08-13	2009-08-17
	"MOBIC" MELOXICAM	BACK STRAIN	15	mg	QD	2009-08-13	2009-08-17
	"BENADRYL" DIPHENHYDRAMINE HYDROCHLORIDE	CHEST/NASAL CONGESTION	25	mg	PRN	2009-09-01	2009-09-06

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 17 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1020	"TYLENOL COLD" COTYLENOL	CHEST/NASAL CONGESTION	200	mg	PRN	2009-09-01	2009-09-06
R1021	"EXTRA STRENGTH TYLENOL" PARACETAMOL	BACK PAIN	500	mg	PRN	2007-12	ONGOING
	"DIET PILL, OTC WATER PILL" DIURETICS	WEIGHT LOSS	1	tablet	BID	2009-05-22	2009-05-28
	"ASPIRIN" ACETYLSALICYLIC ACID	HEADACHE	325	mg	PRN	2009-07-24	2009-08-05
	"NYQUIL" MEDINITE /00448801/	HEADCOLD	2	other, specify: teaspoons	QHS	2009-09-14	2009-09-21

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 18 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1021	"TYLENOL COLD" COTYLENOL	HEADCOLD	1	tablet	Q4H	2009-09-14	2009-09-21
R1022	"IBUPROFEN" IBUPROFEN	MENSTRUAL CRAMPS	500	mg	PRN	1999	ONGOING
	"TYLENOL" PARACETAMOL	MENSTRUAL CRAMPS	500	mg	PRN	1999	ONGOING
	"ALLI" ORLISTAT	SUPPLEMENT	1	other, specify: cap	Once	2009-05-28	2009-05-28
R1023	"VITAMIN C" ASCORBIC ACID	SUPPLEMENT	1000	mg	QD	1985	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 19 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1023	"B 100 COMPLEX" B COMPLEX /02945401/	SUPPLEMENT	1	tablet	QD	1997	ONGOING
	"L-LYSINE" LYSINE HYDROCHLORIDE	SUPPLEMENT	1000	mg	QD	1997	ONGOING
	"VITAMIN E" TOCOPHEROL	SUPPLEMENT	400	other, specify: iu	QD	1997	ONGOING
R1024	"KETOCONAZOLE CREAM" KETOCONAZOLE	TINEO CORPORA	2%	other, specify: cream	QD	2009-07-20	2009-08-02
	"MICONAZOLE NITRATE" MICONAZOLE NITRATE	YEAST INFECTION	2%	other, specify: cream	QD	2009-07-20	2009-07-28

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 20 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1024	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	2009-08-23	2009-10-17
	"DOXYCYCLINE HYCLATE DOSE PACK" DOXYCYCLINE HYCLATE	BRONCHITIS	200	mg	BID	2009-09-18	2009-10-05
	"MEDROL" METHYLPREDNISOLONE	BRONCHITIS	4	mg	QD	2009-09-18	2009-09-23
	"PROVENTIL" SALBUTAMOL SULFATE	BRONCHITIS	UNK	other, specify: inhaler	PRN	2009-09-18	2009-10-17
	"AZITHROMYCIN" AZITHROMYCIN	BRONCHITIS	500	mg	QD	2009-10-08	2009-10-12

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 21 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1024	"PREDNISONONE" PREDNISONONE	BRONCHITIS	20	mg	OTHER, SPECIFY, UNK	2009-10-08	2009-10-17
R1025	"FEMARA" LETROZOLE	PROPHYLACTIC FOR BREAST CANCER	2.5	mg	QD	2006-11	ONGOING
	"BONIVA" IBANDRONATE SODIUM	OSTEOPENIA	1	other, specify: IV bolus injection	OTHER, SPECIFY, EVERY 3 MONTHS	2009-01	ONGOING
R1026	"EQUATE NICOTINE GUM" NICOTINE	SMOKING CESSATION	2	mg	PRN	2009-12-18	ONGOING
R1027	"ENALAPRIL" ENALAPRIL	HYPERTENSION	5	mg	QD	2007	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 22 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1027	"COLD SINUS ADVIL" CO-ADVIL	UPPER RESPIRATORY INFECTION	1	other, specify: capsule	QID	2009-07-19	2009-07-26
R1028	"NATURES CODE MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	2009-06-04	ONGOING
R1029	"DORYX" DOXYCYCLINE HYDROCHLORIDE	HIDRADENITIS SUPPURATIVA	100	mg	QD	2009-07-24	2009-07-28
R1030	"LISINOPRIL" LISINOPRIL	HYPERTENSION	20	mg	QD	2000	ONGOING
	"LOVASTATIN" LOVASTATIN	HIGH CHOLESTEROL	20	mg	QD	2004	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 23 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1030	"CENTRUM" CENTRUM /00554501/	SUPPLEMENT	1	tablet	QD	2009-07-12	ONGOING
	"TUMS" CALCIUM CARBONATE	NAUSEA	5	tablet	QD	2009-08-16	2009-08-18
	"LORTAB" VICODIN	TOOTH EXTRACTION	10	mg	PRN	2010-01-07	2010-01-09
	"NOVOCAINE" PROCAINE HYDROCHLORIDE	TOOTH EXTRACTION	UNK	other, specify: injection	Once	2010-01-07	2010-01-07
	"PENICILLIN VK" PHENOXYMETHYLPENICILLIN POTASSIUM	TOOTH EXTRACTION	500	mg	QD	2010-01-07	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 24 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1030	"CHANTIX" VARENICLINE TARTRATE	SMOKING CESSATION	0.5	mg	BID	2010-01-12	ONGOING
R1031	"MULTI-VITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	1970	ONGOING
	"METABOLIC ENHANCER" ALL OTHER NON-THERAPEUTIC PRODUCTS	SUPPLEMENT	1	tablet	TID	2006	ONGOING
	"MRC-6" ALL OTHER NON-THERAPEUTIC PRODUCTS	SUPPLEMENT	1	tablet	TID	2006	ONGOING
	"MSM 500" METHYLSULFONYLMETHANE	SUPPLEMENT	500	mg	TID	2006	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 25 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1031	"TYLENOL PM" TYLENOL PM /01088101/	HIP PAIN	500	mg	QOD	2009-10-21	ONGOING
	"DICLOFENAC" DICLOFENAC	RIGHT LEG PAIN	75	mg	PRN	2009-12-04	ONGOING
	"VITAMIN D" VITAMIN D AND ANALOGUES	VITAMIN D DEFICENCY	5000	other, specify: units	QS	2009-12-06	2010-01-24
	"DAYQUIL" VICKS FORMULA 44M	SINUSITIS	2	tablet	OTHER, SPECIFY, EVERY FOUR HOURS AS NEEDED	2009-12-26	2010-01-01
	"NYQUIL" MEDINITE /00448801/	SINUSITIS	2	tablet	QHS	2009-12-26	2010-01-01

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 26 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1031	"NICORETTE PATCH" NICOTINE	SMOKING CESSATION	14	mg	QID	2010-01-08	ONGOING
R1032	"IBUPROFEN" IBUPROFEN	JOINT PAIN	800	mg	PRN	1999	ONGOING
	"OCELLA" DROSPIRENONE W/ ETHINYLESTRADIOL	CONTRACEPTIVE	1	tablet	QD	2009-02	2009-07-25
	"SPRINTEC" CILEST	CONTRACEPTIVE	1	tablet	QD	2009-08-02	ONGOING
	"KEFLEX" CEFALEXIN MONOHYDRATE	SPIDER BITE	500	mg	BID	2009-10-16	2009-10-25

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 27 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1033	"IBUPROFEN" IBUPROFEN	HEADACHE	200	mg	PRN	2009-07-06	2009-07-06
R1034	"AMLODIPINE" AMLODIPINE	HYPERTENSION	5	mg	QD	2006	ONGOING
	"TERAZOSIN" TERAZOSIN	PROSTATE/BLADDER CONTROL	2	mg	QD	2008	2009-08-11
	"MULTI-VITAMIN" MULTIVITAMINS	SUPPLEMENT	2	tablet	QD	2009-07-14	ONGOING
	"TERAZOSIN" TERAZOSIN	PROSTATE-BLADDER CONTROL	2	mg	QD	2009-08-19	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 28 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1034	"INFLUENZA INJECTION" INFLUENZA VACCINE	PROPHYLACTIC FLU	0.5	milliliters	Once	2009-10-28	2009-10-28
	"ATENOLOL" ATENOLOL	IRREGULAR HEART BEAT	25	mg	Once	2009-11-21	2009-11-21
	"ATENOLOL" ATENOLOL	IRREGULAR HEART BEAT	25	mg	Once	2009-12-17	2009-12-17
R1035	"PRAVASTATIN" PRAVASTATIN	HYPERCHOLESTER OLEMIA	40	mg	QD	2000	ONGOING
	"GEMFIBROZIL" GEMFIBROZIL	HIGH TRIGLYCERIDES	600	mg	QD	2006	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 29 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1035	"IBUPROFEN" IBUPROFEN	LOWER BACK PAIN	200	mg	PRN	2009	ONGOING
	"MELOXICAM" MELOXICAM	LEFT ELBOW PAIN	15	mg	QD	2009-09-02	2009-09-13
	"AIRBORNE" ALL OTHER THERAPEUTIC PRODUCTS	URI	1	tablet	BID	2009-09-20	2009-09-24
	"EQUATE ALLERGY RELIEF" LORATADINE	UPPER RESPIRATORY INFECTION	10	mg	QD	2009-09-20	2009-09-24
	"LORATADINE" LORATADINE	URI	10	mg	QD	2009-09-20	2009-09-24

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 30 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1035	"ABSORBINE LINIMENT" MENTHOL	LEFT ELBOW PAIN	UNK	other, specify: liniment	PRN	2009-09-21	ONGOING
	"CYCLOBENZAPRINE" CYCLOBENZAPRINE	LEFT ELBOW PAIN	10	mg	TID	2009-10-01	2009-10-02
	"MELOXICAM" MELOXICAM	LEFT ELBOW PAIN	15	mg	Once	2009-10-01	2009-10-02
	"MEDROL" METHYLPREDNISOLONE	LEFT ELBOW PAIN	24	mg	Once	2009-10-15	2009-10-15
	"MEDROL" METHYLPREDNISOLONE	LEFT ELBOW PAIN	20	mg	Once	2009-10-16	2009-10-16

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 31 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1035	"MEDROL" METHYLPREDNISOLONE	LEFT ELBOW PAIN	16	mg	Once	2009-10-17	2009-10-17
	"MEDROL" METHYLPREDNISOLONE	LEFT ELBOW PAIN	12	mg	Once	2009-10-18	2009-10-18
	"MEDROL" METHYLPREDNISOLONE	LEFT ELBOW PAIN	8	mg	Once	2009-10-19	2009-10-19
	"MEDROL" METHYLPREDNISOLONE	LEFT ELBOW PAIN	4	mg	Once	2009-10-20	2009-10-20
	"EQUATE ALLERGY RELIEF" LORATADINE	UPPER RESPIRATORY RELIEF	10	mg	QD	2009-11-09	2009-11-11

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 32 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1035	"CAMEL SNUS" NICOTINE	SMOKING CESSATION	14.5	mg	PRN	2009-12-23	ONGOING
R1036	"SKELAXIN" CLONIXIN LYSINATE	RIGHT SHOULDER PAIN	800	mg	PRN	2009-08-11	2009-08-11
R1037	"FINASTERIDE" FINASTERIDE	ENLARGED PROSTATE	5	mg	QHS	2006	ONGOING
	"TERAZOSIN" TERAZOSIN	ENLARGED PROSTATE	10	mg	QHS	2006	ONGOING
	"ASPIRIN" ACETYLSALICYLIC ACID	PROPHYLACTIC	81	mg	QD	2007	2009-10-20

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 33 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1037	"METFORMIN" METFORMIN	DIABETES	500	mg	TID	2008	ONGOING
	"PRAVASTATIN" PRAVASTATIN	HYPERCHOLESTER OLEMIA	40	mg	QHS	2008	ONGOING
	"CLARITIN" LORATADINE	SNEEZING	10	mg	PRN	2009-08-02	ONGOING
	"ANBESOL" BENZOCAINE	BLISTER ON ROOF OF MOUTH	1	other, specify: application	PRN	2009-08-09	2009-08-11
	"DILUTED PEROXIDE GARGLE" HYDROGEN PEROXIDE	SORE THROAT	NA	other, specify: gargle	QD	2009-08-10	2009-08-10

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 34 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1037	"SALT WATER GARGLE" SODIUM CHLORIDE	SORE THROAT	NA	other, specify: gargle	PRN	2009-08-10	2009-08-15
	"LOPERAMIDE" LOPERAMIDE	DIARRHEA	2	mg	Once	2009-08-17	2009-08-17
	"CYCLOBENZAPRINE" CYCLOBENZAPRINE	BACK STRAIN	10	mg	TID	2009-09-10	2009-09-19
	"KETOROLAC" KETOROLAC	BACK STRAIN	UNK	other, specify: liquid	Once	2009-09-10	2009-09-10
	"IBUPROFEN" IBUPROFEN	BACK STRAIN	400	mg	BID	2009-09-11	2009-09-19

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 35 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1037	"FAMILY CARE COLD & HOT PAIN RELIEF" ALL OTHER THERAPEUTIC PRODUCTS	BACK STRAIN	1	other, specify: patch	PRN	2009-09-21	2009-12-28
	"BENADRYL" DIPHENHYDRAMINE HYDROCHLORIDE	ALLERGIC REACTION	25	mg	Once	2009-09-29	2009-09-29
	"VITAMIN B-12" CYANOCOBALAMIN	SUPPLEMENT	40	mg	QD	2009-11-06	ONGOING
	"NICORETTE GUM" NICOTINE	SMOKING CESSATION	2	mg	BID	2009-11-26	2009-11-26
	"NICORETTE GUM" NICOTINE	SMOKING CESSATION	2	mg	PRN	2010-01-07	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 36 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R1037	"VITAMIN D3" COLECALCIFEROL	SUPPLEMENT	400	other, specify: iu	QD	2010-02-08	ONGOING
R2001	"IBUPROFEN" IBUPROFEN	MUSCLE ACHE AND INFLAMMATION IN BOTH LEGS	1000	mg	PRN	2009-02-15	2009-02-16
	"FLU VACCINE" INFLUENZA VACCINE	PREVENTATIVE	UNK	other, specify: unknown	Once	2009-04-03	2009-04-03
	"MEASLES MUMPS AND RUBELLA VACCINE" MEASLES, MUMPS AND RUBELLA VACCINE	PREVENTATIVE	UNK	other, specify: unknown	Once	2009-04-03	2009-04-03
	"POLIOVIRUS VACCINE" POLIOVIRUS VACCINE	PREVENTATIVE	UNK	other, specify: unknown	Once	2009-04-03	2009-04-03

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 37 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2002	"TOPAMAX" TOPIRAMATE	MIGRAINE PREVENTION	100	mg	QD	2002	ONGOING
	"MIRENA HORMONAL IUD" LEVONORGESTREL	BIRTH CONTROL	20	mg	QD	2007-08	ONGOING
	"CALCIUM MAGNESIUM" CALCIUM W/MAGNESIUM	GENERAL HEALTH	1	tablet	QD	2009-01	ONGOING
	"ESSENTIAL FATTY ACID SOFT GEL" FATTY ACIDS NOS	GENERAL HEALTH	1	tablet	QD	2009-01	ONGOING
	"MULTI-VITAMIN" MULTIVITAMINS	GENERAL HEALTH	2	tablet	QD	2009-01	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 38 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2003	"MULTI-VITAMIN" MULTIVITAMINS	GENERAL HEALTH	1	tablet	QD	1978	ONGOING
	"CHROMIUM PICOLINATE" CHROMIUM PICOLINATE	GENERAL HEALTH	800	ug	QD	1997	ONGOING
	"EXCEDRIN MIGRAINE" THOMAPYRIN N	MIGRAINES	2	other, specify: capsules	PRN	1998	ONGOING
	"PROAIR HFA ALBUTEROL" SALBUTAMOL SULFATE	ASTHMA	2	other, specify: puffs	PRN	1998	ONGOING
	"ORTHO CYCLEN" CILEST	BIRTH CONTROL	1	tablet	QD	2001	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 39 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2003	"ASPIRIN" ACETYLSALICYLIC ACID	GENERAL HEALTH	81	mg	QD	2002	ONGOING
	"MAGNESIUM" MAGNESIUM	GENERAL HEALTH	250	mg	QD	2002	ONGOING
	"VITAMIN B6" PYRIDOXINE HYDROCHLORIDE	GENERAL HEALTH	100	mg	QD	2002	ONGOING
	"VITAMIN C" ASCORBIC ACID	GENERAL HEALTH	1000	mg	QD	2002	ONGOING
	"VITAMIN D" VITAMIN D AND ANALOGUES	GENERAL HEALTH	400	other, specify: international units	QD	2002	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 40 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2003	"VITAMIN E" TOCOPHEROL	GENERAL HEALTH	400	other, specify: international units	QD	2002	ONGOING
	"ZYRTEC" CETIRIZINE HYDROCHLORIDE	ALLERGIES	10	mg	PRN	2005	ONGOING
	"MELATONIN" MELATONIN	INSOMNIA	3	mg	QD	2008	2009-05-17
	"HEALTHY HAIR SKIN AND NAILS PLUS EGCG AND RESVERATROL" ALL OTHER NON-THERAPEUTIC PRODUCTS	GENERAL HEALTH	2	other, specify: capsule	QD	2008-09	ONGOING
	"SUPER-OMEGA 3 FISH OIL" FISH OIL	GENERAL HEALTH	1000	mg	QD	2008-12	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 41 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2003	"VITAMIN B-12" CYANOCOBALAMIN	GENERAL HEALTH	100	ug	QD	2009	ONGOING
	"DIATOMACEOUS EARTH" ALL OTHER NON-THERAPEUTIC PRODUCTS	GENERAL HEATLH	1	other, specify: teaspoon	QD	2009-03	ONGOING
	"ACAI BERRY EDGE" ALL OTHER NON-THERAPEUTIC PRODUCTS	GENERAL HEALTH	1	tablet	BID	2009-03-01	ONGOING
	"SAINT JOHNS WORT" HYPERICUM PERFORATUM	GENERAL HEALTH	350	mg	QD	2009-03-05	ONGOING
	"BROMALITE" ALL OTHER NON-THERAPEUTIC PRODUCTS	GENERAL HEALTH	1	tablet	BID	2009-03-12	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 42 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2003	"MUCINEX DM" TUSSIN DM	SINUS CONGESTION	1	tablet	BID	2009-07-02	2009-07-08
R2004	"DOCUSATE SODIUM" DOCUSATE SODIUM	CONSTIPATION	100	mg	PRN	2009-03-09	ONGOING
	"IBUPROFEN" IBUPROFEN	HEADACHE	400	mg	BID	2009-04-04	2009-04-04
R2005	"IBUPROFEN" IBUPROFEN	HEADACHE	400	mg	Once	2009-04-21	2009-04-21
	"VIGAMOX 0.5% SOLUTION" MOXIFLOXACIN HYDROCHLORIDE	CORNEAL ULCER	1	other, specify: drop	OTHER, SPECIFY, EVERY 5 HOURS	2009-06-22	2009-07-02

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 43 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2005	"FISH OIL" FISH OIL	PREVENTATIVE SUPPLEMENT	1200	mg	QAM	2009-07-02	ONGOING
R2006	"MUCINEX" GUAIFENESIN	MILD COLD	1200	mg	BID	2009-02-28	2009-03-07
	"ACETAMINOPHEN DEXTROMETHORPHAN DOXYLAMINE" DEXTROMETHORPHAN HBR W/ DOXYLAM. SUCC/PARACET.	MILD COLD	UNK	other, specify: liquid	QHS	2009-03-01	2009-03-06
	"PSEUDOEPHEDRINE SULFATE, LORATADINE" NARINE /01202601/	MILD COLD	1	tablet	QD	2009-03-03	2009-03-06
	"DOCUSATE NA" DOCUSATE SODIUM	MILD CONSTIPATION	300	mg	Once	2009-03-10	2009-03-10

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 44 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2006	"AMOXICILLIN" AMOXICILLIN	PHARYNGITIS	875	mg	BID	2009-03-19	2009-03-28
	"IBUPROFEN" IBUPROFEN	HEADACHE	200	mg	Once	2009-03-29	2009-03-29
	"MUCINEX" GUAIFENESIN	CONGESTION	1200	mg	Once	2009-04-06	2009-04-06
	"EXTRA STRENGTH TYLENOL" PARACETAMOL	HEADACHE	500	mg	Once	2009-06-24	2009-06-24
R2007	"C-1000" ASCORBIC ACID	SUPPLEMENT	1000	mg	QD	1989	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 45 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2007	"ROLAIDS" DIHYDROXYALUMINUM SODIUM CARBONATE	HEARTBURN	2	tablet	PRN	1995	ONGOING
	"TUMS" CALCIUM CARBONATE	HEARTBURN	2	tablet	PRN	1995	ONGOING
	"ADVAIR" SERETIDE /01420901/	SHORTNESS OF BREATH	1	other, specify: puff	BID	2003	ONGOING
	"CO Q10" UBIDECARENONE	SUPPLEMENT	100	mg	QD	2005	ONGOING
	"NIACIN" NICOTINIC ACID	SUPPLEMENT	500	mg	QD	2008-01	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 46 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2007	"B-12" CYANOCOBALAMIN-TANNIN COMPLEX	SUPPLEMENT	1500	ug	QD	2009-01	ONGOING
R2008	"NAPROXEN SODIUM" NAPROXEN SODIUM	MENSTRUAL CRAMPS	440	mg	PRN	2009-03	ONGOING
	"C-PHEN DM SYRUP" DEXTROSIN	BRONCHITIS	2	other, specify: teaspoons	PRN	2009-04-17	2009-04-19
	"DOXYCYCLINE" DOXYCYCLINE	BRONCHITIS	100	mg	BID	2009-04-17	2009-04-24
	"METRONIDAZOLE" METRONIDAZOLE	VAGINITIS	500	mg	BID	2009-06-03	2009-06-10

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 47 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2009	"FOCALIN" DEXMETHYLPHENIDATE HYDROCHLORIDE	ATTENTION DEFICIT DISORDER	10	mg	QD	2009-09-25	ONGOING
R2010	"FERROUS SULFATE" FERROUS SULFATE	ANEMIA	130	mg	BID	1979	ONGOING
	"PRILOSEC" OMEPRAZOLE MAGNESIUM	HEARTBURN AND GASTRO ESOPHAGEAL REFLUX DISEASE	20	mg	QD	1990	ONGOING
	"LISINOPRIL" LISINOPRIL	HIGH BLOOD PRESSURE	10	mg	QD	1994	ONGOING
	"GLYBURIDE" GLIBENCLAMIDE	DIABETES	10	mg	BID	1996	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 48 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2010	"METFORMIN" METFORMIN	DIABETES	2500	mg	QD	1996	ONGOING
	"ACTOS" PIOGLITAZONE HYDROCHLORIDE	DIABETES	40	mg	BID	2009	ONGOING
	"CYMBALTA" DULOXETINE HYDROCHLORIDE	DIABETIC NEUROPATHY	60	mg	QD	2009-06-08	ONGOING
R2011	"IBUPROFEN" IBUPROFEN	GENERAL ACHES AND PAIN	400	mg	PRN	1976	ONGOING
	"DIPHENHYDRAMINE HYDROCHLORIDE" DIPHENHYDRAMINE HYDROCHLORIDE	SEASONAL ALLERGIES	50	mg	PRN	2004	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 49 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2011	"B-12" CYANOCOBALAMIN-TANNIN COMPLEX	PREVENTATIVE SUPPLEMENT	250	mg	QD	2007	ONGOING
	"1% CYCLOPENTOLATE" CYCLOPENTOLATE	INJURY TO LEFT EYE	1	other, specify: drop	BID	2009-05-18	2009-05-20
	"AC 1% PREDNISOLONE" PREDNISOLONE ACETATE	INJURY TO LEFT EYE	1	other, specify: drop	OTHER, SPECIFY, EVERY TWO HOURS	2009-05-18	2009-05-22
	"IBUPROFEN" IBUPROFEN	INJURY TO THE LEFT EYE	800	mg	QD	2009-05-18	2009-05-19
	"HYDROCODONE APAP" PROCET /01554201/	RIGHT KNEE PAIN	1000	mg	PRN	2009-09-09	2009-09-23

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 50 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2012	"IBUPROFEN" IBUPROFEN	GENERAL ACHES	200	mg	PRN	1989	ONGOING
	"COMMIT LOZENGES" NICOTINE POLACRILEX	NICOTINE REPLACEMENT	1	other, specify: lozenge	PRN	2009	2009
	"NICOTINE PATCH" NICOTINE	NICOTINE REPLACEMENT	1	other, specify: patch	PRN	2009	2009
	"NYQUIL" MEDINITE /00448801/	DRY COUGH	1	other, specify: tablespoon	Once	2009-05-14	2009-05-14
	"BENADRYL" DIPHENHYDRAMINE HYDROCHLORIDE	SEASONAL ALLERGIES	4	other, specify: capsules	Once	2009-05-24	2009-05-24

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 51 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2013	"BAYER ASPIRIN" ACETYLSALICYLIC ACID	GENERAL ACHES AND PAIN	400	mg	PRN	1979	ONGOING
	"FEXOFENADINE" FEXOFENADINE	SEASONAL ALLERGIES	180	mg	PRN	2009-06-15	ONGOING
	"NAPHCN-A" NAPHCN-A /00827001/	SEASONAL ALLERGIES	2	other, specify: drops	PRN	2009-06-15	ONGOING
	"BAYER ASPIRIN" ACETYLSALICYLIC ACID	RIGHT SHOULDER PAIN	400	mg	PRN	2009-08	2009-09
	"IBUPROFEN" IBUPROFEN	SWELLING RIGHT SHOULDER	600	mg	PRN	2009-08-08	2009-09-14

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 52 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2013	"HYDROCODONE APAP" PROCET /01554201/	PAIN RIGHT ARM	1	tablet	PRN	2009-08-10	2009-09-07
	"METHYLPREDNISOLONE" METHYLPREDNISOLONE	SWELLING RIGHT ARM	6	tablet	Once	2009-08-10	2009-08-10
	"METHYLPREDNISOLONE" METHYLPREDNISOLONE	SWELLING RIGHT ARM	5	tablet	Once	2009-08-11	2009-08-11
	"METHYLPREDNISOLONE" METHYLPREDNISOLONE	SWELLING RIGHT ARM	4	tablet	Once	2009-08-12	2009-08-12
	"METHYLPREDNISOLONE" METHYLPREDNISOLONE	SWELLING RIGHT ARM	3	tablet	Once	2009-08-13	2009-08-13

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 53 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2013	"METHYLPREDNISOLONE" METHYLPREDNISOLONE	SWELLING RIGHT ARM	2	tablet	Once	2009-08-14	2009-08-14
	"METHYLPREDNISOLONE" METHYLPREDNISOLONE	SWELLING RIGHT ARM	1	tablet	Once	2009-08-15	2009-08-15
R2014	"TYLENOL" PARACETAMOL	HEADACHE	1000	mg	Once	2009-07-08	2009-07-08
R2015	"IBUPROFEN" IBUPROFEN	HEADACHE AND BACK PAIN	600	mg	PRN	1994	ONGOING
	"BENADRYL" DIPHENHYDRAMINE HYDROCHLORIDE	ALLERGIES	50	mg	PRN	1995	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 54 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2015	"NORETHINDRONE" NORETHISTERONE	BIRTH CONTROL	0.35	mg	QD	2004	ONGOING
	"CLARITIN-D" NARINE /01202601/	ALLERGIES	5	mg	PRN	2005	ONGOING
	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	2008-08	ONGOING
	"VITAMIN C" ASCORBIC ACID	SUPPLEMENT	500	mg	QD	2008-08	ONGOING
	"VITAMIN D" VITAMIN D AND ANALOGUES	SUPPLEMENT	1000	other, specify: iu	QD	2008-08	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 55 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2015	"ADVAIR" SERETIDE /01420901/	BRONCHITIS	2	other, specify: puffs	PRN	2009-05-08	2009-05-20
	"AZITHROMYCIN" AZITHROMYCIN	BRONCHITIS	500	mg	BID	2009-05-08	2009-05-08
	"PROMETHAZINE WITH CODEINE" PROMETHAZINE W/CODEINE / 01129901/	BRONCHITIS	5	milliliters	PRN	2009-05-08	2009-05-14
	"AZITHROMYCIN" AZITHROMYCIN	BRONCHITIS	250	mg	QD	2009-05-09	2009-05-12
R2016	"GLUCOSAMINE" GLUCOSAMINE	PREVENTATIVE SUPPLEMENT	1500	mg	QD	1994	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 56 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2016	"MULTI-VITAMIN" MULTIVITAMINS	PREVENTATIVE SUPPLEMENT	1	tablet	QD	1994	ONGOING
	"OMEGA-3 FISH OIL" FISH OIL	PREVENTATIVE SUPPLEMENT	1200	mg	QD	1999	ONGOING
	"XTREME TRIM" ALL OTHER NON-THERAPEUTIC PRODUCTS	PREVENTATIVE SUPPLEMENT	2	tablet	QD	2008	ONGOING
	"LIPITOR" ATORVASTATIN CALCIUM	HIGH CHOLESTEROL	10	mg	QD	2008-11	2009-06
	"IBUPROFEN" IBUPROFEN	PAIN RELATED TO OSTEOARTHRITIS	600	mg	PRN	2009-02	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 57 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2016	"LIPITOR" ATORVASTATIN CALCIUM	HIGH CHOLESTEROL	10	mg	QD	2009-10-18	ONGOING
R2017	"IBUPROFEN" IBUPROFEN	HEADACHES	400	mg	PRN	1999	ONGOING
	"NYQUIL" MEDINITE /00448801/	FEVER	2	other, specify: tablespoons	PRN	2009-06-21	2009-06-22
	"CIPROFLOXACIN" CIPROFLOXACIN	FEVER	1000	mg	QD	2009-06-24	2009-07-03
	"PHENTERMINE" PHENTERMINE	WEIGHT LOSS	30	mg	PRN	2009-07-30	2009-08-15

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 58 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2017	"ALEVE COLD SINUS" NAPROXEN SODIUM W/ PSEUDOEPHEDRINE HCL	CONGESTION	1	other, specify: capsule	Once	2009-11-16	2009-11-16
R2018	"B-12" CYANOCOBALAMIN-TANNIN COMPLEX	PREVENTATIVE SUPPLEMENT	1500	mg	QD	1999	ONGOING
	"FISH OIL" FISH OIL	PREVENTATIVE SUPPLEMENT	250	mg	QD	1999	ONGOING
R2019	"PRIMATENE MIST" EPINEPHRINE	ASTHMA	30	milliliters	PRN	2006	ONGOING
	"DILAUDID" HYDROMORPHONE HYDROCHLORIDE	LUMBAR STRAIN	2	mg	Once	2009-07-08	2009-07-08

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 59 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2019	"NORCO" VICODIN	LUMBAR STRAIN	1	tablet	PRN	2009-07-08	2009-08-21
	"PHENERGAN" PROMETHAZINE HYDROCHLORIDE	LUMBAR STRAIN	25	mg	Once	2009-07-08	2009-07-08
	"SOMA" CARISOPRODOL	LUMBAR STRAIN	350	mg	QID	2009-07-08	2009-08-21
R2020	"NONE"						
R2021	"CALCIUM WITH VITAMIN D" CALCIUM D3 /01483701/	OSTEOPOROSIS	2	tablet	QD	2009-04	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 60 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2021	"D-3 VITAMIN" COLECALCIFEROL	OSTEOPOROSIS	1	tablet	QD	2009-04	ONGOING
	"ALENDRONATE" ALENDRONATE SODIUM	OSTEOPOROSIS	70	mg	QS	2009-04-29	2009-05-17
	"CITRACAL" CALCIUM CITRATE	OSTEOPOROSIS	2	tablet	QD	2009-05-17	ONGOING
	"VITAMIN B12 INJECTION" CYANOCOBALAMIN	NUTRITIONAL SUPPLEMENT	1	milliliters	Once	2009-06-01	2009-06-01
	"PERCOCET" OXYCOCET	GASTRO ESOPHAGEAL REFLUX DISEASE	5	mg	PRN	2009-11-13	2009-11-17

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 61 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2022	"NECON" NORMENSAL	ORAL CONTRACEPTIVE	1	tablet	QD	1999	ONGOING
	"MACROBID" NITROFURANTOIN	URINARY TRACT INFECTION	2	other, specify: capsule	BID	2009-06-11	2009-06-15
	"BENZONATATE" BENZONATATE	COLD	200	mg	PRN	2009-10-04	2009-10-30
	"CLARITHROMYCIN" CLARITHROMYCIN	COLD	500	mg	BID	2009-10-04	2009-10-30
	"METRONIDAZOL" METRONIDAZOLE	VAGINAL BACTERIA INFECTION	500	mg	BID	2009-11-07	2009-11-20

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 62 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2023	"LEVOTHYROXINE" LEVOTHYROXINE	HYPOTHYROIDISM	75	ug	QD	2005	ONGOING
	"MAXALT" RIZATRIPTAN BENZOATE	MIGRAINES	10	mg	PRN	2006	ONGOING
R2024	"ALBUTEROL SULFATE" SALBUTAMOL SULFATE	ASTHMA	2	other, specify: puffs	PRN	2008	ONGOING
	"SINGULAIR" MONTELUKAST SODIUM	SEASONAL ALLERGIES	10	mg	QD	2009-05	ONGOING
	"LORATADINE" LORATADINE	SEASONAL ALLERGIES	1	tablet	QD	2010-01-02	2010-01-05

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 63 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2025	"ASPIRIN" ACETYLSALICYLIC ACID	GENERAL ACHES AND PAIN	400	mg	PRN	1995	ONGOING
	"IBUPROFEN" IBUPROFEN	HEADACHES	400	mg	PRN	1995	ONGOING
	"PREDNISONONE" PREDNISONONE	POISON IVY	6	tablet	Once	2009-07-14	2009-07-14
	"PREDNISONONE" PREDNISONONE	POISON IVY	5	tablet	Once	2009-07-15	2009-07-15
	"PREDNISONONE" PREDNISONONE	POISON IVY	4	tablet	Once	2009-07-16	2009-07-16

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 64 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2025	"PREDNISONONE" PREDNISONONE	POISON IVY	3	tablet	Once	2009-07-17	2009-07-17
	"PREDNISONONE" PREDNISONONE	POISON IVY	2	tablet	Once	2009-07-18	2009-07-18
	"PREDNISONONE" PREDNISONONE	POISON IVY	1	tablet	Once	2009-07-19	2009-07-19
R2026	"BABY ASPIRIN" ACETYLSALICYLIC ACID	PREVENTATIVE SUPPLEMENT	81	mg	QD	1979	ONGOING
	"ZETIA" EZETIMIBE	HIGH CHOLESTEROL	10	mg	QD	2009-01	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 65 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2026	"MUCINEX DM" TUSSIN DM	BRONCHITIS	2	tablet	QD	2009-09-09	2009-10-04
	"MUCINEX" GUAIFENESIN	BRONCHITIS	1200	mg	QD	2009-09-09	2009-10-04
	"Z-PACK" AZITHROMYCIN	BRONCHITIS	2	tablet	Once	2009-09-09	2009-09-09
	"Z-PACK" AZITHROMYCIN	BRONCHITIS	1	tablet	QD	2009-09-10	2009-09-13
R2027	"VITAMIN E" TOCOPHEROL	NUTRITIONAL SUPPLEMENT	2	tablet	QD	2009-09	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 66 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2027	"EXTRA STRENGTH TYLENOL" PARACETAMOL	HEADACHE	1000	mg	Once	2009-09-16	2009-09-16
	"CORICIDIN D" CORICIDIN D /00307101/	UPPER RESPIRATORY INFECTION	2	tablet	QID	2010-01-04	2010-01-05
R2028	"IBUPROFEN" IBUPROFEN	TOOTH EXTRACTION PAIN	600	mg	QD	2010-01-08	2010-01-12
	"TYLENOL" PARACETAMOL	TOOTH EXTRACTION PAIN	1500	mg	QD	2010-01-08	2010-01-12
R2029	"MULTIVITAMIN" MULTIVITAMINS	PREVENTATIVE SUPPLEMENT	1	tablet	QD	2004	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 67 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2029	"BENICAR" OLMESARTAN MEDOXOMIL	HIGH BLOOD PRESSURE	20	mg	QD	2006	2009-08-03
	"CRESTOR" ROSUVASTATIN CALCIUM	HIGH CHOLESTEROL	5	mg	QD	2008-11	ONGOING
	"METFORMIN" METFORMIN	DIABETES TYPE II	500	mg	QD	2008-11	2009-12-13
	"ZYRTEC" CETIRIZINE HYDROCHLORIDE	SEASONAL ALLERGIES	5	mg	PRN	2009-04	ONGOING
	"LISINOPRIL" LISINOPRIL	HIGH BLOOD PRESSURE	5	mg	QD	2009-08-12	2009-09-08

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 68 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2029	"MICARDIS" TELMISARTAN	HIGH BLOOD PRESSURE	40	mg	QD	2009-09-08	ONGOING
	"METFORMIN" METFORMIN	DIABETES TYPE II	1000	mg	BID	2009-12-14	ONGOING
R2030	"FISH OIL" FISH OIL	PREVENTATIVE SUPPLEMENT	1500	mg	QD	2009-06	ONGOING
	"GAVISCON" GAVISCON /00237601/	DYSPEPSIA	1000	mg	Once	2009-08-08	2009-08-08
R2031	"TYLENOL" PARACETAMOL	HEADACHES	1000	mg	PRN	1999	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 69 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R2031	"BENADRYL" DIPHENHYDRAMINE HYDROCHLORIDE	INSECT BITE	25	mg	Once	2009	2009
R2032	"MULTIVITAMINS" MULTIVITAMINS	PREVENTATIVE SUPPLEMENT	1	tablet	QD	2008	ONGOING
	"TRINESSA" CILEST	BIRTH CONTROL	1	tablet	QAM	2008-05	ONGOING
	"FLAXSEED OIL" LINUM USITATISSIMUM SEED OIL	PREVENTATIVE SUPPLEMENT	1000	mg	QD	2009-03	ONGOING
R3001	"NONE"						

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 70 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R3002	"LEVOTHROID" LEVOTHYROXINE SODIUM	HYPOTHYROIDISM	150	ug	QD	1983	ONGOING
	"ESTRADIOL" ESTRADIOL	HORMONE REPLACEMENT THERAPY	0.5	mg	QD	2002	ONGOING
	"ASPIRIN" ACETYLSALICYLIC ACID	CARDIAC PROPHYLAXIS	81	mg	QD	2003	ONGOING
	"ROPINIROLE" ROPINIROLE	RESTLESS LEG SYNDROME	1	mg	QD	2007-01	ONGOING
R3003	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	1965	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 71 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R3003	"ACETAMINOPHEN" PARACETAMOL	HEADACHES	1000	mg	PRN	1976	ONGOING
	"SUDAFED 12 HOUR" PSEUDOEPHEDRINE HYDROCHLORIDE	COMMON COLD	120	mg	BID	2009-02-22	2009-02-27
	"FLONASE" FLUTICASONE PROPIONATE	SEASONAL ALLERGIES	100	ug	QD	2009-04-21	2009-05-01
R3004	"TUMS" CALCIUM CARBONATE	HEARTBURN	5	tablet	PRN	2004	ONGOING
R3005	"SIMVASTATIN" SIMVASTATIN	HIGH CHOLESTEROL	40	mg	QD	2005	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 72 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R3005	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	2	tablet	QD	2006	ONGOING
	"VITAMIN D" VITAMIN D AND ANALOGUES	SUPPLEMENT	1	tablet	QD	2006	ONGOING
	"ECOTRIN" ACETYLSALICYLIC ACID	SUPPLEMENT	81	mg	QD	2008	ONGOING
	"ALEVE" NAPROXEN SODIUM	RIGHT HAND SWELLING	220	mg	BID	2009-04-07	ONGOING
R3006	"ASPIRIN" ACETYLSALICYLIC ACID	HEADACHE	325	mg	PRN	1955	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 73 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R3006	"B COMPLEX" B COMPLEX /02945401/	SUPPLEMENT	1	tablet	QD	1967	ONGOING
	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	1967	ONGOING
	"VITAMIN C" ASCORBIC ACID	SUPPLEMENT	1000	mg	QD	1967	ONGOING
	"VITAMIN E" TOCOPHEROL	SUPPLEMENT	200	other, specify: iu	QD	1967	ONGOING
	"ACETAMINOPHEN/DIPHENHYDRA MINE" TYLENOL PM /01088101/	INSOMNIA	1	tablet	OTHER, SPECIFY, AS NEEDED AT BEDTIME	2004	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 74 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R3006	"CALCIUM" CALCIUM	SUPPLEMENT	500	mg	QD	2008-09	ONGOING
	"SIMVASTATIN" SIMVASTATIN	HYPERLIPIDEMIA	40	mg	QD	2008-09	2009-04-09
	"VITAMIN D" VITAMIN D AND ANALOGUES	SUPPLEMENT	2000	other, specify: iu	QD	2008-09	ONGOING
	"ACETAMINOPHEN/CODEINE" GALENIC /PARACETAMOL/ CODEINE/	HEADACHES DUE TO HEAD INJURY	1	tablet	PRN	2008-10	ONGOING
	"AMLODIPINE BESYLATE" AMLODIPINE BESILATE	HYPERTENSION	10	mg	QD	2008-10	2009-04-09

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 75 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R3006	"LISINOPRIL" LISINOPRIL	HYPERTENSION	10	mg	QD	2009-01	2009-02-21
	"ZOLPIDEM" ZOLPIDEM	INSOMNIA	5	mg	PRN	2009-02-02	ONGOING
	"LOSARTAN" LOSARTAN	HIGH BLOOD PRESSURE	50	mg	QD	2009-02-05	ONGOING
	"SIMVASTATIN" SIMVASTATIN	HYPERLIPIDEMIA	40	mg	QD	2009-04-13	ONGOING
	"FLONASE" FLUTICASONE PROPIONATE	ALLERGIES	2	other, specify: sprays each nostril	QD	2009-05-12	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 76 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R3006	"VALTREX" VALACICLOVIR HYDROCHLORIDE	COLD SORES	1	g	QD	2009-08-17	2009-08-19
R3007	"CENTRUM" CENTRUM /00554501/  "EXTRA STRENGTH EXCEDRIN" THOMAPYRIN N	SUPPLEMENT  HEADACHES	1  1	tablet  tablet	PRN  PRN	2009-01  2009-03-03	ONGOING  ONGOING
R3008	"NONE"						
R3009	"EXTRA STRENGTH TYLENOL" PARACETAMOL	TENSION HEADACHES	1000	mg	PRN	1960	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 77 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R3009	"VITAMIN C" ASCORBIC ACID	SUPPLEMENT	1000	mg	QID	1970	ONGOING
	"CALCIUM" CALCIUM	SUPPLEMENT	500	mg	QD	1993	ONGOING
	"GINGER ROOT" ZINGIBER OFFICINALE RHIZOME	GERD	550-1100	mg	PRN	1999	ONGOING
	"ABX" ALL OTHER NON-THERAPEUTIC PRODUCTS	SUPPLEMENT	1	other, specify: cap	PRN	2004	ONGOING
	"CHINESE HERBS" HERBAL PREPARATION	SUPPLEMENT	2	other, specify: caps	QD	2004	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 78 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R3009	"OCUVITE" OCUVITE /01053801/	SUPPLEMENT	1	tablet	QD	2004	ONGOING
	"VITAMIN B COMPLEX" CYANOCOBALAMIN	SUPPLEMENT	1	tablet	QD	2005	ONGOING
	"EVENING PRIMROSE OIL" OENOTHERA BIENNIS OIL	SUPPLEMENT	500	mg	QD	2007	ONGOING
	"VITAMIN D" VITAMIN D AND ANALOGUES	SUPPLEMENT	1000	other, specify: iu	QD	2008-12	ONGOING
	"B AND T COUGH SYRUP" COUGH AND COLD PREPARATIONS	CHRONIC COUGH/UPPER RESPIRATORY TRACT INFECTION	1	other, specify: tsp	PRN	2009-03-11	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 79 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R3010	"IBUPROFEN" IBUPROFEN	BACK PAIN	400	mg	QD	1995	ONGOING
	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	2000	ONGOING
	"TRINESSA" CILEST	CONTRACEPTION	1	tablet	QD	2004	ONGOING
	"LISINOPRIL/HCTZ" PRINZIDE /00977901/	HIGH BLOOD PRESSURE	1	tablet	QD	2008-08	ONGOING
	"EXCEDRIN" THOMAPYRIN N	HEADACHES - INCREASE IN NUMBER OF	2	tablet	QD	2009-03-15	2009-03-16

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 80 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R3011	"PREVACID" LANSOPRAZOLE	HEARTBURN	30	mg	QD	1999	ONGOING
	"NAPROXEN" NAPROXEN	HEADACHES - TENSION	800	mg	PRN	2007	ONGOING
	"ALLEGRA" FEXOFENADINE HYDROCHLORIDE	ALLERGIES- SEASONAL	180	mg	QD	2009-04	ONGOING
R3012	"ADVIL" IBUPROFEN	HEADACHES	200	mg	PRN	2004	ONGOING
	"CIALIS" TADALAFIL	ERECTILE DYSFUNCTION	20	mg	PRN	2007	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 81 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R3013	"NONE"						
R3014	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	1999	ONGOING
	"VITAMIN D WITH CALCIUM" CALCIUM D3 /01483701/	SUPPLEMENT	1	tablet	QD	1999	ONGOING
	"DAYQUIL" VICKS FORMULA 44M	UPPER RESPIRATORY TRACT INFECTION	2	other, specify: caps	PRN	2009-05-20	2009-05-24
R3015	"EXCEDRIN" THOMAPYRIN N	MENSTRUAL CRAMPS	2	tablet	PRN	UNK	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 82 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R3016	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	1989	ONGOING
R3017	"B VITAMINS" VITAMIN B NOS	SUPPLEMENT	1	tablet	QOD	2004	ONGOING
	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	2004	ONGOING
	"VITAMIN E" TOCOPHEROL	SUPPLEMENT	400	other, specify: iu	QD	2004	ONGOING
	"HERBAL THROAT SPRAY" HERBAL PREPARATION	UPPER RESPIRATORY TRACT INFECTION	2	other, specify: sprays	QID	2009-03-24	2009-04-09

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 83 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R3017	"DOXYCYCLINE" DOXYCYCLINE	UPPER RESPIRATORY INFECTION	100	mg	BID	2009-03-26	2009-04-09
R3018	"VITAMIN C" ASCORBIC ACID	SUPPLEMENT	2000	mg	QD	2008-10	ONGOING
	"MULTIVITAMIN-THERAGRAN" THERAGRAN /00554301/	SUPPLEMENT	1	tablet	QD	2009-01	ONGOING
	"CALCIUM PLUS VITAMIN D" CALCIUM D3 /01483701/	SUPPLEMENT	1	tablet	QD	2009-03	ONGOING
	"AZITHROMYCIN" AZITHROMYCIN	UPPER RESPIRATORY TRACT INFECTION	250	mg	QD	2009-05-18	2009-05-24

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 84 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R3018	"OXYCODONE/APAP" OXYCODONE/APAP	DENTAL PAIN	1	tablet	PRN	2009-07-03	2009-08-11
R3019	"CALCIUM" CALCIUM	SUPPLEMENT	1	tablet	PRN	2009-01	2009-04-28
	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	PRN	2009-01	2009-04-28
	"VITAMIN D" VITAMIN D AND ANALOGUES	SUPPLEMENT	1	tablet	PRN	2009-01	2009-04-28
	"CALCIUM AND VITAMIN D" CALCIUM D3 /01483701/	SUPPLEMENT	1	tablet	Once	2009-06-22	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 85 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R3019	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	2009-06-22	ONGOING
	"ROBITUSSIN DM" TUSSIN DM	UPPER RESPIRATORY TRACT INFECTION	2	other, specify: tbsp	PRN	2009-06-22	2009-06-26
	"ASPIRIN" ACETYLSALICYLIC ACID	CARDIAC PROPHYLAXIS	81	mg	QD	2009-07-20	ONGOING
R3020	"EXTRA STRENGTH TYLENOL" PARACETAMOL	HEADACHES	1000	mg	PRN	1990	ONGOING
	"IBUPROFEN" IBUPROFEN	HEADACHES	400	mg	PRN	2000	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 86 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R3020	"OMEGA 3" FISH OIL	SUPPLEMENT	1	other, specify: cap	QD	2008	ONGOING
	"ZITHROMAX" AZITHROMYCIN	UPPER RESPIRATORY TRACT INFECTION	500	mg	QD	2009-05-12	2009-05-16
	"TUMS" CALCIUM CARBONATE	DYSPEPSIA - EXACERBATION	2	tablet	PRN	2009-05-22	ONGOING
	"NAPROSYN" NAPROXEN SODIUM	LOW BACK PAIN	500	mg	Once	2009-08-21	2009-08-21
R3021	"NONE"						

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 87 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R3022	"LORATADINE" LORATADINE	SEASONAL ALLERGIES	10	mg	QD	1999	ONGOING
	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	2	tablet	QD	2009-01	ONGOING
R3023	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	2003	ONGOING
	"CALCIUM/VITAMIN D" CALCIUM D3 /01483701/	SUPPLEMENT	1	tablet	TID	2008-10	ONGOING
	"FISH OIL/FLAX OIL BORAGE" ALL OTHER NON-THERAPEUTIC PRODUCTS	SUPPLEMENT	1	tablet	BID	2008-10	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 88 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R3023	"LIPITOR" ATORVASTATIN CALCIUM	HIGH CHOLESTEROL	10	mg	QD	2009-01	ONGOING
R3024	"NONE"						
R3025	"MIDOL" ACETYLSALICYLIC ACID	MENSTRUAL PAIN	200	mg	PRN	1984	ONGOING
	"MOTRIN" IBUPROFEN	MENSTRUAL PAIN	200	mg	PRN	1984	ONGOING
	"IBUPROFEN" IBUPROFEN	MIGRAINES	600	mg	PRN	2001	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 89 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R3025	"METFORMIN" METFORMIN	POLYCYSTIC OVARY SYNDROME	500	mg	BID	2003	ONGOING
R3026	"MELATONIN" MELATONIN	ANXIETY	2	tablet	QD	2001	ONGOING
	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	2	tablet	QD	2001	ONGOING
	"ST JOHN'S WORT" HYPERICUM PERFORATUM	DEPRESSION	2	other, specify: caps	QD	2001	ONGOING
	"METHADONE" METHADONE	RECURRENT BACK PAIN	20	mg	QD	2008	2009-09-02

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 90 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R3026	"BACH RESCUE REMEDY" ALL OTHER NON-THERAPEUTIC PRODUCTS	ANXIETY	4	other, specify: drops	PRN	2008-08	2009-07-14
	"FLAX SEED OIL" LINUM USITATISSIMUM SEED OIL	SUPPLEMENT	2	other, specify: caps	QD	2009	ONGOING
	"FIBER" POLYCARBOPHIL CALCIUM	SUPPLEMENT	2	tablet	QD	2009-02	ONGOING
	"FISH OIL" FISH OIL	SUPPLEMENT	2	other, specify: caps	QD	2009-02	ONGOING
	"TYLENOL PM" TYLENOL PM /01088101/	INSOMNIA	2	tablet	PRN	2009-04	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 91 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R3026	"VALERIAN ROOT" VALERIANA OFFICINALIS ROOT	ANXIETY	40	other, specify: drops	QD	2009-06-23	ONGOING
R3027	"METRONIDAZOLE" METRONIDAZOLE	VAGINOSIS	500	mg	BID	2009-06-09	2009-06-12
R3028	"NONE"						
R3029	"NONE"						
R3030	"TUMS" CALCIUM CARBONATE	HEARTBURN	2	tablet	PRN	2005	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 92 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R3030	"IBUPROFEN" IBUPROFEN	RECURRENT BACK PAIN DUE TO SCOLIOSIS	400	mg	PRN	2006	ONGOING
R3031	"AMOXICILLIN" AMOXICILLIN	LOWER LEFT MOLAR PAIN	500	mg	TID	2009-08-13	2009-08-20
	"HYDROCODONE/APAP" PROCET /01554201/	LEFT LOWER MOLAR PAIN	1	tablet	PRN	2009-08-13	2009-08-18
R3032	"BENADRYL" DIPHENHYDRAMINE HYDROCHLORIDE	SEASONAL ALLERGIES	25	mg	PRN	1989	ONGOING
	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	2006	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 93 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4001	"SIMVASTATIN" SIMVASTATIN	HIGH CHOLESTEROL	20	mg	QD	2008-12	2009-02-23
R4002	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	2004-01	ONGOING
	"CALCIUM" CALCIUM	SUPPLEMENT	600	mg	QD	2009-08-31	ONGOING
R4003	"ASPIRIN" ACETYLSALICYLIC ACID	CARDIAC PROPHYLAXIS	81	mg	QD	1987	ONGOING
	"OMEPRAZOLE" OMEPRAZOLE	HYPERTENSION	20	mg	BID	1987	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 94 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4003	"ENALAPRIL" ENALAPRIL	ACID REFLUX	10	mg	BID	2005	ONGOING
R4004	"IBUPROFEN" IBUPROFEN	SINUS INFECTION	600	mg	PRN	2009-03-08	2009-03-08
R4005	"SUDAFED" PSEUDOEPHEDRINE HYDROCHLORIDE	VIRAL URI	1	tablet	PRN	2009-03-15	2009-03-15
	"TUSSIN" GUAIFENESIN	VIRAL URI	1	other, specify: teaspoon	PRN	2009-03-15	2009-03-15
	"ROBITUSSIN" GUAIFENESIN	VIRAL URI	1	other, specify: teaspoon	Once	2009-04-26	2009-04-26

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 95 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4005	"TUSSIN" GUAIFENESIN	VIRAL URI	1	other, specify: teaspoon	PRN	2009-04-27	2009-04-27
R4006	"EXCEDRIN SINUS" TYLENOL SINUS MEDICATION	SINUS INFECTION	1	tablet	PRN	1999	ONGOING
	"MELATONIN" MELATONIN	SUPPLEMENT	3	mg	PRN	2009	ONGOING
	"METRONIDAZOLE" METRONIDAZOLE	BACTERIAL INFECTION	1000	mg	QD	2009-02-23	2009-03-01
	"ALKA SELTZER PLUS" ACETYLSALICYLIC ACID	VIRAL UPPER RESPIRATORY INFECTION AND HEADACHE	2	tablet	PRN	2009-04-01	2009-04-01

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 96 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4007	"CRANBERRY PILLS" VACCINIUM MACROCARPON	URINARY TRACT INFECTION	2	other, specify: capsules	TID	2009-03-16	2009-03-20
	"KEFLEX" CEFALEXIN MONOHYDRATE	URINARY TRACT INFECTION	200	mg	BID	2009-03-16	2009-03-20
R4008	"LEXAPRO" ESCITALOPRAM OXALATE	STRESS	0.025	mg	Once	2007-01	2009-03-11
	"ASPIRIN" ACETYLSALICYLIC ACID	JOINT PAIN	325	mg	Once	2009-02-23	2009-02-23
	"ASPIRIN" ACETYLSALICYLIC ACID	NAUSEA	162.5	mg	PRN	2009-03-23	2009-03-23

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 97 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4008	"ASPIRIN" ACETYLSALICYLIC ACID	LOW BACK PAIN	325	mg	PRN	2009-04-03	2009-04-03
	"ASPIRIN" ACETYLSALICYLIC ACID	CONTUSIONS FROM FALL	325	mg	PRN	2009-04-20	2009-04-22
	"ASPIRIN" ACETYLSALICYLIC ACID	LEFT MANDIBULAR PAIN	UNKNOWN	tablet	OTHER, SPECIFY, UNKNOWN	UNK	UNK
R4009	"NABUMETONE" NABUMETONE	ARTHRALGIA LEFT WRIST	500	mg	BID	2009-05-14	2009-06-17
	"TRAMADOL APAP" ULTRACET	ARTHRALGIA LEFT WRIST	1	tablet	PRN	2009-05-14	2009-06-17

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 98 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4010	"CALCIUM + VITAMIN D" CALCIUM D3 /01483701/	SUPPLEMENT	1	tablet	QD	2000	ONGOING
	"ESTRADIOL" ESTRADIOL	HORMONE REPLACEMENT THERAPY	2	mg	QD	2000	ONGOING
	"LISINOPRIL" LISINOPRIL	BLOOD PRESSURE	10	mg	QD	2000	ONGOING
	"VITAMIN D" VITAMIN D AND ANALOGUES	SUPPLEMENT	1	tablet	QD	2000	ONGOING
	"TYLENOL" PARACETAMOL	STRESS HEADACHE	2	tablet	Once	2009-03-10	2009-03-10

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 99 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4010	"RECLAST" ZOLEDRONIC ACID	SUPPLEMENT	1	other, specify: injection	Once	2009-04-22	2009-04-22
	"DEPO MEDROL" METHYLPREDNISOLONE ACETATE	ARTHRALGIA LEFT SHOULDER	80	mg	Once	2009-05-19	2009-05-19
	"OXYCODONE APAP" OXYCODONE/APAP	ARTHRALGIA LEFT SHOULDER	1	tablet	TID	2009-05-19	2009-05-22
	"AZITHROMYCIN" AZITHROMYCIN	COUGH	250	mg	QD	2009-08-15	2009-08-20
	"TUSSICAPS" TUSSIONEX PENNKINETIC	COUGH	1	other, specify: capsule	QD	2009-08-15	2009-08-20

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 100 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4011	"ESTRGN METHTEST" ESTRATEST HS	HORMONE REPLACEMENT THERAPY	2.5	mg	QD	1991	ONGOING
R4012	"ESTRACE CREAM" ESTRADIOL	HORMONE REPLACEMENT	2.5	mg	OTHER, SPECIFY, TWICE A WEEK	2009-01	ONGOING
	"IBUPROFEN" IBUPROFEN	HEAD COLD	800	mg	Once	2009-03-01	2009-03-01
	"TYLENOL COLD" COTYLENOL	HEAD COLD	2	tablet	Once	2009-03-01	2009-03-01
R4013	"ALEVE" NAPROXEN SODIUM	HEADACHE	2	tablet	Once	2009-03-02	2009-03-02

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 101 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4014	"ONE A DAY VITAMIN" ONE A DAY /02262701/	SUPPLEMENT	1	tablet	QD	2004	ONGOING
	"EXCEDRIN" THOMAPYRIN N	HEADACHE	2	other, specify: capsule	Once	2009-02-27	2009-02-27
	"NYQUIL" MEDINITE /00448801/	VIRAL URI	2	other, specify: tablespoons	QD	2009-04-04	2009-04-15
	"DAYQUIL" VICKS FORMULA 44M	VIRAL URI	2	other, specify: tablespoons	QD	2009-04-05	2009-04-15
R4015	"SUPHEDRINE" PSEUDOEPHEDRINE HYDROCHLORIDE	SINUS CONGESTION HEADACHE	60	mg	PRN	1998	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 102 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4015	"TRIAMINIC" TRIAMINIC EXPECTORANT / 00539501/	SINUS CONGESTION	1	other, specify: teaspoon	PRN	2000	ONGOING
	"CALCIUM + D" CALCIUM D3 /01483701/	SUPPLEMENT	1	tablet	QD	2006	ONGOING
	"MAGNESIUM" MAGNESIUM	SUPPLEMENT	1	tablet	QD	2007	ONGOING
	"ESTRING ESTRADIOL VAG RING" ESTRADIOL	HORMONE REPLACEMENT THERAPY	2	mg	OTHER, SPECIFY, EVERY 90 DAYS	2008-02-13	ONGOING
	"ASPIRIN" ACETYLSALICYLIC ACID	HEADACHE	650	mg	PRN	2009-04-07	2009-04-07

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 103 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4015	"BENEFIBER" CYAMOPSIS TETRAGONOLOBA GUM	CONSTIPATION	1-2	tablet	PRN	2009-04-16	UNK
	"ASPIRIN" ACETYLSALICYLIC ACID	POST DENTAL TREATMENT	650	mg	PRN	2009-05-19	2009-05-19
	"ASPIRIN" ACETYLSALICYLIC ACID	SINUS HEADACHE	325	mg	Once	2009-06-29	2009-06-29
R4016	"ZICAM" ZICAM /01792001/	NASAL CONGESTION	1	other, specify: spray	BID	2009-03-20	2009-03-23
	"FLEXERIL" CYCLOBENZAPRINE HYDROCHLORIDE	BACK PAIN	5	mg	QD	2009-04-14	2009-04-20

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 104 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4016	"LORTAB" VICODIN	BACK PAIN	5	mg	PRN	2009-04-14	2009-04-20
	"LORTAB" VICODIN	LEFT ANKLE SPRAIN	5	mg	PRN	2009-05-21	2009-05-21
	"PHENERGAN" PROMETHAZINE HYDROCHLORIDE	LEFT ANKLE SPRAIN	5	mg	PRN	2009-05-21	2009-05-21
	"FLU VACCINE" INFLUENZA VACCINE	VACCINATION	1	other, specify: injection	Once	2009-09-21	2009-09-21
R4017	"IBUPROFEN" IBUPROFEN	HEADACHE AND RHINORRHEA	400	mg	PRN	2009-03-13	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 105 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4017	"TYLENOL" PARACETAMOL	CATARACT REMOVAL	650	mg	PRN	2009-08-28	UNK
R4018	"ORTHO TRI-CYCLEN" CILEST	BIRTH CONTROL	1	tablet	QD	2008-09	ONGOING
	"TYLENOL EXTRA STRENGTH" PARACETAMOL	HEADACHE	1000	mg	PRN	2009-03-07	2009-03-07
	"CLARITIN" LORATADINE	VIRAL URI	1	tablet	QD	2009-03-19	2009-03-28
	"TYLENOL EXTRA STRENGTH" PARACETAMOL	VIRAL URI	1000	mg	PRN	2009-03-19	2009-03-26

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 106 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4018	"ROBITUSSIN" GUAIFENESIN	VIRAL URI	2	other, specify: teaspoon	QD	2009-03-25	2009-03-26
	"CLARITIN" LORATADINE	NASAL CONGESTION	1	tablet	PRN	2009-04-07	2009-04-12
	"NYQUIL" MEDINITE /00448801/	NASAL CONGESTION	UNKNOWN	other, specify: unknown	QD	2009-04-08	2009-04-12
	"LORTAB" VICODIN	STREP PHARYNGITIS	1-2	tablet	PRN	2009-05-06	2009-05-07
	"PENICILLIN" PENICILLIN NOS	STREP PHARYNGITIS, OTITIS MEDIA	1	other, specify: capsule	TID	2009-05-06	2009-05-09

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 107 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4018	"CLARITIN" LORATADINE	SEASONAL ALLERGIES	1	tablet	QD	2009-05-18	ONGOING
	"TYLENOL" PARACETAMOL	FEVER	500	mg	PRN	2009-07-29	UNK
	"Z-PACK" AZITHROMYCIN	ABDOMINAL PAIN	1	tablet	QD	2009-07-31	2009-08-02
	"CORTISONE" CORTISONE	ABDOMINAL PAIN	1	other, specify: injection	Once	2009-08-01	2009-08-01
	"HYDROCODONE" HYDROCODONE	ABDOMINAL PAIN	5	mg	PRN	2009-08-01	UNK

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 108 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4019	"ALEVE" NAPROXEN SODIUM	DYSMENORRHEA	440	mg	PRN	2009-05-13	2009-05-13
	"ASPIRIN" ACETYLSALICYLIC ACID	DYSMENORRHEA	81	mg	PRN	2009-05-13	2009-05-13
	"IBUPROFEN" IBUPROFEN	DYSMENORRHEA	200	mg	PRN	2009-05-13	2009-05-13
	"IBUPROFEN" IBUPROFEN	TEETH FILLING REPAIR	400	mg	Once	2009-08-10	2009-08-10
	"NOVOCAINE" PROCAINE HYDROCHLORIDE	TEETH FILLING REPAIR	1	other, specify: injection	Once	2009-08-10	2009-08-10

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 109 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4019	"WAL-PHED" PSEUDOEPHEDRINE HYDROCHLORIDE	MILD UPPER RESPIRATORY INFECTION	30	mg	PRN	2009-10-07	2009-10-09
R4020	"NON PSEUDOEPHEDRINE COLD RELIEF" COUGH AND COLD PREPARATIONS	NASAL CONGESTION	2	tablet	PRN	2007	2009-03-27
	"CENTRUM" CENTRUM /00554501/	SUPPLEMENT	1	tablet	QD	2008	ONGOING
	"SINUS AND PAIN" OTHER COLD COMBINATION PREPARATIONS	HEADACHE	2	tablet	QD	2009-04-01	UNK
	"TYLENOL" PARACETAMOL	UNKNOWN	2	tablet	QD	2009-04-10	2009-04-12

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 110 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4020	"TYLENOL" PARACETAMOL	VIRAL URI	2	tablet	PRN	2009-04-12	2009-09-30
	"TYLENOL" PARACETAMOL	UNKNOWN	2	tablet	QD	2009-04-14	UNK
	"UNKNOWN" ALL OTHER THERAPEUTIC PRODUCTS	SINUS HEADACHE	2	tablet	QD	2009-04-15	UNK
	"TYLENOL" PARACETAMOL	UNKNOWN	2	tablet	QD	2009-04-16	UNK
	"SINUS AND HEADACHE RELIEF" OTHER COLD COMBINATION PREPARATIONS	ALLERGIC RHINITIS	2	tablet	PRN	2009-04-20	2009-09-30

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 111 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4020	"NYQUIL" MEDINITE /00448801/	VIRAL UPPER RESPIRATORY INFECTION	1	other, specify: teaspoon	PRN	2009-04-24	2009-04-26
	"DAYQUIL" VICKS FORMULA 44M	VIRAL UPPER RESPIRATORY INFECTION	1	other, specify: teaspoon	QD	2009-04-27	2009-05-01
	"SINUS AND HEADACHE" OTHER COLD COMBINATION PREPARATIONS	SINUS HEADACHE/ALLER GIES	2	tablet	PRN	2009-06-19	UNK
	"TYLENOL" PARACETAMOL	ALLERGIC RHINITIS	650	mg	PRN	2009-07-15	2009-07-16
	"UNKNOWN" ALL OTHER THERAPEUTIC PRODUCTS	SINUS HEADACHE	2	tablet	QD	UNK	UNK

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 112 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4021	"CEPHALEXIN" CEFALEXIN MONOHYDRATE	SINUSITIS	250	mg	QID	2009-03-26	2009-04-02
	"PROMETHAZINE HYDROCHLORIDE" PROMETHAZINE HYDROCHLORIDE	SINUSITIS	2	other, specify: teaspoon	QID	2009-03-26	2009-04-02
	"DECADRON" DEXAMETHASONE	SINUSITIS	1	other, specify: injection	Once	2009-04-03	2009-04-03
	"BENADRYL" DIPHENHYDRAMINE HYDROCHLORIDE	SINUSITIS	1	tablet	PRN	2009-04-08	2009-04-15
R4022	"DIFLUCAN" FLUCONAZOLE	TOE NAIL FUNGUS	200	mg	Once	2009-05-25	2009-05-25

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 113 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4023	"VIVELLE" ESTRADIOL	HORMONE REPLACEMENT THERAPY	0.1	mg	OTHER, SPECIFY, TWICE A WEEK	2008-09	ONGOING
R4024	"PEPCID COMPLETE" FAMOTIDINE	HEARTBURN	1	tablet	PRN	2006	ONGOING
	"CENTRUM" CENTRUM /00554501/	SUPPLEMENT	1	tablet	QD	2009-01	ONGOING
	"ALLTELL" ALL OTHER NON-THERAPEUTIC PRODUCTS	INSOMNIA	1	tablet	PRN	2009-02	ONGOING
	"PERCOCET" OXYCOCET	BACK PAIN	1	tablet	QID	2009-05-08	2009-05-12

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 114 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4025	"ASPIRIN" ACETYLSALICYLIC ACID	CARDIAC HEALTH	81	mg	QD	2007	ONGOING
	"AVANDAMET" AVANDAMET	DIABETES	500	mg	QD	2007	ONGOING
	"LISINOPRIL" LISINOPRIL	HYPERTENSION	20	mg	QD	2007	ONGOING
	"CHEST CONGESTION RELIEF PE" GUA/PE	HEAD COLD	1	tablet	PRN	2009-03-13	2009-03-16
	"EQUATE NITE-TIME" DEXTROMETHORPHAN HBR W/ DOXYLAM. SUCC/PARACET.	HEAD COLD	2	tablet	PRN	2009-03-13	2009-03-16

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 115 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4026	"VITAMIN D" VITAMIN D AND ANALOGUES	SUPPLEMENT	2000	mg	QD	2009-07-10	ONGOING
	"NYQUIL" MEDINITE /00448801/	COUGH	UNKNOWN	other, specify: unknown	QD	2009-07-25	2009-07-28
R4027	"EXCEDRIN" THOMAPYRIN N	TENSION HEADACHE	975	mg	Once	2009-04-02	2009-04-02
	"EXCEDRIN" THOMAPYRIN N	HEADACHE	3	tablet	PRN	2009-04-21	UNK
	"BENADRYL" DIPHENHYDRAMINE HYDROCHLORIDE	INSECT BITES	2	tablet	QD	2009-07-12	UNK

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 116 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4027	"ADVIL" IBUPROFEN	HEADACHE	650	mg	Once	2009-08-04	2009-08-04
	"BENADRYL" DIPHENHYDRAMINE HYDROCHLORIDE	INSECT BITE	50	mg	Once	2009-08-04	2009-08-04
R4028	"CLARINEX" DESLORATADINE	ALLERGIES	5	mg	QD	1989	ONGOING
	"IRON" IRON	ANEMIA	65	mg	QD	1994	ONGOING
	"ZOLPIDEM" ZOLPIDEM	INSOMNIA	5	mg	PRN	2000	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 117 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4028	"CALCIUM" CALCIUM	SUPPLEMENT	500	mg	QD	2002	ONGOING
	"ESTRADIOL PATCH" ESTRADIOL	HOT FLASHES	0.05	mg	QS	2002	ONGOING
	"RHINOCORT" BUDESONIDE	ALLERGIES	32	ug	QD	2002	ONGOING
	"NEXIUM" ESOMEPRAZOLE SODIUM	HEARTBURN	80	mg	QD	2003	ONGOING
	"ROPINIROLE" ROPINIROLE	RESTLESS LEG SYNDROME	1	mg	QD	2008-10	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 118 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4028	"MIRAPEX" PRAMIPEXOLE DIHYDROCHLORIDE	RESTLESS LEG SYNDROME	1	tablet	QD	2009-05-20	ONGOING
	"BACTRIM" BACTRIM /00086101/	URINARY TRACT INFECTION	500	mg	BID	2009-07-30	2009-08-04
	"SUDAFED" PSEUDOEPHEDRINE HYDROCHLORIDE	ALLERGIES	2	tablet	PRN	2009-09-05	UNK
R4029	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	1994	ONGOING
	"SULFAMETHOXAZOLE" SULFAMETHOXAZOLE	DRY CHAPPED HANDS	1	tablet	BID	2009-04-04	2009-04-17

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 119 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4029	"PREDNISONONE" PREDNISONONE	DRY CHAPPED HANDS	20	mg	QID	2009-04-10	2009-04-17
	"WAL-DRYL ALLERGY" DIPHENHYDRAMINE	DRY AND ITCHING HANDS	1	other, specify: capsule	QD	2009-04-11	2009-04-14
	"IBUPROFEN" IBUPROFEN	HAND PAIN DUE TO ATOPIC DERMATITIS	400	mg	QD	2009-04-13	2009-04-13
	"ADVIL" IBUPROFEN	HEADACHE	400	mg	Once	2009-04-26	2009-04-26
R4030	"NONE"						

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 120 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4031	"B-12 VITAMIN" CYANOCOBALAMIN-TANNIN COMPLEX	SUPPLEMENT	500	mg	QD	2008	ONGOING
	"FISH OIL" FISH OIL	SUPPLEMENT	1000	mg	QD	2008	ONGOING
	"LECITHIN" LECITHIN	SUPPLEMENT	1200	mg	QD	2008	ONGOING
	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	2008	ONGOING
	"VITAMIN C" ASCORBIC ACID	SUPPLEMENT	500	mg	QD	2008	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 121 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4031	"ASPIRIN" ACETYLSALICYLIC ACID	PREVENTATIVE	81	mg	QD	2009-02	ONGOING
	"NASAL DECONGESTANT" NASAL DECONGESTANTS FOR SYSTEMIC USE	SINUS HEADACHE	2	tablet	Once	2009-03-30	2009-03-30
	"FIBER CHOICE" POLYCARBOPHIL CALCIUM	SUPPLEMENT	2	tablet	QD	2009-04	ONGOING
	"TYLENOL" PARACETAMOL	MUSCLE ACHES	1000	mg	Once	2009-04-13	2009-04-13
R4032	"DEPO-PROVERA" MEDROXYPROGESTERONE ACETATE	BIRTH CONTROL	1	other, specify: injection	OTHER, SPECIFY, EVERY THREE MONTHS	2007-08	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 122 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4032	"CALCIUM" CALCIUM	SUPPLEMENT	1	tablet	QD	2008-05	ONGOING
	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	2008-05	ONGOING
	"VITAMIN D" VITAMIN D AND ANALOGUES	SUPPLEMENT	1	tablet	QD	2008-05	ONGOING
	"VITAMIN E" TOCOPHEROL	SUPPLEMENT	1	tablet	QD	2008-05	ONGOING
	"TYLENOL" PARACETAMOL	VIRAL UPPER RESPIRATORY INFECTION	2	tablet	OTHER, SPECIFY, FREQUENCY UNKNOWN	2009-10-29	2009-11-02

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 123 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4033	"DULCOLAX" BISACODYL	BOWEL MOVEMENT	2	tablet	Once	2009-04-14	2009-04-14
	"TYLENOL" PARACETAMOL	TENSION HEADACHE	650	mg	Once	2009-04-14	2009-04-14
	"ZYRTEC" CETIRIZINE HYDROCHLORIDE	ALLERGIC RHINITIS	10	mg	PRN	2009-04-26	2009-04-26
	"HYDROXYZINE" HYDROXYZINE	ALLERGIC RHINITIS	25	mg	PRN	2009-05-17	2009-05-17
	"ALLEGRA D" GALENIC /FEXOFENADINE HCL/PSEUDOEPHEDRINE/	SEROUS OTITIS	1	tablet	QD	2009-06-01	2009-06-05

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 124 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4033	"AZITHROMYCIN" AZITHROMYCIN	SEROUS OTITIS	500	mg	QD	2009-06-01	2009-06-03
	"MILK OF MAGNESIA" MAGNESIUM HYDROXIDE	CONSTIPATION	15	g	BID	2009-06-04	2009-06-05
	"HYDROXYZINE" HYDROXYZINE	ALLERGIC RHINITIS	25	mg	PRN	2009-06-06	2009-06-07
	"METHYLPREDNISOLONE" METHYLPREDNISOLONE	CONTACT DERMATITIS	6	tablet	Once	2009-06-06	2009-06-06
	"TRIAMCINOLONE" TRIAMCINOLONE	CONTACT DERMATITIS	1	other, specify: application	QID	2009-06-06	2009-06-12

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 125 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4033	"METHYLPREDNISOLONE" METHYLPREDNISOLONE	CONTACT DERMATITIS	5	tablet	Once	2009-06-07	2009-06-07
	"METHYLPREDNISOLONE" METHYLPREDNISOLONE	CONTACT DERMATITIS	4	tablet	Once	2009-06-08	2009-06-08
	"METHYLPREDNISOLONE" METHYLPREDNISOLONE	CONTACT DERMATITIS	3	tablet	Once	2009-06-09	2009-06-09
	"METHYLPREDNISOLONE" METHYLPREDNISOLONE	CONTACT DERMATITIS	2	tablet	Once	2009-06-10	2009-06-10
	"METHYLPREDNISOLONE" METHYLPREDNISOLONE	CONTACT DERMATITIS	1	tablet	Once	2009-06-11	2009-06-11

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 126 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4033	"AMOX-TR-K" SPEKTRAMOX /02043401/	LACERATION LEFT LEG	1	tablet	BID	2009-06-14	2009-06-14
	"AVINZA" MORPHINE SULFATE	LACERATION LEFT LEG PAIN	1	tablet	PRN	2009-06-14	2009-06-14
	"NOVOCAINE" PROCAINE HYDROCHLORIDE	LACERATION LEFT LEG	1	other, specify: injection	Once	2009-06-14	2009-06-14
	"TETANUS" TETANUS VACCINE	LACERATION LEFT LEG	1	other, specify: injection	Once	2009-06-14	2009-06-14
	"ZOLPIDEM TARTRATE" ZOLPIDEM TARTRATE	INSOMNIA	10	mg	PRN	2009-06-14	2009-06-14

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 127 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4033	"MONISTAT 3" MICONAZOLE NITRATE	VAGINAL CANDIDIASIS	1	other, specify: application	Once	2009-06-15	2009-06-15
	"IMITREX" SUMATRIPTAN SUCCINATE	MIGRAINE HEADACHE	1	tablet	PRN	2009-06-16	2009-06-17
	"CEPHALEXIN" CEFALEXIN MONOHYDRATE	SINUSITIS	500	mg	QID	2009-09-04	2009-09-11
	"UNKNOWN" ALL OTHER THERAPEUTIC PRODUCTS	ALLERGIC RHINITIS	10	mg	PRN	2009-11-08	UNK
R4034	"EXCEDRIN ES" THOMAPYRIN N	MUSCLE ACHES	2	tablet	PRN	2008	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 128 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4034	"IBUPROFEN" IBUPROFEN	MUSCLE ACHES	400	mg	PRN	2008	ONGOING
R4035	"IBUPROFEN" IBUPROFEN	HEADACHE	600	mg	PRN	2009-05-14	2009-05-14
	"IBUPROFEN" IBUPROFEN	HEADACHE	400	mg	PRN	2009-05-31	2009-05-31
	"ALLEGRA" FEXOFENADINE HYDROCHLORIDE	VIRAL UPPER RESPIRATORY INFECTION	1	tablet	Once	2009-07-30	2009-07-30
	"BENADRYL" DIPHENHYDRAMINE HYDROCHLORIDE	VIRAL UPPER RESPIRATORY INFECTION	1	other, specify: capsule	Once	2009-07-30	2009-07-30

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 129 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4035	"ROBITUSSIN" GUAIFENESIN	VIRAL UPPER RESPIRATORY INFECTION	3	other, specify: tablespoons	PRN	2009-07-30	2009-08-15
	"AMOXICILLIN" AMOXICILLIN	VIRAL UPPER RESPIRATORY INFECTION	500	mg	TID	2009-07-31	2009-08-09
	"ZYRTEC" CETIRIZINE HYDROCHLORIDE	ALLERGIES	10	mg	QD	2009-09-07	2009-10-18
R4036	"NONE"						
R4037	"HCTZ" HYDROCHLOROTHIAZIDE	HYPERTENSION	12.5	mg	QD	2003	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 130 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4037	"OMEPRAZOLE" OMEPRAZOLE	GASTRO ESOPHAGEAL REFLUX DISEASE	40	mg	QD	2003	ONGOING
	"PROPRANOLOL" PROPRANOLOL	HYPERTENSION	40	mg	BID	2003	ONGOING
	"TETANUS VACCINE" TETANUS VACCINE	LACERATION LEFT HAND	1	other, specify: injection	Once	2009-06-06	2009-06-06
R4038	"METFORMIN" METFORMIN	DIABETES	850	mg	BID	1986	ONGOING
	"ACTOS" PIOGLITAZONE HYDROCHLORIDE	DIABETES	45	mg	QD	1990	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 131 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4038	"GAS RELIEF" DIMETICONE, ACTIVATED	GAS RELIEF	125	mg	PRN	2004	ONGOING
	"LISINOPRIL" LISINOPRIL	CHOLESTEROL	10	mg	QD	2004	ONGOING
	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	2004	ONGOING
	"LANTUS SOLOSTAR" INSULIN GLARGINE	DIABETES	10	other, specify: units	QHS	2008	ONGOING
	"PENICILLIN" PENICILLIN NOS	SINUSITIS	1	tablet	TID	2009-06-02	2009-06-21

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 132 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4039	"ASPIRIN" ACETYLSALICYLIC ACID	BACKACHE	650	mg	Once	2009-05-04	2009-05-04
	"NIGHT TIME COLD LIQUID" COUGH AND COLD PREPARATIONS	COUGH	1	other, specify: tablespoon	Once	2009-11-03	2009-11-03
R4040	"ASPIRIN" ACETYLSALICYLIC ACID	HEADACHE	500	mg	PRN	2006-05-05	2009-05-27
	"RANITIDINE" RANITIDINE	HEARTBURN	150	mg	BID	2009-04-22	2009-04-22
	"ASPIRIN" ACETYLSALICYLIC ACID	HEADACHE	500	mg	Once	2009-04-26	2009-04-26

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 133 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4040	"IMODIUM" LOPERAMIDE HYDROCHLORIDE	GASTROENTERITIS	1-2	tablet	PRN	2009-09-15	2009-09-16
	"PEPTO-BISMOL" BISMUTH SUBSALICYLATE	GASTROENTERITIS	1-2	other, specify: tablespoons	PRN	2009-09-15	2009-09-16
	"MOTRIN" IBUPROFEN	MYALGIA	600	mg	BID	2009-11-09	ONGOING
R4041	"EXCEDRIN" THOMAPYRIN N	HEADACHE	2	tablet	PRN	2009-05-15	2009-05-15
	"ESTRACE" ESTRADIOL	HORMONE REPLACEMENT THERAPY	1	other, specify: patch	BID	2009-09-09	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 134 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4042	"LEVAQUIN" LEVOFLOXACIN	OTITIS MEDIA	500	mg	QD	2009-07-01	2009-07-07
	"ROCEPHIN" CEFTRIAZONE SODIUM	OTITIS MEDIA	3	mg	QD	2009-07-01	2009-07-07
R4043	"MULTIVITAMIN" MULTIVITAMINS	HEALTH AID	1	tablet	QD	2009-03	ONGOING
	"PREMPRO" PROVELLA-14	HORMONE REPLACEMENT THERAPY	1	tablet	QD	2009-03	ONGOING
	"TYLENOL" PARACETAMOL	NECK MUSCLE STRAIN	2	tablet	PRN	2009-05-05	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 135 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4044	"NONE"						
R4045	"PRO FEMA VITAMIN" ALL OTHER NON-THERAPEUTIC PRODUCTS	SUPPLEMENT	1	tablet	OTHER, SPECIFY, 3 TIMES A WEEK	2008-09	2009-04-07
	"COD LIVER OIL" COD-LIVER OIL	SUPPLEMENT	1	other, specify: capsule	OTHER, SPECIFY, THREE TIMES WEEK	2009-01	2009-04-07
	"MELATONIN" MELATONIN	INSOMNIA	600	ug	PRN	2009-06-10	ONGOING
	"ADVIL" IBUPROFEN	HEADACHE	1	tablet	PRN	2009-07-28	2009-08-04

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 136 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4045	"CIMIFIN" ALL OTHER NON-THERAPEUTIC PRODUCTS	HOT FLASHES	140	mg	QD	2009-08-19	ONGOING
R4046	"LIPITOR" ATORVASTATIN CALCIUM	CHOLESTEROL	20	mg	QD	2005	ONGOING
	"TYLENOL PM" TYLENOL PM /01088101/	INSOMNIA	1000	mg	QHS	2005	ONGOING
	"ZETIA" EZETIMIBE	CHOLESTEROL	10	mg	QD	2006	ONGOING
	"CIALIS" TADALAFIL	ERECTILE DYSFUNCTION	5	mg	OTHER, SPECIFY, TWICE WEEKLY	2008-02-14	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 137 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4046	"IBUPROFEN" IBUPROFEN	CHRONIC KNEE PAIN	200	mg	PRN	2009-05-02	2009-06-16
	"ASPIRIN" ACETYLSALICYLIC ACID	VIRAL SYNDROME	650	mg	PRN	2009-05-18	2009-05-19
	"ASPIRIN" ACETYLSALICYLIC ACID	CHRONIC KNEE PAIN	650	mg	PRN	2009-06-17	ONGOING
R4047	"NUTRILITE" ALL OTHER NON-THERAPEUTIC PRODUCTS	SUPPLEMENT	1	tablet	QD	1990	ONGOING
	"ANTI FUNGAL CREAM" ANTIFUNGALS	ATHLETE'S FOOT	1	other, specify: application	OTHER, SPECIFY, Once MONTHLY	2006	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 138 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4047	"LORATADINE" LORATADINE	ALLERGIES	10	mg	QD	2009-04-17	2009-04-18
	"NOVOCAINE" PROCAINE HYDROCHLORIDE	MOLE REMOVAL	UNK	other, specify: injection	Once	2009-05-23	2009-05-23
R4048	"SIMVASTATIN" SIMVASTATIN	HIGH CHOLESTEROL	20	mg	QD	2009-04-28	ONGOING
R4049	"IMITREX" SUMATRIPTAN SUCCINATE	MIGRAINES	1	other, specify: injection	PRN	2002	ONGOING
	"METHADONE" METHADONE	NECK PAIN	5	mg	QID	2002	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 139 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4049	"OXYCODONE" OXYCODONE	NECK PAIN	1	tablet	PRN	2002	ONGOING
	"PHENERGAN" PROMETHAZINE HYDROCHLORIDE	NAUSEA	25	mg	PRN	2002	ONGOING
	"IMITREX" SUMATRIPTAN SUCCINATE	MIGRAINES	50	mg	PRN	2003	ONGOING
	"REGLAN" METOCLOPRAMIDE HYDROCHLORIDE	NAUSEA	10	mg	PRN	2003	ONGOING
	"ZANTAC" RANITIDINE HYDROCHLORIDE	HEARTBURN	150	mg	QD	2004	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 140 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4049	"MIRALAX" MACROGOL	CONSTIPATION	2	other, specify: tablespoons	QD	2006	ONGOING
	"NAPROXEN" NAPROXEN	INFLAMMATION DUE TO NECK PAIN	500	mg	OTHER, SPECIFY, 1-3 TIMES DAILY	2009	ONGOING
	"VESICARE" SOLIFENACIN SUCCINATE	OVERACTIVE BLADDER	10	mg	QD	2009	ONGOING
	"MUCINEX" GUAIFENESIN	VIRAL UPPER RESPIRATORY INFECTION	1	tablet	QD	2009-11-20	2009-11-27
R4050	"ASPIRIN" ACETYLSALICYLIC ACID	CARDIAC PROPHYLAXIS	81	mg	QD	2000	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 141 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4050	"GINKGO BILOBA" GINKGO BILOBA	SUPPLEMENT	60	mg	QD	2000	ONGOING
	"GLUCOSAMINE CHONDROITIN" GLUCOSAMINE W/ CHONDROITIN SULFATE	SUPPLEMENT	1	other, specify: capsule	QD	2000	ONGOING
	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	2000	ONGOING
	"VITAMIN D" VITAMIN D AND ANALOGUES	SUPPLEMENT	1000	other, specify: iu	QD	2000	ONGOING
	"ALLEGRA" FEXOFENADINE HYDROCHLORIDE	SINUS ALLERGIES	180	mg	QD	2007	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 142 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4050	"FISH OIL" FISH OIL	SUPPLEMENT	1	tablet	QD	2008	ONGOING
	"LASIX" FUROSEMIDE SODIUM	PEDAL EDEMA	20	mg	QOD	2009-06-29	2009-09-29
	"POTASSIUM CHLORIDE EXTENDED RELEASE" POTASSIUM CHLORIDE	PEDAL EDEMA	10	mg	QOD	2009-06-29	2009-09-29
R4051	"VYTORIN" INEGY	HIGH CHOLESTEROL	1	tablet	QD	2009-06-05	ONGOING
R4052	"LEVOTHYROXINE" LEVOTHYROXINE	HYPOTHYROIDISM	112	mg	QD	1999	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 143 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4053	"MIDRIN" MIDRID /00450801/	MIGRAINE HEADACHE	1	other, specify: cap	PRN	2009-08-03	2009-08-04
	"CHANTIX" VARENICLINE TARTRATE	SMOKING CESSATION	UNK	other, specify: unk	OTHER, SPECIFY, UNK	2009-08-24	ONGOING
R4054	"LISINOPRIL" LISINOPRIL	HYPERTENSION	1	tablet	QD	2004	ONGOING
	"LOVASTATIN" LOVASTATIN	CHOLESTEROL	40	mg	OTHER, SPECIFY, EVERY FIVE HOURS	2004	ONGOING
	"ONE A DAY VITAMIN" ONE A DAY /02262701/	SUPPLEMENT	1	tablet	QD	2004	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 144 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4055	"AMOXICILLIN" AMOXICILLIN	OTITIS	125	mg	BID	2009-09-24	2009-10-04
	"LOHIST" LORATADINE	OTITIS	45	mg	BID	2009-09-24	2009-10-04
	"CEFUROXIME AXETIL" CEFUROXIME AXETIL	OTITIS	500	mg	BID	2009-10-30	2009-11-08
	"IBUPROFEN" IBUPROFEN	OTITIS	800	mg	PRN	2009-10-30	2009-11-08
	"MUCINEX D" RESPAIRE-SR-120	COUGH	1	tablet	BID	2009-10-30	2009-11-08

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 145 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4055	"DELSYM" DEXTROMETHORPHAN HYDROBROMIDE	COUGH	2	other, specify: teaspoons	PRN	2009-11-03	2009-11-08
	"HEP B VACCINE" HEPATITIS B VACCINE	PROPHYLAXIS	1	other, specify: injection	Once	2009-11-19	2009-11-19
R4056	"IBUPROFEN" IBUPROFEN	LEG ACHES	400	mg	Once	2009-05-27	2009-05-27
	"PHENTERMINE" PHENTERMINE	WEIGHT LOSS	37.5	mg	QD	2009-06-30	ONGOING
	"SHOTZ ENERGY" ALL OTHER NON-THERAPEUTIC PRODUCTS	TO STAY AWAKE	1	other, specify: drink	QS	UNK	2009-05-20

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 146 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4057	"CIPROFLOXACIN HCL" CIPROFLOXACIN HYDROCHLORIDE	BLADDER INFECTION	500	mg	BID	2009-05-22	2009-06-01
R4058	"NATURAL C" ASCORBIC ACID	SUPPLEMENT	500	mg	BID	2004	ONGOING
	"B-12" CYANOCOBALAMIN-TANNIN COMPLEX	SUPPLEMENT	500	ug	QD	2007	ONGOING
	"WOMEN'S ONE A DAY" ONE-A-DAY WOMEN'S	SUPPLEMENT	1	tablet	QD	2007	ONGOING
	"B COMPLEX" B COMPLEX /02945401/	SUPPLEMENT	1	tablet	QD	2008	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 147 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4058	"NATURAL VITAMIN D" VITAMIN D AND ANALOGUES	SUPPLEMENT	400	other, specify: iu	BID	2008	ONGOING
	"OMEGA 3 FISH OIL" FISH OIL	SUPPLEMENT	2000	mg	BID	2008	ONGOING
	"VITAMIN E" TOCOPHEROL	SUPPLEMENT	400	other, specify: iu	QD	2009-06-08	ONGOING
	"EXTRA STRENGTH EXCEDRIN BACK AND BODY" THOMAPYRIN N	OCCASIONAL LOW BACK PAIN	2	other, specify: caplets	PRN	2009-08-15	2009-08-15
	"IBUPROFEN" IBUPROFEN	HEADACHE	400	mg	PRN	2009-09-16	2009-09-30

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 148 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4059	"SIMVASTATIN" SIMVASTATIN	CHOLESTEROL	80	mg	QD	1998	ONGOING
	"ASPIRIN" ACETYLSALICYLIC ACID	PREVENTATIVE	81	mg	QD	2004	ONGOING
	"METFORMIN HCL ER" METFORMIN HYDROCHLORIDE	DIABETES	1000	mg	QHS	2004	ONGOING
	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	2004	ONGOING
	"LISINOPRIL" LISINOPRIL	HYPERTENSION	10	mg	QD	2008	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 149 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4059	"GLIPIZIDE" GLIPIZIDE	DIABETES	10	mg	QAM	2009-05-01	ONGOING
R4060	"OMEPRAZOLE" OMEPRAZOLE	ACID REFLUX	20	mg	QOD	2002	ONGOING
	"AMLODIPINE BESYLATE" AMLODIPINE BESILATE	ELEVATED BLOOD PRESSURE	5	mg	QHS	2008	ONGOING
	"ASPIRIN" ACETYLSALICYLIC ACID	GENERAL HEALTH	81	mg	QD	2008	ONGOING
	"BENICAR HCT" BENICAR HCT	ELEVATED BLOOD PRESSURE	1	tablet	QD	2008	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 150 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4060	"THERAGRAN M" THERAGRAN /00554301/	GOOD HEALTH	1	tablet	QD	2008	ONGOING
	"ALEVE" NAPROXEN SODIUM	ODONTALGIA	1	tablet	QD	2009-07-12	2009-07-14
	"CEPHALEXIN" CEFALEXIN MONOHYDRATE	ODONTALGIA	500	mg	QID	2009-07-12	2009-07-14
	"ANTACID" ANTACIDS	DYSPEPSIA	3	tablet	PRN	2009-07-30	ONGOING
	"DIMETAPP" GUAIFENESIN	VIRAL UPPER RESPIRATORY INFECTION	2	other, specify: tablespoons	PRN	2009-09-05	2009-09-08

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 151 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4061	"EXCEDRIN" THOMAPYRIN N	HEADACHE	2	tablet	Once	2009-06-19	2009-06-19
R4062	"ALEVE" NAPROXEN SODIUM	NEURALGIA RIGHT LEG	2	tablet	PRN	2009-08-27	2009-11-20
	"PRILOSEC" OMEPRAZOLE MAGNESIUM	DYSPEPSIA	1	tablet	PRN	2009-09-03	2009-09-18
R4063	"ASPIRIN" ACETYLSALICYLIC ACID	PREVENTATIVE	81	mg	QD	2006	ONGOING
	"LISINOPRIL" LISINOPRIL	HYPERTENSION	20	mg	QD	2006	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 152 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4063	"SIMVASTATIN" SIMVASTATIN	HYPERCHOLESTEROLEMIA	40	mg	QD	2009-01	ONGOING
	"FLU SHOT" INFLUENZA VACCINE	PROPHYLAXIS	1	other, specify: shot	Once	2009-10-11	2009-10-11
R4064	"TYLENOL PM" TYLENOL PM /01088101/	INSOMNIA	3	other, specify: capsule	OTHER, SPECIFY, 1X PER WEEK PRN	2008	ONGOING
	"WALGREENS COUGH MEDICINE" COUGH AND COLD PREPARATIONS	COUGH	2	other, specify: tablespoons	PRN	2009-09-01	2009-09-08
R4065	"TYLENOL EXTRA STRENGTH" PARACETAMOL	HEADACHE	1	tablet	Once	2009-07-29	2009-07-29

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 153 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4065	"HALLS" HALL'S MENTHO-LYPTUS	COUGH	1	tablet	PRN	2009-09-09	2009-10-25
	"CAMEL SNUS" NICOTINE	SMOKING CESSATION	10	other, specify: pouches	QD	2009-12-02	2010-02-15
R4066	"FLEXERIL" CYCLOBENZAPRINE HYDROCHLORIDE	SHOULDER PAIN	1	tablet	Once	2009-06-12	2009-06-12
R4067	"TRAZODONE" TRAZODONE	INSOMNIA	200	mg	QHS	2004	ONGOING
	"DARVOCET" PROPACET	FIBROMYALGIA	1	tablet	QD	2006	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 154 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4067	"TIZANIDINE HCL" TIZANIDINE HYDROCHLORIDE	FIBROMYALGIA	8	mg	PRN	2006	ONGOING
	"IMITREX" SUMATRIPTAN SUCCINATE	MIGRAINES	6	mg	PRN	2007	ONGOING
	"ZOMIG" ZOLMITRIPTAN	MIGRAINES	2.5	mg	PRN	2009-02	ONGOING
	"OMEPRAZOLE" OMEPRAZOLE	ACID REFLUX	20	mg	QD	2009-04	ONGOING
	"EXCEDRIN MIGRAINE" THOMAPYRIN N	MIGRAINES	2	tablet	PRN	2009-05	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 155 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4067	"SILVADENE" SULFADIAZINE SILVER	SUNBURN	1	other, specify: application	PRN	2009-06-06	2009-06-06
	"NORCO HYDROCODONE" VICODIN	ARTHRALGIA - KNEE	1	tablet	BID	2009-06-29	ONGOING
R4068	"ESTRADIOL" ESTRADIOL	HORMONE REPLACEMENT THERAPY	1	other, specify: patch	QS	2007	ONGOING
	"AZITHROMYCIN" AZITHROMYCIN	VIRAL SYNDROME	500	mg	QD	2009-09-25	2009-09-30
	"ROBITUSSIN COUGH SYRUP" GUAIFENESIN	VIRAL SYNDROME	1	other, specify: teaspoon	PRN	2009-09-25	2009-09-30

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 156 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4068	"TAMIFLU" OSELTAMIVIR PHOSPHATE	VIRAL SYNDROME	75	mg	BID	2009-09-25	2009-09-30
	"XOPENEX HFA" LEVOSALBUTAMOL TARTRATE	VIRAL SYNDROME	2	other, specify: puffs	QID	2009-09-25	2009-09-30
R4069	"NONE"						
R4070	"TUMS" CALCIUM CARBONATE	HEARTBURN	2	tablet	PRN	2008	ONGOING
	"SKELAXIN" CLONIXIN LYSINATE	BACK PAIN	1	other, specify: injection	Once	2009-08-06	2009-08-06

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 157 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4070	"CHLORASEPTIC THROAT SPRAY" PHENOL	DENTAL INFECTION	1	other, specify: spray	PRN	2009-09-08	2009-09-12
	"PEN VK" PHENOXYMETHYLPENICILLIN POTASSIUM	DENTAL INFECTION	500	mg	QID	2009-09-09	2009-09-19
R4071	"NONE"						
R4072	"VIAGRA" SILDENAFIL CITRATE	ERECTILE DYSFUNCTION	100	mg	PRN	1997	ONGOING
	"SPECTRAVITE" ALL OTHER NON-THERAPEUTIC PRODUCTS	SUPPLEMENT	1	tablet	QD	1999	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 158 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4072	"VALTREX" VALACICLOVIR HYDROCHLORIDE	GENITAL HERPES	500	mg	BID	1999	ONGOING
	"GABAPENTIN" GABAPENTIN	NEUROPATHY	600	mg	TID	2006	ONGOING
	"FLOMAX" TAMSULOSIN HYDROCHLORIDE	BENIGN PROSTATIC HYPERTROPHY	0.4	mg	QD	2008	ONGOING
	"PANTOPRAZOLE" PANTOPRAZOLE	HEARTBURN	40	mg	QD	2009-05	ONGOING
	"GEMFIBROZIL" GEMFIBROZIL	HYPERTRIGLYCERD EMIA	600	mg	BID	2009-07-27	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 159 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4073	"CYMBALTA" DULOXETINE HYDROCHLORIDE	DEPRESSION/BIPOLAR	120	mg	QD	2006	ONGOING
	"TEMAZEPAM" TEMAZEPAM	INSOMNIA	30	mg	QHS	2007	ONGOING
	"LAMOTRIGINE" LAMOTRIGINE	BIPOLAR	150	mg	BID	2008	ONGOING
	"1% TRIFLURIDINE" TRIFLURIDINE	HERPES INFECTION OF RIGHT EYE	1	other, specify: drop	OTHER, SPECIFY, EVERY THREE HOURS AS NEEDED	2009-06	ONGOING
	"SULFAMETHOXAZOLE TMP" BACTRIM /00086101/	SKIN INFECTION BACK OF NECK	2	tablet	BID	2009-08-20	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 160 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4074	"NONE"						
R4075	"IBUPROFEN" IBUPROFEN	KNEE PAIN	400	mg	PRN	2009-06-12	ONGOING
	"MUCINEX D" RESPIRE-SR-120	NASAL CONGESTION	2	tablet	QD	2009-08-22	ONGOING
	"AMOXICILLIN" AMOXICILLIN	BRONCHITIS	500	mg	TID	2009-09-12	2009-09-22
	"SUDAFED" PSEUDOEPHEDRINE HYDROCHLORIDE	CONGESTION	30	mg	Once	2009-10-28	2009-10-28

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 161 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4076	"NICOTINE PATCH" NICOTINE	SMOKING CESSATION	21	mg	QD	2009-09-28	ONGOING
R4077	"IBUPROFEN" IBUPROFEN	MENSTRUAL CRAMPS	400	mg	OTHER, SPECIFY, EVERY FOURS HOURS AS NEEDED	2002	ONGOING
	"PM PAIN RELIEVER" OTHER ANALGESICS AND ANTIPYRETICS	MENSTRUAL CRAMPS	1000	mg	PRN	2002	ONGOING
	"COMPLETE ALLERGY" DIPHENHYDRAMINE HYDROCHLORIDE	ALLERGIC RHINITIS	50	mg	BID	2003	ONGOING
R4078	"PRILOSEC" OMEPRAZOLE MAGNESIUM	HEARTBURN	20	mg	QD	2000	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 162 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4079	"PRENATAL VITAMINS" PRENATAL VITAMINS / 01549301/	PRE AND POST NATAL	1	tablet	QD	2008	2009-08-24
	"ZYRTEC" CETIRIZINE HYDROCHLORIDE	SEASONAL ALLERGIES	10	mg	QD	2008-10	ONGOING
	"AMBIEN" ZOLPIDEM TARTRATE	INSOMNIA	1	tablet	PRN	2009	2009-10-14
	"BETAMETHASONE" BETAMETHASONE	DERMATITIS- HANDS	1	other, specify: application	TID	2009-01-05	ONGOING
	"AMOXICILLIN" AMOXICILLIN	INFECTED TOOTH	250	mg	QID	2009-06-01	2009-06-05

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 163 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4079	"DIFLUCAN" FLUCONAZOLE	PREVENTATIVE	1	tablet	Once	2009-06-05	2009-06-05
	"PHENTERMINE HCL" PHENTERMINE HYDROCHLORIDE	WEIGHT LOSS	30	mg	QD	2009-07-30	2009-08-17
	"ALPRAZOLAM" ALPRAZOLAM	ANXIETY	0.5	mg	TID	2009-08-06	2009-10-07
	"LEXAPRO" ESCITALOPRAM OXALATE	ANXIETY	20	mg	QD	2009-09-04	2009-09-06
	"KLONOPIN" CLONAZEPAM	INSOMNIA	2.5	mg	QD	2009-09-07	UNK

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 164 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4079	"DIFLUCAN" FLUCONAZOLE	DERMATITIS- HANDS	10	mg	QD	2009-10-28	2009-11-28
	"DOXYCYCLINE" DOXYCYCLINE	PNEUMONIA	100	mg	BID	2009-11-07	2009-11-21
	"ROBITUSSIN DM" TUSSIN DM	PNEUMONIA	1	other, specify: tablespoon	PRN	2009-11-07	2009-11-07
	"KLONOPIN" CLONAZEPAM	INSOMNIA	0.5	mg	QID	UNK	ONGOING
R4080	"NONE"						

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 165 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4081	"ALEVE" NAPROXEN SODIUM	MUSCLE ACHES	2	tablet	Once	2009-06-21	2009-06-21
R4082	"HYDROCODONE" HYDROCODONE	BACK PAIN	1	tablet	PRN	2006	2009-06-08
	"PM PAIN RELIEF" OTHER ANALGESICS AND ANTIPYRETICS	INSOMNIA	2	tablet	QHS	2008	2009-06-10
	"BACTRIM" BACTRIM /00086101/	MRSA	500	mg	TID	2009-07-25	ONGOING
R4083	"ATENOLOL" ATENOLOL	HYPERTENSION	50	mg	BID	2008	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 166 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4084	"IBUPROFEN" IBUPROFEN	FOOT PAIN	200	mg	PRN	2009-01	ONGOING
	"MEDROL DOSEPAK" METHYLPREDNISOLONE	PLANTAR FASCIITIS PAIN	UNKNOWN	tablet	OTHER, SPECIFY, DESCENDING DOSE	2009-08-11	2009-08-14
R4085	"PREDNISONE" PREDNISONE	ALLERGIC REACTION	20	mg	Once	2009-07-04	2009-07-04
	"WAL-DRYL" DIPHENHYDRAMINE	ALLERGIC REACTION	2	tablet	Once	2009-07-04	2009-07-04
	"PREDNISONE" PREDNISONE	ALLERGIC REACTION	10	mg	QD	2009-07-05	2009-07-15

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 167 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4085	"WAL-DRYL" DIPHENHYDRAMINE	ALLERGIC REACTION	1	tablet	QD	2009-07-05	2009-07-07
	"STEROID" CORTICOSTEROID NOS	UNKNOWN	UNKNOWN	other, specify: unknown	OTHER, SPECIFY, UNKNOWN	UNK	UNK
R4086	"NONE"						
R4087	"SYNTHROID" LEVOTHYROXINE SODIUM	HYPOTHYROIDISM	100	ug	QD	1994	ONGOING
	"MULTIVITAMIN" MULTIVITAMINS	TO PREVENT ACHES (GENERAL)	500	mg	BID	2000	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 168 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4087	"PRINZIDE" PRINZIDE /00977901/	HYPERTENSION	1	tablet	QOD	2005	ONGOING
	"ALEVE" NAPROXEN SODIUM	"NO REASON"	220	mg	QD	2007	ONGOING
	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	2008	ONGOING
	"ERYTHROMYCIN" ERYTHROMYCIN	BRONCHITIS	2	tablet	Once	2009-08-17	2009-08-17
	"ERYTHROMYCIN" ERYTHROMYCIN	BRONCHITIS	1	tablet	QD	2009-08-18	2009-08-27

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 169 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4088	"MIRENA" LEVONORGESTREL	CONTRACEPTION	1	other, specify: iud	OTHER, SPECIFY, UNKNOWN	2006	ONGOING
	"BAYER" ACETYLSALICYLIC ACID	GENERAL PAIN	2	tablet	Once	2009-06-15	2009-06-15
	"BAYER PM" ACETYLSALICYLIC ACID	KNEE PAIN	2	tablet	Once	2009-06-18	2009-06-18
	"SUDAFED" PSEUDOEPHEDRINE HYDROCHLORIDE	HEADACHE	10	mg	Once	2009-06-20	2009-06-20
	"TYLENOL SINUS" TYLENOL SINUS MEDICATION	CONGESTION	2	tablet	Once	2009-07-01	2009-07-01

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 170 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4088	"BENADRYL" DIPHENHYDRAMINE HYDROCHLORIDE	SEASONAL ALLERGIES	1	tablet	Once	2009-07-02	2009-07-02
	"IBUPROFEN" IBUPROFEN	BACK PAIN	800	mg	PRN	2009-08-10	UNK
R4089	"PRILOSEC OTC" OMEPRAZOLE MAGNESIUM	GERD	20	mg	QD	2003	ONGOING
	"BENADRYL TOPICAL CREAM" DIPHENHYDRAMINE HYDROCHLORIDE	CONTACT DERMATITIS	1	other, specify: application	TID	2009-07-10	2009-07-18
	"BENADRYL" DIPHENHYDRAMINE HYDROCHLORIDE	CONTACT DERMATITIS	50	mg	BID	2009-07-10	2009-07-18

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 171 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4089	"BENADRYL TOPICAL CREAM" DIPHENHYDRAMINE HYDROCHLORIDE	CONTACT DERMATITIS	1	other, specify: application	TID	2009-09-01	2009-09-11
	"BENADRYL" DIPHENHYDRAMINE HYDROCHLORIDE	CONTACT DERMATITIS	50	mg	BID	2009-09-01	2009-09-11
R4090	"IBUPROFEN" IBUPROFEN	DYSMENORRHEA	200	mg	Once	2009-06-05	2009-06-05
R4091	"TYLENOL EX" PARACETAMOL	HEADACHE	1	other, specify: caplet	Once	2009-07-06	2009-07-06
	"TYLENOL" PARACETAMOL	HEADACHE	1	other, specify: caplet	Once	2010-02-03	2010-02-03

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 172 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4092	"CLONAZEPAM" CLONAZEPAM	INSOMNIA	1	mg	PRN	2006	UNK
	"ROPINIROLE" ROPINIROLE	INSOMNIA	1	mg	PRN	2009-01	UNK
	"B COMPLEX" B COMPLEX /02945401/	SUPPLEMENT	1	tablet	QD	2009-06	UNK
	"TOP CARE PAIN RELIEF" PARACETAMOL	ARTHRALGIA KNEE PAIN	440	mg	QD	2009-06	UNK
	"AMOXICILLIN" AMOXICILLIN	SINUSITIS	500	mg	TID	2009-07-14	2009-07-24

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 173 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4093	"VIAGRA" SILDENAFIL CITRATE	ERECTILE DYSFUNCTION	1	tablet	PRN	1999	ONGOING
R4094	"ALLERGY SHOT" ALL OTHER THERAPEUTIC PRODUCTS	SEASONAL ALLERGIES	1	other, specify: injection	OTHER, SPECIFY, EVERY MONTH	2008	ONGOING
	"TRIAMTERENE/HCTZ" DIAZIDE	DIURETIC	1	other, specify: capsule	QD	2008-06	ONGOING
	"FISH OIL" FISH OIL	SUPPLEMENT	1200	mg	BID	2008-09	ONGOING
	"PLAQUENIL" HYDROXYCHLOROQUINE	RHEUMATOID ARTHRITIS	200	mg	QD	2008-09	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 174 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4094	"MELOXICAM" MELOXICAM	RHEUMATOID ARTHRITIS	15	mg	QD	2008-11	ONGOING
	"METHOTREXATE" METHOTREXATE	RHEUMATOID ARTHRITIS	15	mg	OTHER, SPECIFY, TWICE WEEKLY	2009-02	ONGOING
	"FOLIC ACID" FOLIC ACID	SUPPLEMENT	1	mg	QD	2009-05	ONGOING
	"POTASSIUM GLUCONATE" POTASSIUM GLUCONATE	SUPPLEMENT TO PREVENT LEG CRAMPS	550	mg	QD	2009-05	ONGOING
R4095	"NONE"						

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 175 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4096	"ORTHO TRICYCLEN LO" CILEST	CONTRACEPTION	1	tablet	QD	2001	2009-06
	"YAZ" DROSPIRENONE W/ ETHINYLESTRADIOL	CONTRACEPTION	1	tablet	QD	2009-06	ONGOING
	"XYZAL" LEVOCETIRIZINE DIHYDROCHLORIDE	CONTACT DERMATITIS	5	mg	QD	2009-07-10	2009-08-11
	"ALEVE" NAPROXEN SODIUM	SPRAINED ANKLE	440	mg	QD	2009-07-21	2009-07-23
	"ALKA-SELTZER PLUS" ACETYLSALICYLIC ACID	INFLUENZA	2	tablet	PRN	2009-07-26	2009-07-28

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 176 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4096	"DAYQUIL" VICKS FORMULA 44M	INFLUENZA	1	other, specify: capsule	QD	2009-07-28	2009-08-02
	"NYQUIL" MEDINITE /00448801/	INFLUENZA	1	other, specify: capsule	QD	2009-07-28	2009-08-02
	"ZICAM" ZICAM /01792001/	INFLUENZA	1	other, specify: spray	QD	2009-07-28	2009-08-02
	"METHYLPREDNISOLONE" METHYLPREDNISOLONE	CONTACT DERMATITIS	7	mg	QD	2009-08-15	2009-09-14
	"DICLOFENAC SODIUM" DICLOFENAC SODIUM	NEURALGIA UPPER EXTREMITIES	50	mg	BID	2009-08-19	2009-09-02

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 177 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4096	"GABAPENTIN" GABAPENTIN	NEURALGIA UPPER EXTREMITIES	300	mg	QD	2009-08-19	2009-08-25
	"GABAPENTIN" GABAPENTIN	NEURALGIA UPPER EXTREMITIES	300	mg	TID	2009-08-26	2009-09-02
R4097	"BETA CAROTENE" BETACAROTENE	SUPPLEMENT	25000	other, specify: iu	QOD	2008	ONGOING
	"VITAMIN A" RETINOL	SUPPLEMENT	8000	other, specify: iu	QD	2008	ONGOING
	"NYQUIL" MEDINITE /00448801/	COUGH	1	other, specify: dose	Once	2009-08-14	2009-08-14

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 178 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4097	"FLUOCINONIDE" FLUOCINONIDE	ECZEMA CHEST	1	other, specify: tablespoon, cream	PRN	2009-10-24	2009-10-27
R4098	"YASMIN" DROSPIRENONE W/ ETHINYLESTRADIOL	CONTRACEPTION	1	tablet	QD	1995	2009-09-12
	"ALLEGRA D" GALENIC /FEXOFENADINE HCL/PSEUDOEPHEDRINE/	ALLERGIES	0.5	tablet	PRN	2008	ONGOING
	"NEXIUM" ESOMEPRAZOLE SODIUM	ACID REFLUX	40	mg	QD	2009-03	2009-08-15
	"MISOPROSTOL" MISOPROSTOL	PRE ESSURE PROCEDURE	200	mg	BID	2009-06-23	2009-06-23

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 179 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4098	"DOXYCYCLINE HYC" DOXYCYCLINE HYCLATE	POST ESSURE PROCEDURE	100	mg	BID	2009-06-24	2009-06-26
	"HYDROCODONE" HYDROCODONE	POST ESSURE PROCEDURE	1	tablet	BID	2009-06-24	2009-06-24
	"ONDANSETRON HYDROCHLORIDE" ONDANSETRON HYDROCHLORIDE	PRE ESSURE PROCEDURE	8	mg	Once	2009-06-24	2009-06-24
	"DOXYCYCLINE" DOXYCYCLINE	PRE-PROCEDURE INFECTION PREVENTION	100	mg	BID	2009-07-07	2009-07-07
	"IBUPROFEN" IBUPROFEN	HEADACHE	600	mg	PRN	2009-07-21	2009-07-21

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 180 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4098	"AMOXICILLIN" AMOXICILLIN	VIRAL UPPER RESPIRATORY INFECTION	1	tablet	TID	2009-09-24	2009-09-28
R4099	"TUMS" CALCIUM CARBONATE	HEARTBURN	2000	mg	PRN	2007	ONGOING
	"XANAX" ALPRAZOLAM	ANXIETY	0.25	mg	PRN	2008	ONGOING
	"MUCINEX" GUAIFENESIN	SINUS CONGESTION	1200	mg	PRN	2009-06-16	2009-06-19
	"Z-PACK" AZITHROMYCIN	SINUSITIS	1	tablet	QD	2009-07-18	2009-07-22

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 181 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4099	"TYLENOL" PARACETAMOL	SORE BACK	1000	mg	Once	2009-07-26	2009-07-26
	"FLEXERIL" CYCLOBENZAPRINE HYDROCHLORIDE	BACK PAIN	10	mg	TID	2009-07-31	2009-08-09
	"IBUPROFEN" IBUPROFEN	SORE BACK	800	mg	TID	2009-07-31	2009-08-09
	"STEROID INJECTION" CORTICOSTEROID NOS	SORE BACK	1	other, specify: injection	Once	2009-07-31	2009-07-31
	"SUDAFED 12 HOUR" PSEUDOEPHEDRINE HYDROCHLORIDE	SINUSITIS	120	mg	BID	2009-11-13	2009-11-18

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 182 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4100	"ADVIL" IBUPROFEN	BACK PAIN	200	mg	Once	2009-08-19	2009-08-19
	"CITALOPRAM" CITALOPRAM	ANXIETY	20	mg	QD	2009-11-27	ONGOING
R4101	"ASPIRIN" ACETYLSALICYLIC ACID	HEADACHE	2	other, specify: capsules	Once	2009-07-19	2009-07-19
R4102	"LISINOPRIL HCTZ" PRINZIDE /00977901/	HYPERTENSION	1	tablet	QD	2008-11	ONGOING
R4103	"NONE"						

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 183 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4104	"NONE"						
R4105	"IBUPROFEN" IBUPROFEN	TOOTH PAIN	800	mg	PRN	2010-02-01	2010-02-11
	"PENICILLIN" PENICILLIN NOS	TOOTH PAIN	500	mg	QID	2010-02-01	2010-02-11
R4106	"BYSTOLIC" NEBIVOLOL HYDROCHLORIDE	HYPERTENSION	5	mg	QD	2008	ONGOING
	"ASPIRIN" ACETYLSALICYLIC ACID	CARDIO PREVENTION	81	mg	QD	2009-04	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 184 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4107	"SYNTHROID" LEVOTHYROXINE SODIUM	HYPOTHYROIDISM	200	mg	QD	1997	ONGOING
	"VALERIAN" VALERIANA OFFICINALIS ROOT	INSOMNIA	3	tablet	QHS	2009-07-10	2009-07-20
	"ALEVE" NAPROXEN SODIUM	DYSMENORRHEA	1	tablet	TID	2009-07-16	2009-07-18
	"IBUPROFEN" IBUPROFEN	DYSMENORRHEA	400	mg	Once	2009-07-19	2009-07-19
	"LORTAB" VICODIN	ARTHRALGIA RIGHT WRIST	2	tablet	OTHER, SPECIFY, EVERY FOUR TO SIX HOURS	2009-08-14	2009-08-15

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 185 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4107	"ALEVE" NAPROXEN SODIUM	ARTHRALGIA RIGHT WRIST	220	mg	PRN	2009-08-15	2009-11-12
	"IBUPROFEN" IBUPROFEN	ARTHRALGIA RIGHT WRIST	600	mg	PRN	2009-08-15	2009-11-20
	"KEFLEX" CEFALEXIN MONOHYDRATE	PREVENT INFECTION	500	mg	QID	2009-08-15	2009-09-03
	"PERCOCET" OXYCOCET	ARTHRALGIA RIGHT WRIST	1	tablet	OTHER, SPECIFY, EVERY FOUR TO SIX HOURS	2009-08-15	2009-09-17
R4108	"CORTISONE" CORTISONE	VIRAL UPPER RESPIRATORY INFECTION	1	other, specify: injection	Once	2009-09-04	2009-09-04

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 186 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4108	"LISINOPRIL" LISINOPRIL	HYPERTENSION	10	mg	QD	2009-09-04	ONGOING
	"UNKNOWN ANTIBIOTIC" ANTIBIOTICS	VIRAL UPPER RESPIRATORY INFECTION	UNK	other, specify: unk	OTHER, SPECIFY, UNKNOWN	2009-09-04	2009-09-08
	"MEDROL DOSE PACK" METHYLPREDNISOLONE	VIRAL UPPER RESPIRATORY INFECTION	UNK	other, specify: unk	OTHER, SPECIFY, UNKNOWN	2009-09-09	2009-09-20
	"UNKNOWN ANTIBIOTIC" ANTIBIOTICS	VIRAL UPPER RESPIRATORY INFECTION	UNK	other, specify: unk	OTHER, SPECIFY, UNKNOWN	2009-09-09	2009-09-22
R4109	"VITAMIN B6" PYRIDOXINE HYDROCHLORIDE	SUPPLEMENT	50	mg	OTHER, SPECIFY, 3 TIMES A WEEK	2009-05	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 187 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4109	"DOXYCYCLINE" DOXYCYCLINE	SKIN INFECTION	1000	mg	QD	2009-07-29	2009-08-10
	"IBUPROFEN" IBUPROFEN	HEADACHE	400	mg	PRN	UNK	ONGOING
R4110	"VEMMA" ALL OTHER NON-THERAPEUTIC PRODUCTS	SUPPLEMENT	2	other, specify: ounces	QD	2009-04	2009-08-01
	"ACETAMINOPHEN" PARACETAMOL	HEADACHE	1000	mg	PRN	2009-07-23	2009-07-23
	"HYDROCODONE/APAP" PROCET /01554201/	ABDOMINAL PAIN	1-2	tablet	PRN	2009-08-13	2009-08-20

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 188 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4110	"PROTONIX" PANTOPRAZOLE SODIUM	ABDOMINAL PAIN	40	mg	QD	2009-08-13	2009-08-20
R4111	"NONE"						
R4112	"IBUPROFEN" IBUPROFEN	BACK PAIN	800	mg	PRN	2007	ONGOING
	"EXCEDRIN MIGRAINE" THOMAPYRIN N	HEADACHES	2	tablet	PRN	2008	ONGOING
	"RAPID SLIM SX" RAPID FAT BURNER	WEIGHT LOSS	2	other, specify: capsules	BID	2009-03	2009-08-06

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 189 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4112	"SINUS CONGESTION AND PAIN" OTHER COLD COMBINATION PREPARATIONS	SINUS CONGESTION	2	other, specify: capsules	QD	2009-07-06	2009-07-07
	"KEFLEX" CEFALEXIN MONOHYDRATE	SINUS INFECTION	750	mg	QD	2009-07-10	2009-07-23
R4113	"BETAMETHASONE DIPROPIONATE" BETAMETHASONE DIPROPIONATE	RECURRENT RASHES	1	other, specify: application	PRN	2008-07	ONGOING
	"FLEXERIL" CYCLOBENZAPRINE HYDROCHLORIDE	CERVICAL MYALGIA	10	mg	OTHER, SPECIFY, AT BEDTIME WHEN NECESSARY	2010-02-01	ONGOING
	"TRAMADOL" TRAMADOL	CERVICAL MYALGIA	50	mg	OTHER, SPECIFY, TWICE DAILY WHEN NECESSARY	2010-02-01	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 190 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4114	"ALENDRONATE" ALENDRONATE SODIUM	OSTEOPOROSIS	70	mg	QS	2009-02	ONGOING
	"TIMOLOL" TIMOLOL	GLAUCOMA	1	other, specify: drop left eye	QD	2009-03	ONGOING
	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	2009-05	ONGOING
	"STOMACH RELIEF" ALIMENTARY TRACT AND METABOLISM	STOMACH UPSET/HEARTBURN	1	other, specify: tablespoon	PRN	2009-07-17	2009-07-17
	"DIFLUCAN" FLUCONAZOLE	VAGINITIS	150	mg	Once	2009-08-25	2009-08-25

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 191 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4114	"DOXYCYCLINE HYCLATE" DOXYCYCLINE HYCLATE	VIRAL UPPER RESPIRATORY INFECTION	100	mg	BID	2009-12-30	2010-01-10
	"METHYLPREDNISOLONE" METHYLPREDNISOLONE	VIRAL RESPIRATORY INFECTION	1-2	tablet	QD	2010-01-07	2010-01-12
R4115	"SUBOXONE" SUBOXONE	OPIATE INHIBITOR	16	mg	QD	2004	ONGOING
R4116	"FLU SHOT" INFLUENZA VACCINE	PROPHYLACTIC	1	other, specify: injection	Once	2009-09-21	2009-09-21
	"NO TIME FOR COLDS LOZENGES" COUGH AND COLD PREPARATIONS	VIRAL UPPER RESPIRATORY INFECTION	3	other, specify: lozenges	PRN	2009-09-22	2009-09-23

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 192 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4117	"TUMS" CALCIUM CARBONATE	DYSPEPSIA	1	tablet	PRN	2009-07-23	ONGOING
	"OPHTHALMIC ANTIBIOTIC" ANTIBIOTICS	CORNEAL ABRASION	1	other, specify: drop	QID	2009-08-07	2009-08-11
	"FLU SHOT" INFLUENZA VACCINE	PROPHYLACTIC	1	other, specify: injection	Once	2009-11-06	2009-11-06
	"AMOXICILLIN" AMOXICILLIN	SINUS INFECTION	500	mg	QD	2010-01-11	2010-01-18
R4118	"LO OVRAL" ETHINYL ESTRADIOL W/ NORGESTREL	ORAL CONTRACEPTION	1	tablet	QD	2009-05	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 193 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4118	"ADVIL" IBUPROFEN	HEADACHE	400	mg	PRN	2009-06-20	ONGOING
	"AFRIN" OXYMETAZOLINE	NASAL CONGESTION	1	other, specify: spray per nostril	PRN	2009-07-14	2009-07-19
	"SUDAFED PE" PHENYLEPHRINE HYDROCHLORIDE	NASAL CONGESTION	1	tablet	PRN	2009-07-14	2009-07-19
	"AMOXICILLIN" AMOXICILLIN	GINGIVITIS	500	mg	QD	2009-07-29	2009-08-03
	"CRESTOR" ROSUVASTATIN CALCIUM	HYPERCHOLESTER OLEMIA	5	mg	QD	2009-10-16	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 194 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4118	"OMEPRAZOLE" OMEPRAZOLE	HEARTBURN	20	mg	QD	2009-10-16	ONGOING
	"LISINOPRIL" LISINOPRIL	HYPERTENSION	5	mg	QD	2010-01-28	ONGOING
R4119	"PAIN RELIEVER PM" DOZOL /00435101/	FOOT PAIN	2	tablet	BID	2008	ONGOING
R4120	"ADVIL COLD AND SINUS" CO-ADVIL	SINUS HEADACHE	UNK	other, specify: unknown	PRN	1985	ONGOING
	"ADVIL" IBUPROFEN	GENERAL ACHES AND PAINS	400	mg	PRN	1985	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 195 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4120	"FEMCREME" PROGESTERONE	ESTROGEN REPLACEMENT THERAPY	1	other, specify: dime size cream	OTHER, SPECIFY, 21 DAYS A MONTH	1999	ONGOING
	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	3	tablet	QS	1999	ONGOING
	"SYNTHROID" LEVOTHYROXINE SODIUM	HYPOTHYROIDISM	1	tablet	QD	2001	ONGOING
R4121	"IBUPROFEN" IBUPROFEN	HEADACHE	400	mg	PRN	2009-07-15	2009-07-19
	"IBUPROFEN" IBUPROFEN	HEADACHE	400	mg	PRN	2009-08-02	2009-08-02

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 196 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R4121	"IBUPROFEN" IBUPROFEN	HEADACHE	400	mg	PRN	2009-08-18	UNK
R5001	"TUMS" CALCIUM CARBONATE	DYSPEPSIA DUE TO TOMATOES	750	mg	PRN	1995	ONGOING
	"TUMS" CALCIUM CARBONATE	DYSPEPSIA	750	mg	QD	2009-08-10	2009-09-30
R5002	"CALCIUM" CALCIUM	SUPPLEMENT	600	mg	QD	2008-02	ONGOING
	"ESTRACE" ESTRADIOL	HORMONE REPLACEMENT THERAPY	1	mg	QD	2008-02	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 197 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R5002	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENTAL	1	tablet	QD	2008-02	ONGOING
R5003	"TYLENOL" PARACETAMOL	INSOMNIA AND SHOULDER PAIN	2	tablet	Once	2009-06-01	2009-06-01
	"MUCINEX" GUAIFENESIN	UPPER RESPIRATORY INFECTION	1200	mg	BID	2009-10-18	2009-11-09
R5004	"NONE"						
R5005	"CLONIDINE" CLONIDINE	HIGH BLOOD PRESSURE	0.3	mg	BID	2005	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 198 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R5005	"DILTIAZEM" DILTIAZEM	HIGH BLOOD PRESSURE	300	mg	QD	2005	ONGOING
	"LISINOPRIL HCTZ" PRINZIDE /00977901/	HIGH BLOOD PRESSURE	1	tablet	BID	2005	ONGOING
R5006	"MUCINEX" GUAIFENESIN	CHEST CONGESTION	1200	mg	BID	2009-05-15	2009-06-22
	"AMOXICILLIN" AMOXICILLIN	MULTIPLE CAT BITES	875	mg	BID	2009-06-17	2009-06-23
	"AUGMENTIN" AMOXICILLIN W/ CLAVULANATE POTASSIUM	MULTIPLE CAT BITES	500	mg	Once	2009-06-17	2009-06-17

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 199 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R5006	"IM MORPHINE" MORPHINE	KNEE AND SHOULDER PAIN	4	mg	Once	2009-06-17	2009-06-17
	"MOTRIN" IBUPROFEN	KNEE AND SHOULDER PAIN	400	mg	Once	2009-06-17	2009-06-17
	"NORCO" VICODIN	KNEE AND SHOULDER PAIN	5	mg	Once	2009-06-17	2009-06-17
	"ZOFTRAN ODT" ONDANSETRON HYDROCHLORIDE	KNEE AND SHOULDER PAIN	4	mg	Once	2009-06-17	2009-06-17
	"TUSSIONEX" TUSSIONEX /00140501/	ALLERGIC RHINITIS	1	other, specify: teaspoon	QHS	2009-06-18	2009-06-21

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 200 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R5006	"XANAX" ALPRAZOLAM	ANXIETY	1.25	mg	Once	2009-06-18	2009-06-18
	"ADVIL" IBUPROFEN	EXACERBATION OF NECK PAIN	400	mg	PRN	2009-07-15	ONGOING
	"BENADRYL" DIPHENHYDRAMINE HYDROCHLORIDE	ALLERGIC RHINITIS	25	mg	QD	2009-11-02	2009-11-16
	"MUCINEX" GUAIFENESIN	ALLERGIC RHINITIS	600	mg	QD	2009-11-02	ONGOING
	"TUSSIONEX" TUSSIONEX /00140501/	ALLERGIC RHINITIS	1	other, specify: teaspoon	QD	2009-12-31	2010-01-27

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 201 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R5007	"THYROID MEDICATION - NAME UNKNOWN" THYROID	UNKNOWN	100	ug	QD	2005	2009-06-20
R5008	"TUMS" CALCIUM CARBONATE	HEARTBURN	2	tablet	PRN	2005-02	2009-06-25
	"THYROXINE" LEVOTHYROXINE SODIUM	HYPOTHYROIDISM	1	tablet	QD	2009-07-28	ONGOING
	"CEFPROZIL" CEFPROZIL	URINARY TRACT INFECTION - A/E	500	mg	BID	2009-10-20	2009-10-27
R5009	"NONE"						

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 202 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R5010	"PRILOSEC" OMEPRAZOLE MAGNESIUM	HEARTBURN	UNKNOWN	tablet	QD	2004-01-01	ONGOING
	"CVS 12 HOUR NASAL DECONGESTANT" OXYMETAZOLINE HYDROCHLORIDE	ALLERGIES	1	other, specify: nasal spray	PRN	2009	ONGOING
	"ASPIRIN" ACETYLSALICYLIC ACID	PREVENTATIVE	1	tablet	PRN	2009-06	2009-06
	"BENADRYL" DIPHENHYDRAMINE HYDROCHLORIDE	ALLERGIES/SINUSE S	50	mg	PRN	2009-08	2009-09
R5011	"NONE"						

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 203 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R5012	"MULTIVITAMIN" MULTIVITAMINS	HEALTH	12	other, specify: capsules	QD	1984	2009-07-05
	"UNKNOWN - PAIN MEDICATION" OTHER ANALGESICS AND ANTIPYRETICS	MULTIPLE FRACTURES RIGHT ANKLE	UNKNOWN	other, specify: unknown	OTHER, SPECIFY, UNKNOWN	2009-08-07	2009-08-26
R5013	"SUMATRIPTAN SUCCINATE" SUMATRIPTAN SUCCINATE	MIGRAINE HEADACHES	100	mg	PRN	2000	ONGOING
	"VIVELLE-DOT PATCH" ESTRADIOL	HORMONE REPLACEMENT THERAPY	0.05	mg	QD	2008-01	ONGOING
	"EXCEDRIN MIGRAINE" THOMAPYRIN N	MIGRAINE HEADACHES	2	tablet	Once	2009-09-20	2009-09-20

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 204 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R5014	"ALKA SELTZER PLUS COLD" SINE-OFF /00693501/	UPPER RESPIRATORY INFECTION	1	other, specify: pouch	Once	2009-08-07	2009-08-07
	"SUDAFED" PSEUDOEPHEDRINE HYDROCHLORIDE	TOOTHACHE	1	tablet	Once	2009-08-09	2009-08-09
	"IBUPROFEN" IBUPROFEN	TOOTHACHE	1	tablet	Once	2009-08-10	2009-08-10
	"ALKA SELTZER" ACETYLSALICYLIC ACID	UPPER RESPIRATORY INFECTION	1	tablet	QD	2009-09-02	2009-09-05
R5015	"TYLENOL" PARACETAMOL	INTERMITTENT HEADACHES	500	mg	PRN	2009-07-14	2009-09-14

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 205 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R5015	"PEPTO BISMOL" BISMUTH SUBSALICYLATE	DYSPEPSIA	1	other, specify: tablespoon	Once	2009-07-17	2009-07-17
R5016	"LOTREL" AMLODIPINE BESYLATE W/ BENAZEPRIL HYDROCHLOR.	HIGH BLOOD PRESSURE	20	mg	QD	2005	ONGOING
	"ASPIRIN" ACETYLSALICYLIC ACID	PREVENTATIVE	81	mg	QD	2007	ONGOING
	"ESTRO NATURE" ALL OTHER NON-THERAPEUTIC PRODUCTS	HOT FLASHES	1	tablet	QD	2007	ONGOING
	"SPIRIVA" TIOTROPIUM BROMIDE	ASTHMA	1	other, specify: puff	QD	2008	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 206 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R5016	"CONTAC-D" CONTAC /00014501/	UPPER RESPIRATORY INFECTION	1	tablet	QD	2009-08-12	2009-09-02
	"Z-PACK" AZITHROMYCIN	ORAL THRUSH	1	tablet	QD	2009-10-17	2009-10-22
	"FLUCONAZOLE" FLUCONAZOLE	ORAL THRUSH	250	mg	QD	2009-11-09	2009-11-14
R5017	"NEXIUM" ESOMEPRAZOLE SODIUM	FLATULENCE	1	tablet	QD	2008	2009-07-05
	"ADVIL" IBUPROFEN	HEADACHE	500	mg	Once	2009-07-05	2009-07-05

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 207 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R5017	"BENADRYL" DIPHENHYDRAMINE HYDROCHLORIDE	POISON IVY	2	tablet	QD	2009-07-05	2009-07-06
	"ADVIL" IBUPROFEN	HEADACHE	500	mg	Once	2009-09-11	2009-09-11
	"TRIAMTERENE" TRIAMTERENE	HYPERTENSION	37.5	mg	QD	2009-10-06	ONGOING
R5018	"NONE"						
R5019	"NONE"						

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 208 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R5020	"ALLERGY ANTIHISTAMINE" ANTIHISTAMINES	SLEEP AID	50	mg	QD	1999	ONGOING
	"IBUPROFEN" IBUPROFEN	PAIN	600	mg	QD	1999	ONGOING
	"MULTIVITAMIN" MULTIVITAMINS	SUPPLEMENT	1	tablet	QD	1999	ONGOING
	"D-3 VITAMIN" COLECALCIFEROL	SUPPLEMENT	1000	other, specify: international units	QD	2008	ONGOING
	"GREEN TEA EXTRACT" CAMELLIA SINENSIS	ANTIOXIDANT	300	mg	QD	2008	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 209 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R5020	"OMEGA 1+" OTHER LIPID MODIFYING AGENTS	SUPPLEMENT	2	tablet	QD	2008	ONGOING
	"CALCIUM D" CALCIUM D3 /01483701/	SUPPLEMENT	600	mg	QD	2009-03-03	ONGOING
	"CYCLOBENZAPRINE" CYCLOBENZAPRINE	PRE-EXISTING BACK SPASMS INTERMITTENT	5	mg	PRN	2009-08-11	2009-09-11
R5021	"MIDOL" ACETYLSALICYLIC ACID	MENSTRUAL CRAMPS	1	tablet	Once	2009-07-07	2009-07-07
	"BENADRYL" DIPHENHYDRAMINE HYDROCHLORIDE	HEADACHE	25	mg	Once	2009-09-08	2009-09-08

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 210 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R5022	"NONE"						
R5023	"ADDERALL XR" OBETROL /01345401/	ATTENTION DEFICIT DISORDER	30	mg	PRN	2005	ONGOING
	"CARISOPRODOL" CARISOPRODOL	NECK PAIN	350	mg	QHS	2009-07-22	ONGOING
	"CERVICAL EPIDURAL STEROID" CORTICOSTEROID NOS	NECK PAIN	UNKNOWN	other, specify: injection	OTHER, SPECIFY, SERIES OF 3 SHOTS BEGINNING 22- JUL	2009-07-22	2009-08-12
	"NAPROXEN" NAPROXEN	NECK PAIN	500	mg	QD	2009-07-22	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 211 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R5024	"ASPIRIN" ACETYLSALICYLIC ACID	HEALTH SUPPLEMENT	325	mg	QD	2001	ONGOING
	"AMBIEN" ZOLPIDEM TARTRATE	INSOMNIA	10	mg	PRN	2009-02	ONGOING
R5025	"SUDAFED" PSEUDOEPHEDRINE HYDROCHLORIDE	BLOCKED SINUSES	200	mg	PRN	2004-09	2009-07-10
	"SYNTHROID" LEVOTHYROXINE SODIUM	HYPOTHYROIDISM	0.15	mg	QD	2004-09	ONGOING
	"MEGA-3 FISH OIL" FISH OIL	SUPPLEMENT	1200	mg	QD	2006	ONGOING

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 212 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R5025	"CENTRUM COMPLETE" CENTRUM /00554501/	SUPPLEMENT/ANTI OXIDANT	3	tablet	QD	2009-01	ONGOING
	"FLEXERIL" CYCLOBENZAPRINE HYDROCHLORIDE	TMJ	5	mg	PRN	2009-03	ONGOING
	"PEPCID AC" FAMOTIDINE	FLATULENCE	10	g	Once	2009-07-20	2009-07-22
R5026	"NONE"						
R5027	"ADIPEX" PHENTERMINE	WEIGHT LOSS	1	tablet	QD	2008	2009-07-17

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 213 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R5027	"PRENATAL VITAMINS" PRENATAL VITAMINS / 01549301/	PREGNANCY	1	tablet	QD	2009-12-13	ONGOING
R5028	"CALCIUM PLUS D" CALCIUM D3 /01483701/	SUPPLEMENT	2	tablet	QD	1976	2009-07-13
	"JUICE PLUS" JUICE PLUS	SUPPLEMENT	5	other, specify: capsule	QD	2004	2009-07-13
	"VITALITY" ALL OTHER NON-THERAPEUTIC PRODUCTS	SUPPLEMENT	10	tablet	QD	2009-07-01	2009-07-13
	"DEPO MEDROL IM" METHYLPREDNISOLONE ACETATE	FLU SYMPTOMS	UNKNOWN	other, specify: unknown	Once	2009-09-08	2009-09-08

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 214 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R5028	"METRONIDAZOLE" METRONIDAZOLE	FLU SYMPTOMS	500	mg	TID	2009-09-08	UNK
	"NOREL SR" GUAIFENESIN W/ PHENYLPROPANOLA./ PHENYLEPH.HCL	FLU SYMPTOMS	UNKNOWN	other, specify: unknown	OTHER, SPECIFY, UNKNOWN	2009-09-08	UNK
	"ROCEPHIN IM" CEFTRIAZONE SODIUM	FLU SYMPTOMS	UNKNOWN	other, specify: unknown	Once	2009-09-08	2009-09-08
	"VITAMIN B-12 SHOT" CYANOCOBALAMIN	FLU SYMPTOMS	UNKNOWN	other, specify: unknown	Once	2009-09-08	2009-09-08
	"CHERATUSSIN CODEINE" CHERATUSSIN /01381201/	FLU SYMPTOMS	180	milliliters	PRN	2009-09-09	2009-09-13

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

Listing 16.2.5-2 Previous and Concomitant Medications by Subject

(Page 215 of 215)

Study Population: ITT

Subject Number	"Verbatim Term" Preferred Term	Indication	Dose	Unit	Frequency	Start Date	Stop Date
R5028	"LEVAQUIN" LEVOFLOXACIN	FLU SYMPTOMS	500	mg	QD	2009-09-09	2009-09-19
	"TRITAL SR" DEXTROSIN	UPPER RESPIRATORY INFECTION	1	tablet	QD	2009-12-12	2009-12-14

NOTE: Medications were coded using WHODrug (Version September 2008); UNK=UNKNOWN.

### **16.2.5.1 Bioanalytical Report**

**AMENDMENT TO FINAL REPORT**

Study Number:	8233095	
Amendment Issue Date:	02 Aug 2012	
Amendment Number:	1	
Study Title:	Determination of Cotinine in Human Plasma Samples from a Multicenter, Randomised, Double Blind Placebo Controlled Trial of the Ability of a Traditional Swedish Smokeless Tobacco Product ("Snus") to Increase the Quit Rate Among Cigarette Smokers Who Wish to Stop Smoking (Sponsor Reference number SM 08-01) using Ultra High Performance Liquid Chromatography with Tandem Mass Spectrometric Detection (LC-MS/MS)	
Authorised By:	<i>S Fenton</i>	2/8/12
	Sarah Fenton Study Director	Date
Quality Assurance Audit:	<i>SPowell</i>	2/8/12
	Simon Powell QA Representative	Date
Distribution:	Study Director, QA, Sponsor and CSR	
This amendment to final report contains 154 pages including these two.		
Documentation		
Sections amended and explanation for the change		
The final report has been updated after database updates were received from Covance Central Laboratories Services (CCLS) changing sample demographics.		
All changes are documented below.		
All page headers have been amended to state Amended Final Report 1.		
Page 1: The title page has been updated to state Amended Final Report 1. A MacDougall has been added to the list of Authors. The Report Issued date and the Page Number have been updated.		
Page 2: The Study Director Authentication Statement has been re-signed.		
Page 3: The Quality Assurance Statement has been updated to include audit of the Amended Final Report 1 and the QA auditor details have been updated and the page has been re-signed.		
Page 4: The Scientific Review Statement page has been removed as this is no longer required to be present in reports.		
Page 5: Amended final report 1 issue date row added to the study schedule.		

Page 6: The archive statement has been updated to include the retention of the Amended Final Report 1.

Page 7 and 8: The contents page has been updated as additional information has been added to the report.

Page 9: First paragraph ended with a double full stop (..) the additional full stop has been removed.

Page 12: Last paragraph, a connecting space has been added to nominal -80°C so that it appears on one line.

Page 17 and 18: Section 5.1 updated.

Pages 26-60: Table 4 has been regenerated and replaced in the report after the database was updated at CCLS request.

Page 61: The sample originally identified by CCLS as subject R01008, Week 16 was later updated to the Early Term sampling occasion as instructed by CCLS. The report table has been updated to state Early Term instead of Week 16.

Page 90 and 91: The second and third samples listed in the table have been updated at the request of CCLS from subject R01029 to subject R01028. The subject demographics have been altered in the report table.

The two samples received for R04068, Week 6 were not reported at the instruction of CCLS. Therefore these samples have been removed from the reassay table.

The sample for subject S02051, screening was originally identified by CCLS as subject S00051, the table has been updated to S02051 in the report at the request of CCLS.

The sample for subject R05026, screening was originally identified by CCLS as subject S05016, the table has been updated to R05026 in the report at the request of CCLS.

Page 99: Additional space removed from parentheses before the number of pages for the second bullet point.

# Amended Final Report 1

Study Title	Determination of Cotinine in Human Plasma Samples from a Multicenter, Randomised, Double-Blind Placebo Controlled Trial of the Ability of a Traditional Swedish Smokeless Tobacco Product ("Snus") to Increase the Quit Rate Among Cigarette Smokers Who Wish to Stop Smoking (Sponsor Reference number SM 08-01) using Ultra High Performance Liquid Chromatography with Tandem Mass Spectrometric Detection (LC-MS/MS)
Authors	S Fenton B Ajayi A MacDougall
Sponsor	Swedish Match AB Rosenlundsgatan 36 SE-118 85 Stockholm SWEDEN
Analytical Study Monitor	Lars-Erik Rutqvist
Test Facility	Covance Laboratories Limited Otley Road, Harrogate North Yorkshire, HG3 1PY ENGLAND
Covance Study Number	8233095
Covance Client Identifier	1000025
Sponsor Reference Number	SM 08-01
Report Issued	02 August 2012
Page Number	1 of 152

## STUDY DIRECTOR AUTHENTICATION STATEMENT

### **Determination of Cotinine in Human Plasma Samples from a Multicenter, Randomised, Double-Blind Placebo Controlled Trial of the Ability of a Traditional Swedish Smokeless Tobacco Product (“Snus”) to Increase the Quit Rate Among Cigarette Smokers Who Wish to Stop Smoking (Sponsor Reference number SM 08-01) using Ultra High Performance Liquid Chromatography with Tandem Mass Spectrometric Detection (LC-MS/MS)**


I, the undersigned, hereby declare that the work was performed by me or under my supervision and that the findings provide a true and accurate record of the results obtained.


The study was performed in accordance with the agreed protocol and with Covance Laboratories Limited, Standard Operating Procedures, unless otherwise stated, and the study objectives were achieved#. This study involved the analysis of human samples generated as part of a clinical trial, and as such was not within the scope of Good Laboratory Practice (GLP) regulations. No formal claim of compliance with GLP was therefore made, although all work was conducted in a facility that is a member of the UK MHRA GLP monitoring programme following laboratory procedures commensurate with International Standards of GLP.

As part of a clinical study, the work was conducted in accordance with the following:

- UK Statutory Instrument 2004 No. 1031: The Medicines for Human Clinical Use (Clinical Trials) Regulations 2004 plus subsequent amendments
- Good Clinical Practice: Consolidated Guideline ICH Topic E6, adopted by CPMP, July 1996, issued as CPMP/ICH/135/95

# Study samples were analysed outside the known stability period (samples were already outside the known stability period prior to shipment to Covance) and therefore the data generated in this report should be considered with this in mind.

  
\_\_\_\_\_  
S Fenton PhD  
Study Director  
Covance Laboratories Limited

  
\_\_\_\_\_  
Date

**QUALITY ASSURANCE STATEMENT**

**Determination of Cotinine in Human Plasma Samples from a Multicenter, Randomised, Double-Blind Placebo Controlled Trial of the Ability of a Traditional Swedish Smokeless Tobacco Product (“Snus”) to Increase the Quit Rate Among Cigarette Smokers Who Wish to Stop Smoking (Sponsor Reference number SM 08-01) using Ultra High Performance Liquid Chromatography with Tandem Mass Spectrometric Detection (LC-MS/MS)**

This study has been reviewed by the GLP Quality Assurance Unit of Covance and the report accurately reflects the raw data. The following inspections were conducted and findings reported to the study director (SD) and associated management.

Critical procedures, which are performed routinely in an operational area, may be audited as part of a "process" inspection programme. This can be in addition to phases scheduled on an individual study basis. Selected process inspections conducted and considered applicable to this study are included below.

In addition to the inspection programmes detailed below, a facility inspection programme is also operated. Details of this programme, which covers all areas of the facility annually (at a minimum), are set out in standard operating procedures.

Inspection Dates		Phase	Date Reported to SD and SD Management
From	To		
16 Mar 2011	18 Mar 2011	Protocol Review	18 Mar 2011
07 Jul 2011	13 Jul 2011	Draft Report and Data Review - Bioanalytical	13 Jul 2011
15 Aug 2011	15 Aug 2011	Sign off Inspection Record	15 Aug 2011
15 Aug 2011	15 Aug 2011	Final Report Review	15 Aug 2011
31 Jul 2012	31 Jul 2012	Report Amendment Review	31 Jul 2012

Inspection Dates		Phase	Date Reported to SD and SD Management
From	To		
18 Mar 2011	18 Mar 2011	Sample Tracking	18 Mar 2011
15 Mar 2011	21 Mar 2011	Extraction Laboratory	21 Mar 2011
22 Mar 2011	22 Mar 2011	Mass Spectrometry Laboratory	22 Mar 2011
08 Apr 2011	08 Apr 2011	Extraction Laboratory	08 Apr 2011
15 Apr 2011	15 Apr 2011	Sample Tracking	15 Apr 2011



S Powell BSc  
Quality Assurance Unit



Date

## STUDY SCHEDULE

**Determination of Cotinine in Human Plasma Samples from a Multicenter, Randomised, Double-Blind Placebo Controlled Trial of the Ability of a Traditional Swedish Smokeless Tobacco Product (“Snus”) to Increase the Quit Rate Among Cigarette Smokers Who Wish to Stop Smoking (Sponsor Reference number SM 08-01) using Ultra High Performance Liquid Chromatography with Tandem Mass Spectrometric Detection (LC-MS/MS)**

The study schedule was as follows:

Study initiation	09 March 2011 (date Study Director signed protocol)
Experimental Start Date	21 March 2011 (data capture, first analysed batch)
Experimental End Date	18 April 2011 (final data capture, last analysed batch)
Report Issue Date	(Date the final report is signed by the Study Director)
Amended Final Report 1 Issue Date	(Date the amended final report 1 is signed by the Study Director)

## ARCHIVE STATEMENT

### **Determination of Cotinine in Human Plasma Samples from a Multicenter, Randomised, Double-Blind Placebo Controlled Trial of the Ability of a Traditional Swedish Smokeless Tobacco Product (“Snus”) to Increase the Quit Rate Among Cigarette Smokers Who Wish to Stop Smoking (Sponsor Reference number SM 08-01) using Ultra High Performance Liquid Chromatography with Tandem Mass Spectrometric Detection (LC-MS/MS)**

All primary data (including electronic data), or authenticated copies thereof, protocol the final report, the amended final report 1 will be retained using appropriate storage media in the Covance Laboratories Limited archives for one year after issue of the amended final report 1. At this time, the Sponsor will be contacted to determine whether the data should be returned, retained or destroyed on their behalf. Sponsors will be notified of the financial implications of each of these options at that time.

Specimens or samples requiring frozen storage at Covance are specifically excluded from the above. These will be retained for as long as the material permits further evaluation or up to a maximum of three months after issue of the draft report. At this time, the Sponsor will be contacted to determine whether samples should be returned, retained or destroyed on their behalf. Any financial implications of these options will also be notified at this time. Samples will not be destroyed without prior approval of the Study Director.

## CONTENTS

STUDY DIRECTOR AUTHENTICATION STATEMENT .....	2
QUALITY ASSURANCE STATEMENT .....	3
STUDY SCHEDULE.....	4
ARCHIVE STATEMENT .....	5
CONTENTS .....	6
1 SUMMARY .....	8
1.1 Objective.....	8
1.2 Method.....	8
1.3 Results.....	8
1.4 Conclusion .....	9
2 MATERIALS AND METHODS .....	10
2.1 Test Article .....	10
2.2 Internal Standard.....	10
2.3 Materials and Methods.....	10
2.4 Computer Systems .....	11
3 STUDY SAMPLE ANALYSIS .....	11
3.1 Study Samples.....	11
3.2 Sample Analysis .....	11
3.3 Sample Acceptance Criteria.....	12
3.4 Criteria for Repeat Analysis.....	12
4 RESULTS .....	13
4.1 System Suitability .....	13
4.2 Quality Control Sample Data.....	13
4.3 Calibration Standard Data.....	13
4.4 Selectivity .....	13
4.5 Carryover .....	14
4.6 Injection Order.....	14
4.7 Study Sample Data.....	14
4.8 Incurred Sample Reproducibility .....	14
5 DISCUSSION .....	16
5.1 Sample Analysis .....	16
5.2 Assay Performance .....	17
5.3 Conclusion .....	17
6 REFERENCE.....	18
7 TABLES.....	19
Table 1 Determination of Cotinine in Human Plasma: Quality Control Sample Data .....	20
Table 2 Determination of Cotinine in Human Plasma: Calibration Standard Data .....	22
Table 3 Determination of Cotinine in Human Plasma: Calibration Standard Data Regression Characteristics .....	24
Table 4 Determination of Cotinine in Human Plasma: Study Sample Data.....	25
Table 5 Determination of Cotinine in Human Plasma: Incurred Sample Reproducibility .....	56

8	APPENDICES .....	58
	Appendix 1 Certificates of Analysis .....	59
	Appendix 2 Representative Chromatograms.....	64
	Appendix 3 Repeat Analysis Summary.....	84
	Appendix 4 Batch Analysis Summary .....	88
	Appendix 5 Deviations from Protocol and Analytical Procedure .....	90
	Appendix 6 Protocol Observations.....	92
9	ANNEX.....	94

## 1 SUMMARY

### 1.1 Objective

The objective of this study was to determine the concentrations of Cotinine in human plasma containing K<sub>3</sub>EDTA as an anticoagulant using solid phase extraction for sample preparation and liquid chromatography with tandem mass spectrometric detection (LC-MS/MS). The method has been validated at Covance Laboratories Limited (Covance Study number 8202356 [1]) for the determination of Nicotine and Cotinine in human plasma (lithium heparin) and has a lower limit of quantification (LLOQ) of 1.5 ng/mL for Nicotine and 0.5 ng/mL for Cotinine using 100 µL of plasma. However since the samples have been taken into tubes containing K<sub>3</sub>EDTA, further validation was performed to validate for the determination of Nicotine and Cotinine in human plasma using K<sub>3</sub>EDTA as an anticoagulant (Covance Study number 8235697) [2]. Sample analysis was carried out using 50 µL of plasma.

The analytical procedure HB-10-082 has been validated for the determination of Nicotine and Cotinine. However, only concentrations of Cotinine were determined in this study.

### 1.2 Method

Details of the analytical method, the reagents and study specific equipment used are presented in the analytical procedure (HB-10-082).

### 1.3 Results

Numerical data may have been rounded for presentation. Therefore, manual recalculation may give slightly different values to those shown.

Precision values, based upon relative standard deviation (RSD%) of quality control (QC) samples, were less than or equal to 3.2%. Mean data are summarised below:

	QC 1.5 ng/mL (LoQC)	QC 15 ng/mL (MeQC)	QC 400 ng/mL (HiQC)	QC 2500 ng/mL (DiQC)*
Mean (ng/mL)	1.49	15.1	395	2540
Accuracy (%)	99.3	100.7	98.8	101.6
RSD (%)	3.1	2.4	2.6	3.2
n	30	30	30	6

\* analysed after ten-fold dilution with blank human plasma

The accuracy values, based upon the calibration standards across the range, were between 97.5% and 102.0% and are summarised below:

	Calibration levels (ng/mL)								
	0.5	1.00	2.50	5.00	10.0	50.0	200	450	500
Mean (ng/mL)	0.505	0.979	2.49	5.05	10.1	50.5	195	448	510
Accuracy (%)	101.0	97.9	99.6	101.0	101.0	101.0	97.5	99.6	102.0
RSD (%)	1.1	2.4	1.7	2.2	2.0	2.4	2.2	3.1	2.7
n	15	15	15	15	15	15	15	15	15

The correlation coefficients (r) obtained for the calibration curves used in this study varied between 0.9989 and 0.9999.

#### 1.4 Conclusion

Calibration standard data, QC sample data and chromatograms indicate that the method performed acceptably during the study sample analysis.

The incurred sample reproducibility data was considered to be within the variability of the assay, however the criteria documented in the protocol was not met.

A total of 817 samples were successfully analysed in 15 reported batches. Samples were collected between 08 January 2009 and 23 February 2010. However, sample analysis did not commence until 21 March 2011 due to a delay in the completion of validation work. As stability has been confirmed (nominal -80°C) for up to six months, these data should therefore be considered with this in mind.

## 2 MATERIALS AND METHODS

### 2.1 Test Article

Cotinine (Lot No. 120M4046V) was supplied to Covance on 13 January 2011. The purity of Cotinine was stated as 99.0% and the retest date was stated as November 2013. On receipt, the compound was stored refrigerated over desiccant (nominal 2-8°C) (the Certificate of Analysis is presented in [Appendix 1](#)).

Nicotine (available as (-)-nicotine hydrogen tartrate salt) (Lot No. 129K0021) was supplied to Covance on 08 September 2010. Nicotine exists as a hydrochloride salt, stock solutions have been corrected for salt content. A correction factor of 0.320 has been applied using a purity value of 98% in error. However the Certificate of Analysis states the purity to be 100%. Using a purity of 98% compared to 100% produces a difference of 0.006. This is deemed to have no significant impact on the integrity of the data. The expiry date was not provided by Sigma Aldrich. On receipt, the compound was stored at room temperature (15-25°C) (the Certificate of Analysis is presented in [Appendix 1](#)).

### 2.2 Internal Standard

Cotinine-methyl-d<sub>3</sub> (Lot No. IS1107), the internal standard was supplied to Covance on 10 June 2009. The purity of the compound was stated as 99.4%. On receipt, the internal standard was stored at room temperature nominal 15-25 °C (the Certificate of Analysis is presented in [Appendix 1](#)).

Nicotine-D<sub>3</sub> Salicylate Salt (Lot No. 048K4040), the internal standard was supplied to Covance 23 June 2010. The purity of the compound was stated as 99.5%. On receipt, the internal standard was stored at room temperature nominal 15-25 °C (the Certificate of Analysis is presented in [Appendix 1](#)).

### 2.3 Materials and Methods

Internal standard solution (25µL, 40/20 ng/mL) was added to thawed 50 µL plasma samples containing K<sub>3</sub>EDTA as an anticoagulant in a 2 mL 96 deep well plate. The samples were vortex mixed and 200 µL of acetonitrile added and samples vortex mixed again. The plate containing the samples were then centrifuged (ca. 5 minutes, ca. 2000 g, nominal 4°C). The plate was then placed on the flexus system and 100 µL of the supernatant sample was automatically transferred to a 1.2mL 96 deep well plate. 10mM ammonium acetate (50 µL) was added to all wells. The plate was capped, vortex mixed and centrifuged (ca. 5 minutes, ca. 2000g, nominal 4°C) before being submitted for LC-MS/MS analysis.

Concentrations of Cotinine in calibration standards, QC samples and study samples were determined using least squares quadratic regression with the reciprocal of the concentration ( $1/x^2$ ) as weighting.

Details of the analytical method, the reagents and equipment used are presented in the analytical procedure (HB-10-082-V3) as presented in the Annex. Version V1 of this analytical procedure was used for the analysis of batches PB001 to PB015.

Any batches that deviated from this procedure in any way are discussed in the deviations section in the report.

## 2.4 Computer Systems

The following computer systems were used in this study: The version numbers of the systems are held on file at Covance.

System	Use
Nautilus	Laboratory Information Management System (LIMS)
Report Submitter	Data table generation
Analyst	Data collection and processing for all Sciex MS/MS instruments

## 3 STUDY SAMPLE ANALYSIS

### 3.1 Study Samples

The samples were generated from multiple sites (estimated six sites) in the United States and were transferred to Covance, Harrogate, UK via Covance Central Laboratories Services, Indianapolis, USA (Sponsor Study number SM 08-01).

The study design was a multi-centre, randomised, double-blind, placebo-controlled, Phase III trial of approximately 250 subjects receiving either snus (a low nitrosamine smokeless tobacco product) or placebo in a 1:1 ratio for 16 weeks. Plasma samples for analysis were taken from subjects from pre-screening and at weeks 6, 16 and 28. Each subject was expected to generate four samples for analysis. In addition an early termination sample was taken for subjects that did not complete the study.

The total number of plasma samples analysed were 817.

### 3.2 Sample Analysis

All samples from each occasion for each of the subjects were initially analysed in the same batch. Study samples were divided into analytical batches consisting of a maximum of approximately 96 plasma samples including the calibration standards and QC samples.

Samples from subjects receiving placebo were not analysed or received.

Single analysis was initially performed on each sample. The result obtained is reported for pharmacokinetic purposes.

The analytical programme was conducted in accordance with the definitive protocol presented in the Annex.

Observations and Deviations from the protocol are presented [Appendix 5](#). The study samples were received on 02 September 2010. They were stored frozen at nominal -80°C prior to analysis.

### **3.3 Sample Acceptance Criteria**

The acceptance criteria are defined in the study protocol.

### **3.4 Criteria for Repeat Analysis**

Repeat analysis was carried out for analytical reasons. The criteria for repeat analysis are present in the study protocol (Annex).

## 4 RESULTS

Numerical data may have been rounded for presentation. Therefore, manual recalculation may give slightly different values to those shown.

Representative chromatograms generated during the determination of Cotinine in human plasma study samples are presented in [Appendix 2](#).

Batches PB007 and PB012 have not been reported as the incorrect reagent was used during LC-MS/MS analysis. The reagent was re-prepared correctly and the batches successfully re-injected as batches PB007i and PB012i respectively.

Batch PB012i was injected before batches PB008, PB009 and PB010 as it contained ISR samples.

A complete repeat analysis summary is included in [Appendix 3](#).

A complete batch analysis summary is presented in [Appendix 4](#).

### 4.1 System Suitability

A system suitability check was performed as routine at the start of each sample batch. The purpose of the system suitability was to check the chromatography of the system by evaluating the retention time window of the test article, the internal standard and also to check the system response, ensuring that required sensitivity could be achieved.

The system suitability as used throughout the sample analysis comprised of a LLOQ extracted sample followed by a ULOQ extracted sample, followed by an injection of blank matrix.

The system suitability check was found to be acceptable before the injection of each batch. When two batches were injected consecutively the system suitability assessment was therefore made on the first batch. Therefore, for this study the system suitability samples in batches PB003, PB004, PB005, PB008, PB011 and PB012i were not assessed as they were injected directly after the following batches:

PB002, PB003, PB004, PB012i, PB010 and PB007i respectively.

### 4.2 Quality Control Sample Data

The QC sample data in each reported batch were within the acceptance criteria as stated in the protocol. The data are presented in [Table 1](#).

### 4.3 Calibration Standard Data

All calibration standards utilised within the regression had back calculated values that were within the acceptance criteria as stated in the protocol. The data are presented in [Table 2](#). The regression characteristics are presented in [Table 3](#).

### 4.4 Selectivity

There were no interferent peaks (>20% of the LLOQ) detected in reagent and matrix blanks in the retention window of Cotinine with the exception of the following:

In batches PB014 and PB015, a peak >20% of the LLOQ was detected in the reagent blank sample in the retention window of Cotinine (32.3% and 20.8% respectively of the LLOQ). The LLOQ calibration was raised to Cal 1 ng/mL. There were no samples with concentrations below the raised LLOQ. Interferences are evaluated using peak areas.

Additionally, there were no interferent peaks detected at the internal standard retention time, >10% of the internal standard peak area for the reagent and matrix blanks.

#### **4.5 Carryover**

There was no evidence of carryover (>20% of the LLOQ) to the blank matrix extracts when injected directly after the two highest calibration standards with exception of the following:

In batch PB005, a peak of 51.4% of the LLOQ was detected in the first matrix blank carryover (MBCO) at the retention window of Cotinine. However, in the second MBCO and all other matrix blanks peaks were <20% of the LLOQ. The LLOQ level was therefore not raised. Interferences are evaluated using peak areas.

Additionally, there were no interferent peaks detected at the internal standard retention time, >10% of the internal standard peak area for the matrix blanks.

#### **4.6 Injection Order**

Calibration standards and QC samples were chromatographed with study samples interspersed between them.

#### **4.7 Study Sample Data**

Study sample data are presented in [Table 4](#).

There were 40 samples reanalysed for analytical reasons.

A total of 817 samples were analysed in 15 batches.

In batch PB013, two samples were annotated as interference peak (IP) as an interferent peak was observed on initial and repeat analysis.

All plasma samples were stored at nominal -80°C when they arrived at Covance Laboratories Limited. Samples were collected between 08 September 2009 and 23 February 2010. However, sample analysis did not commence until 21 March 2011 due to a delay in the start of validation. As only six months stability has been confirmed (nominal -80°C), these data should therefore be considered with this in mind.

#### **4.8 Incurred Sample Reproducibility**

A total of 24 samples were reanalysed for the assessment of incurred sample reproducibility. Of these 24 samples, 12 samples had repeat values that were within 20% of each other (50%) and this is outside the acceptance criteria. The results outside the acceptance criteria have been assessed and no analytical reason can be confirmed for the differences. The chromatography and internal standard variability

were acceptable and the calibration standards and QC samples met the acceptance criteria. Although study samples were analysed outside their known stability period, the original and repeat analysed were carried out within 7 days of each other and therefore any instability of cotinine in human plasma was considered not to have affected the concentration data generated for the ISR assessment.

The variability considered acceptable for quality control samples is  $\pm 15\%$  from nominal value and this would be equivalent to a percentage difference between two values of less than or equal to 30%. 87.5% (21 out of 24) of the repeat results and original results were within 30% of each other demonstrating that the assay reproducibility in study samples, for cotinine is comparable to the acceptable variability of the quality control samples.

The analytical procedure is therefore considered to have performed with acceptable reproducibility during the study sample analysis.

The data are presented in [Table 5](#).

## 5 DISCUSSION

### 5.1 Sample Analysis

For subject R03022, two week 16 samples were received from Covance CCLS with different collection dates. This was queried with Covance CCLS and it was confirmed that the sample with the collection date of the 25th August 2009 should be reported. The other sample with the collection date of the 24th August 2009 was not reported.

For subject R04030, two screening samples were received with different collection dates (15th April 2009 and 10th July 2009). This was queried with Covance CCLS and it was confirmed that the sample taken on the 15th April 2009 was the actual screening sample and will be reported. For the sample collected on the 10th July 2009 CCLS could not confirm the actual sampling occasion and therefore this was not reported.

For subject R04053, two samples were received originally as the screening occasion with different collection dates 2nd June 2009 and 10th March 2009. When an initial update was provided by CCLS one of these samples was changed to week 6. This resulted in two week 6 occasions being available for this subject with different collection dates. This was again queried with CCLS. The sample which had remained the screening occasion with the collection date of 10th March 2009 was determined to be a screening failure. This sample was therefore not reported. The sample which had previously been changed to week 6 was confirmed to be the screening repeat and is reported as the screening occasion. The visit has been corrected and reported.

For subject R05023, two week 28 samples were received and analysed. Upon review of the data it was noted that these samples had the same collection date (8th February 2010) and were assumed therefore to be set 1 and set 2 samples. However, upon checking of the concentration data it was noted that the variation between the results for these samples was >30%, therefore seeming unlikely that these were the set 1 and set 2 samples. This was queried with CCLS. However no further clarification could be provided and therefore no reason could be provided as to why these samples had such different concentrations. Therefore the data for this subject and occasion have not been reported.

For subject R04068 week 6 samples, it appeared that two samples had been received on the 3rd August 2009. This was queried with CCLS however no further information could be provided and therefore the data was not reported for this occasion.

For subject R04050, the correct visit/occasion was unable to be confirmed for two samples. Screening occasion was originally stated on the inventory for both samples. However the collection dates of these samples were different (2nd June 2009 and 15th April 2009), therefore it cannot be confirmed if the samples are set 1 and set 2. CCLS were unable to confirm the identity of these samples and therefore the data was not reported.

For 19 subjects no randomisation number was provided by CCLS upon sample receipt. An updated list was provided by CCLS and the randomisation numbers were confirmed for all except two subjects which were not randomised onto the study and

therefore a screening number has been added as the subject number. These samples have been annotated in the data tables in the comment field, subjects S02051 and S02053.

Two samples were taken by CCLS but were not shipped to Harrogate for analysis in error. As these samples appear in the CCLS database a record was requested to be added with the collection date included in the data table. These samples (subjects R04005, week 6 and subject R04094, week 6) have been reported as No Samples (NS) in the data table.

Upon initial sample receipt four samples arrived labelled as subject R01029 and two samples for subject R01028. These samples were then later confirmed by CCLS to be identified as the other subject. Therefore the demographic database was updated and there are now four samples reported for subject R01028 and two samples reported for R01029, these samples are annotated with a comment in the data table.

A total of 32 samples were identified as above the limit of quantification upon initial analysis and were therefore reanalysed with dilution and the repeat result reported.

A total of five samples were identified as above the limit of quantification and having a high internal standard upon initial analysis and were therefore reanalysed with dilution. The repeat result is reported.

One sample had a high internal standard response upon initial analysis and was repeated with dilution (due to insufficient sample). The repeat result has been reported.

For two samples, interferent peaks were observed upon initial and repeat analysis. The repeat results have been reported and the samples annotated interference peak (IP) in the data tables.

## **5.2 Assay Performance**

The calibration standard and QC sample data indicate that the method performed acceptably during the study sample analyses.

All reported batches complied with the calibration and QC sample acceptance criteria.

## **5.3 Conclusion**

Calibration standard data, QC sample data and chromatograms indicate that the method performed acceptably during the study sample analysis.

The incurred sample reproducibility data was considered to be within the variability of the assay, however the criteria documented in the protocol was not met.

A total of 817 samples were successfully analysed in 15 reported batches. Samples were collected between 08 January 2009 and 23 February 2010. However, sample analysis did not commence until 21 March 2011 due to a delay in the completion of validation work. As stability has been confirmed (nominal -80°C) for up to six months, these data should therefore be considered with this in mind.

## 6 REFERENCE

- [1] B V Bailey: Validation of an Analytical Procedure for the Determination of Nicotine and Cotinine in Human Plasma using Solid Phase Extraction and Liquid Chromatography with Tandem Mass Spectrometric Detection (LC-MS/MS), Covance Study Number 8202356 (stability experiments ongoing study not yet finalised)
- [2] S Fenton: Validation of an Analytical Procedure for the Determination of Nicotine and Cotinine in Human Plasma (EDTA) using Solid Phase Extraction and Liquid Chromatography with Tandem Mass Spectrometric Detection (LC-MS/MS), Covance Study Number 8235697 (stability experiments ongoing study not yet finalised)

## 7 TABLES

**Table 1**  
**Determination of Cotinine in Human Plasma:**  
**Quality Control Sample Data**

Batch	Theoretical Concentration (ng/mL)		
	1.50	15.0	400
PB001	1.45	15.0	391
	1.49	15.0	393
PB002	1.44	15.2	390
	1.53	15.5	392
PB003	1.47	14.6	379
	1.50	15.3	396
PB004	1.46	14.6	392
	1.49	15.5	401
PB005	1.43	15.0	384
	1.49	15.1	400
PB006	1.45	15.4	392
	1.48	15.4	395
PB007i	1.45	14.7	383
	1.47	15.0	398
PB008	1.45	14.9	388
	1.46	15.7	404
PB009	1.43	14.2	398
	1.47	15.2	422
PB010	1.50	14.6	380
	1.52	15.2	391
PB011	1.52	15.0	401
	1.55	15.0	404

**Table 1 Continued**  
**Determination of Cotinine in Human Plasma:**  
**Quality Control Sample Data**

Batch	Theoretical Concentration (ng/mL)			
	1.50	15.0	400	2500 (10x)
PB012i	1.47	15.3	397	2480
	1.48	15.5	401	2530
PB013	1.44	14.6	387	2410
	1.52	15.2	388	2560
PB014	1.46	15.2	382	
	1.57	15.7	406	
PB015	1.57	14.8	396	2600
	1.62	14.9	422	2630
n	30	30	30	6
Mean	1.49	15.1	395	2540
SD	0.0458	0.357	10.3	80.7
RSD (%)	3.1	2.4	2.6	3.2
Accuracy(%)	99.3	100.7	98.8	101.6

(10x) analysed after ten-fold dilution with blank plasma

**Table 2**  
**Determination of Cotinine in Human Plasma:**  
**Calibration Standard Data**

Batch	Theoretical Concentration (ng/mL)								
	0.500	1.00	2.50	5.00	10.0	50.0	200	450	500
PB001	0.505	0.985	2.44	5.10	10.1	50.8	195	441	517
PB002	0.501	0.998	2.47	5.02	9.94	51.1	197	448	506
PB003	0.507	0.965	2.51	4.96	10.5	49.7	193	446	516
PB004	0.498	1.00	2.55	4.89	10.1	49.6	200	443	510
PB005	0.505	0.974	2.50	5.21	9.82	51.3	188	460	506
PB006	0.509	0.965	2.49	4.96	10.3	50.5	197	446	508
PB007i	0.499	0.986	2.59	5.09	9.89	49.4	193	460	504
PB008	0.505	0.994	2.43	4.94	10.1	51.2	204	441	501
PB009	0.508	0.970	2.45	5.15	10.2	50.2	195	433	530
PB010	0.512	0.946	2.53	5.04	9.92	52.6	189	438	526

**Table 2 Continued**  
**Determination of Cotinine in Human Plasma:**  
**Calibration Standard Data**

Batch	Theoretical Concentration (ng/mL)									
	0.500	1.00	2.50	5.00	10.0	50.0	200	450	500	
PB011	0.507	0.971	2.48	5.02	10.2	49.9	199	439	514	
PB012i	0.494	1.02	2.50	5.10	9.96	49.6	192	457	506	
PB013	0.514	0.930	2.51	5.25	10.4	48.0	196	447	514	
PB014	0.499	1.01	LLOQ	2.48	4.88	9.94	52.7	193	436	522
PB015	0.506	0.976	LLOQ	2.47	5.14	10.0	50.6	191	489	471
n	15	15	15	15	15	15	15	15	15	
Mean	0.505	0.979	2.49	5.05	10.1	50.5	195	448	510	
SD	0.00547	0.0236	0.0420	0.112	0.197	1.22	4.25	14.0	13.6	
RSD (%)	1.1	2.4	1.7	2.2	2.0	2.4	2.2	3.1	2.7	
Accuracy(%)	101.0	97.9	99.6	101.0	101.0	101.0	97.5	99.6	102.0	

LLOQ Lower limits of quantification

**Table 3**  
**Determination of Cotinine in Human Plasma:**  
**Calibration Standard Data Regression Characteristics**

Batch	2nd Degree (A)	1st Degree (B)	Intercept (C)	Correlation Coefficient
PB001	-2.31E-04	4.39E-01	8.60E-05	0.9998
PB002	-2.14E-04	4.33E-01	3.12E-02	0.9999
PB003	-2.14E-04	4.33E-01	9.34E-03	0.9996
PB004	-2.51E-04	4.48E-01	-9.78E-03	0.9999
PB005	-2.23E-04	4.38E-01	4.50E-03	0.9994
PB006	-1.95E-04	4.22E-01	2.30E-02	0.9997
PB007i	-2.49E-04	4.40E-01	2.24E-02	0.9997
PB008	-2.21E-04	4.28E-01	3.57E-02	0.9998
PB009	-2.53E-04	4.36E-01	8.61E-03	0.9996
PB010	-2.09E-04	4.29E-01	2.55E-02	0.9991
PB011	-2.12E-04	4.26E-01	3.19E-02	0.9998
PB012i	-2.26E-04	4.33E-01	3.49E-02	0.9998
PB013	-2.39E-04	4.36E-01	3.26E-02	0.9989
PB014	-1.94E-04	4.47E-01	5.18E-02	0.9995
PB015	-2.02E-04	4.45E-01	3.97E-02	0.9994

$$y = Ax^2 + Bx + C$$

**Table 4**  
**Determination of Cotinine in Human Plasma:**  
**Study Sample Data**

Subject Number	Visit	Concentration	Units	Dilution Factor	TP Comment	Collection Date	Parent Aliquot Name	Batch	Batch Date
R01001	Screening	234	ng/mL	1		18-Feb-09	HB-2405671-1	PB001	21-Mar-11
R01001	Week 6	247	ng/mL	1		14-Apr-09	HB-2405672-1	PB001	21-Mar-11
R01001	Week 16	33.2	ng/mL	1		22-Jun-09	HB-2405673-1	PB001	21-Mar-11
R01001	Week 28	190	ng/mL	1		11-Sep-09	HB-2405674-1	PB001	21-Mar-11
R01002	Screening	138	ng/mL	1		18-Feb-09	HB-2405682-1	PB001	21-Mar-11
R01002	Week 6	42.4	ng/mL	1		13-Apr-09	HB-2405683-1	PB001	21-Mar-11
R01002	Week 16	154	ng/mL	1		24-Jun-09	HB-2405684-1	PB001	21-Mar-11
R01002	Week 28	12.0	ng/mL	1		16-Sep-09	HB-2405685-1	PB001	21-Mar-11
R01003	Screening	202	ng/mL	1		18-Feb-09	HB-2405756-1	PB001	21-Mar-11
R01003	Early Term	207	ng/mL	1	Collection date updated at CCLS request	09-Mar-09	HB-2405757-1	PB001	21-Mar-11
R01004	Screening	243	ng/mL	1		02-Mar-09	HB-2405758-1	PB001	21-Mar-11
R01004	Week 6	181	ng/mL	1		22-Apr-09	HB-2405759-1	PB001	21-Mar-11
R01004	Week 16	247	ng/mL	1		02-Jul-09	HB-2405760-1	PB001	21-Mar-11
R01004	Week 28	216	ng/mL	1		21-Sep-09	HB-2405761-1	PB001	21-Mar-11
R01005	Screening	227	ng/mL	1		02-Mar-09	HB-2405752-1	PB001	21-Mar-11
R01005	Week 6	170	ng/mL	1		20-Apr-09	HB-2405753-1	PB001	21-Mar-11
R01005	Week 16	147	ng/mL	1		06-Jul-09	HB-2405754-1	PB001	21-Mar-11
R01005	Week 28	210	ng/mL	1		22-Sep-09	HB-2405755-1	PB001	21-Mar-11
R01006	Screening	344	ng/mL	1		03-Mar-09	HB-2405675-1	PB001	21-Mar-11
R01006	Week 6	422	ng/mL	1		22-Apr-09	HB-2405676-1	PB001	21-Mar-11

R01006	Week 16	290	ng/mL	1	01-Jul-09	HB-2405677-1	PB001	21-Mar-11
R01006	Week 28	271	ng/mL	1	23-Sep-09	HB-2405678-1	PB001	21-Mar-11
R01007	Screening	289	ng/mL	1	05-Mar-09	HB-2405729-1	PB001	21-Mar-11
R01007	Week 6	466	ng/mL	1	24-Apr-09	HB-2405730-1	PB001	21-Mar-11
R01007	Week 16	186	ng/mL	1	02-Jul-09	HB-2405731-1	PB001	21-Mar-11
R01007	Week 28	268	ng/mL	1	23-Sep-09	HB-2405732-1	PB001	21-Mar-11
R01008	Screening	272	ng/mL	1	04-Mar-09	HB-2405679-1	PB001	21-Mar-11
R01008	Week 6	256	ng/mL	1	27-Apr-09	HB-2405680-1	PB001	21-Mar-11
R01008	Early Term	244	ng/mL	1	28-May-09	HB-2405681-1	PB001	21-Mar-11
R01009	Screening	133	ng/mL	1	02-Mar-09	HB-2405686-1	PB001	21-Mar-11
R01009	Week 6	35.2	ng/mL	1	27-Apr-09	HB-2405687-1	PB001	21-Mar-11
R01009	Week 16	121	ng/mL	1	01-Jun-09	HB-2405688-1	PB001	21-Mar-11
R01010	Screening	418	ng/mL	1	19-Mar-09	HB-2405762-1	PB001	21-Mar-11
R01010	Week 6	437	ng/mL	1	12-May-09	HB-2405763-1	PB001	21-Mar-11
R01010	Week 16	584	ng/mL	5	14-Jul-09	HB-2405764-1	PB013	06-Apr-11
R01010	Week 28	290	ng/mL	1	06-Oct-09	HB-2405765-1	PB001	21-Mar-11
R01011	Screening	110	ng/mL	1	03-Apr-09	HB-2405778-1	PB001	21-Mar-11
R01011	Week 6	134	ng/mL	1	29-May-09	HB-2405779-1	PB001	21-Mar-11
R01011	Week 16	151	ng/mL	1	07-Aug-09	HB-2405780-1	PB001	21-Mar-11
R01011	Week 28	136	ng/mL	1	29-Oct-09	HB-2405781-1	PB001	21-Mar-11
R01012	Screening	132	ng/mL	1	01-Apr-09	HB-2405689-1	PB001	21-Mar-11
R01012	Week 6	229	ng/mL	1	29-May-09	HB-2405690-1	PB001	21-Mar-11
R01012	Week 16	311	ng/mL	1	24-Aug-09	HB-2405691-1	PB001	21-Mar-11
R01012	Week 28	222	ng/mL	1	29-Oct-09	HB-2405692-1	PB001	21-Mar-11
R01013	Screening	250	ng/mL	1	08-Apr-09	HB-2405766-1	PB001	21-Mar-11
R01013	Week 6	122	ng/mL	1	03-Jun-09	HB-2405767-1	PB001	21-Mar-11
R01013	Week 16	29.7	ng/mL	1	12-Aug-09	HB-2405768-1	PB001	21-Mar-11

R01013	Week 28	72.0	ng/mL	1	04-Nov-09	HB-2405769-1	PB001	21-Mar-11
R01014	Screening	186	ng/mL	1	08-Apr-09	HB-2405751-1	PB011	01-Apr-11
R01015	Screening	272	ng/mL	1	16-Apr-09	HB-2405782-1	PB001	21-Mar-11
R01015	Week 6	233	ng/mL	1	12-Jun-09	HB-2405783-1	PB001	21-Mar-11
R01015	Week 16	303	ng/mL	1	24-Aug-09	HB-2405784-1	PB001	21-Mar-11
R01015	Week 28	168	ng/mL	1	10-Nov-09	HB-2405785-1	PB001	21-Mar-11
R01016	Screening	105	ng/mL	1	08-May-09	HB-2405794-1	PB001	21-Mar-11
R01016	Week 6	110	ng/mL	1	26-Jun-09	HB-2405795-1	PB001	21-Mar-11
R01016	Week 16	80.0	ng/mL	1	04-Sep-09	HB-2405796-1	PB001	21-Mar-11
R01016	Week 28	84.7	ng/mL	1	24-Nov-09	HB-2405797-1	PB001	21-Mar-11
R01017	Screening	220	ng/mL	1	08-May-09	HB-2405737-1	PB001	21-Mar-11
R01017	Week 6	153	ng/mL	1	26-Jun-09	HB-2405738-1	PB001	21-Mar-11
R01017	Week 16	146	ng/mL	1	04-Sep-09	HB-2405739-1	PB001	21-Mar-11
R01017	Week 28	205	ng/mL	1	20-Nov-09	HB-2405740-1	PB001	21-Mar-11
R01018	Screening	185	ng/mL	1	06-May-09	HB-2405791-1	PB001	21-Mar-11
R01018	Week 6	226	ng/mL	1	30-Jun-09	HB-2405792-1	PB001	21-Mar-11
R01018	Early Term	219	ng/mL	1	24-Jul-09	HB-2405793-1	PB001	21-Mar-11
R01019	Screening	169	ng/mL	1	08-May-09	HB-2405699-1	PB001	21-Mar-11
R01019	Week 6	266	ng/mL	1	02-Jul-09	HB-2405700-1	PB001	21-Mar-11
R01019	Week 16	317	ng/mL	1	18-Sep-09	HB-2405701-1	PB001	21-Mar-11
R01019	Week 28	244	ng/mL	1	04-Dec-09	HB-2405702-1	PB001	21-Mar-11
R01020	Screening	84.4	ng/mL	1	29-May-09	HB-2405774-1	PB001	21-Mar-11
R01020	Week 6	< 0.500	ng/mL	1	17-Jul-09	HB-2405775-1	PB001	21-Mar-11
R01020	Week 16	< 0.500	ng/mL	1	25-Sep-09	HB-2405776-1	PB001	21-Mar-11
R01020	Week 28	1.33	ng/mL	1	23-Nov-09	HB-2405777-1	PB001	21-Mar-11
R01021	Screening	159	ng/mL	1	29-May-09	HB-2405703-1	PB002	23-Mar-11
R01021	Week 6	248	ng/mL	1	16-Jul-09	HB-2405704-1	PB002	23-Mar-11

R01021	Week 16	183	ng/mL	1		24-Sep-09	HB-2405705-1	PB002	23-Mar-11
R01021	Week 28	190	ng/mL	1		17-Dec-09	HB-2405706-1	PB002	23-Mar-11
R01022	Screening	240	ng/mL	1		29-May-09	HB-2405741-1	PB002	23-Mar-11
R01022	Week 6	295	ng/mL	1		23-Jul-09	HB-2405742-1	PB002	23-Mar-11
R01022	Week 16	257	ng/mL	1		29-Sep-09	HB-2405743-1	PB002	23-Mar-11
R01022	Week 28	238	ng/mL	1		30-Dec-09	HB-2405744-1	PB002	23-Mar-11
R01023	Screening	320	ng/mL	1		11-Jun-09	HB-2405707-1	PB002	23-Mar-11
R01023	Early Term	366	ng/mL	1		30-Jul-09	HB-2405708-1	PB002	23-Mar-11
R01024	Screening	349	ng/mL	1		16-Jun-09	HB-2405770-1	PB002	23-Mar-11
R01024	Week 6	412	ng/mL	1		04-Aug-09	HB-2405771-1	PB002	23-Mar-11
R01024	Week 16	336	ng/mL	1		15-Oct-09	HB-2405772-1	PB002	23-Mar-11
R01024	Week 28	358	ng/mL	1		06-Jan-10	HB-2405773-1	PB002	23-Mar-11
R01025	Screening	306	ng/mL	1		16-Jun-09	HB-2405721-1	PB002	23-Mar-11
R01025	Week 6	123	ng/mL	1		06-Aug-09	HB-2405722-1	PB002	23-Mar-11
R01025	Week 16	< 0.500	ng/mL	1		15-Oct-09	HB-2405723-1	PB002	23-Mar-11
R01025	Week 28	< 0.500	ng/mL	1		07-Jan-10	HB-2405724-1	PB002	23-Mar-11
R01026	Screening	254	ng/mL	1		16-Jun-09	HB-2405725-1	PB002	23-Mar-11
R01026	Week 6	185	ng/mL	1		06-Aug-09	HB-2405726-1	PB002	23-Mar-11
R01026	Week 16	352	ng/mL	1		15-Oct-09	HB-2405727-1	PB002	23-Mar-11
R01026	Week 28	275	ng/mL	1		07-Jan-10	HB-2405728-1	PB002	23-Mar-11
R01027	Screening	294	ng/mL	1		25-Jun-09	HB-2405786-1	PB002	23-Mar-11
R01027	Early Term	274	ng/mL	1		28-Jul-09	HB-2405787-1	PB002	23-Mar-11
R01028	Screening	436	ng/mL	5	Subject changed from R01029 at CCLS instruction	25-Jun-09	HB-2405709-1	PB013	06-Apr-11
R01028	Week 6	7.04	ng/mL	1	Subject changed from R01029 at CCLS instruction	13-Aug-09	HB-2405710-1	PB002	23-Mar-11
R01028	Week 16	439	ng/mL	1	Subject changed from R01029 at CCLS instruction	22-Oct-09	HB-2405711-1	PB002	23-Mar-11
R01028	Week 28	499	ng/mL	5	Subject changed from R01029 at CCLS instruction	29-Jan-10	HB-2405712-1	PB013	06-Apr-11
R01029	Screening	291	ng/mL	1	Subject changed from R01028 at CCLS instruction	25-Jun-09	HB-2405697-1	PB002	23-Mar-11

R01029	Week 6	101	ng/mL	1	Subject changed from R01028 at CCLS instruction	17-Aug-09	HB-2405698-1	PB002	23-Mar-11
R01030	Screening	78.7	ng/mL	1		07-Jul-09	HB-2405717-1	PB002	23-Mar-11
R01030	Week 6	< 0.500	ng/mL	1		27-Aug-09	HB-2405718-1	PB002	23-Mar-11
R01030	Week 16	67.9	ng/mL	1		05-Nov-09	HB-2405719-1	PB002	23-Mar-11
R01030	Week 28	13.1	ng/mL	1		28-Jan-10	HB-2405720-1	PB002	23-Mar-11
R01031	Screening	149	ng/mL	1		09-Jul-09	HB-2405747-1	PB002	23-Mar-11
R01031	Week 6	349	ng/mL	1		31-Aug-09	HB-2405748-1	PB002	23-Mar-11
R01031	Week 16	325	ng/mL	1		05-Nov-09	HB-2405749-1	PB002	23-Mar-11
R01031	Week 28	114	ng/mL	1		28-Jan-10	HB-2405750-1	PB002	23-Mar-11
R01032	Screening	94.3	ng/mL	1		09-Jul-09	HB-2405788-1	PB002	23-Mar-11
R01032	Week 6	11.2	ng/mL	1		28-Aug-09	HB-2405789-1	PB002	23-Mar-11
R01032	Week 16	< 0.500	ng/mL	1		06-Nov-09	HB-2405790-1	PB002	23-Mar-11
R01033	Screening	159	ng/mL	1		07-Jul-09	HB-2405669-1	PB002	23-Mar-11
R01033	Week 16	200	ng/mL	1		04-Sep-09	HB-2405670-1	PB002	23-Mar-11
R01034	Screening	439	ng/mL	5		23-Jul-09	HB-2405693-1	PB013	06-Apr-11
R01034	Week 6	492	ng/mL	1		11-Sep-09	HB-2405694-1	PB002	23-Mar-11
R01034	Week 16	448	ng/mL	1		19-Nov-09	HB-2405695-1	PB002	23-Mar-11
R01034	Week 28	356	ng/mL	1		11-Feb-10	HB-2405696-1	PB002	23-Mar-11
R01035	Screening	262	ng/mL	1		28-Jul-09	HB-2405713-1	PB002	23-Mar-11
R01035	Week 6	265	ng/mL	1		10-Sep-09	HB-2405714-1	PB002	23-Mar-11
R01035	Week 16	289	ng/mL	1		19-Nov-09	HB-2405715-1	PB002	23-Mar-11
R01035	Week 28	229	ng/mL	1		11-Feb-10	HB-2405716-1	PB002	23-Mar-11
R01036	Screening	223	ng/mL	1		28-Jul-09	HB-2405745-1	PB002	23-Mar-11
R01036	Week 6	55.3	ng/mL	1		10-Sep-09	HB-2405746-1	PB002	23-Mar-11
R01037	Screening	252	ng/mL	1		28-Jul-09	HB-2405733-1	PB002	23-Mar-11
R01037	Week 6	301	ng/mL	1		22-Sep-09	HB-2405734-1	PB002	23-Mar-11
R01037	Week 16	260	ng/mL	1		20-Nov-09	HB-2405735-1	PB002	23-Mar-11

R01037	Week 28	402	ng/mL	5		12-Feb-10	HB-2405736-1	PB013	06-Apr-11
R02001	Week 6	214	ng/mL	1		18-May-09	HB-2405847-1	PB002	23-Mar-11
R02001	Early Term	261	ng/mL	1		18-May-09	HB-2405848-1	PB002	23-Mar-11
R02002	Screening	170	ng/mL	1		06-Mar-09	HB-2405861-1	PB002	23-Mar-11
R02002	Week 6	191	ng/mL	1		29-Apr-09	HB-2405862-1	PB002	23-Mar-11
R02002	Week 16	27.3	ng/mL	1		07-Jul-09	HB-2405863-1	PB002	23-Mar-11
R02002	Week 28	< 0.500	ng/mL	1		29-Sep-09	HB-2405864-1	PB002	23-Mar-11
R02003	Screening	156	ng/mL	1		05-Mar-09	HB-2405798-1	PB002	23-Mar-11
R02003	Week 6	57.4	ng/mL	1		29-Apr-09	HB-2405799-1	PB002	23-Mar-11
R02003	Week 16	35.8	ng/mL	1		08-Jul-09	HB-2405800-1	PB002	23-Mar-11
R02003	Week 28	0.671	ng/mL	1	Collection date updated at CCLS request	01-Oct-09	HB-2405801-1	PB002	23-Mar-11
R02004	Screening	279	ng/mL	1		11-Mar-09	HB-2405835-1	PB002	23-Mar-11
R02004	Early Term	241	ng/mL	1		14-May-09	HB-2405836-1	PB002	23-Mar-11
R02005	Screening	207	ng/mL	1		12-Mar-09	HB-2405810-1	PB002	23-Mar-11
R02005	Week 6	21.8	ng/mL	1		05-May-09	HB-2405811-1	PB002	23-Mar-11
R02005	Week 16	88.4	ng/mL	1		14-Jul-09	HB-2405812-1	PB002	23-Mar-11
R02005	Week 28	90.8	ng/mL	1		06-Oct-09	HB-2405813-1	PB002	23-Mar-11
R02006	Screening	286	ng/mL	1		12-Mar-09	HB-2405832-1	PB003	23-Mar-11
R02006	Week 6	156	ng/mL	1		07-May-09	HB-2405833-1	PB003	23-Mar-11
R02006	Early Term	368	ng/mL	1		04-Aug-09	HB-2405834-1	PB003	23-Mar-11
R02007	Screening	265	ng/mL	1		07-Apr-09	HB-2405843-1	PB003	23-Mar-11
R02007	Week 6	189	ng/mL	1		28-May-09	HB-2405844-1	PB003	23-Mar-11
R02007	Week 16	231	ng/mL	1		06-Aug-09	HB-2405845-1	PB003	23-Mar-11
R02007	Week 28	262	ng/mL	1		29-Oct-09	HB-2405846-1	PB003	23-Mar-11
R02008	Screening	271	ng/mL	1		07-Apr-09	HB-2405841-1	PB003	23-Mar-11
R02008	Week 6	396	ng/mL	1		04-Jun-09	HB-2405842-1	PB003	23-Mar-11
R02009	Screening	297	ng/mL	1		08-Apr-09	HB-2405849-1	PB003	23-Mar-11

R02009	Week 6	5.09	ng/mL	1	02-Jun-09	HB-2405850-1	PB003	23-Mar-11
R02009	Week 16	175	ng/mL	1	11-Aug-09	HB-2405851-1	PB003	23-Mar-11
R02009	Week 28	293	ng/mL	1	03-Nov-09	HB-2405852-1	PB003	23-Mar-11
R02010	Screening	220	ng/mL	1	09-Apr-09	HB-2405802-1	PB003	23-Mar-11
R02010	Week 6	184	ng/mL	1	02-Jun-09	HB-2405803-1	PB003	23-Mar-11
R02010	Week 16	240	ng/mL	1	12-Aug-09	HB-2405804-1	PB003	23-Mar-11
R02010	Week 28	269	ng/mL	1	04-Nov-09	HB-2405805-1	PB003	23-Mar-11
R02011	Screening	292	ng/mL	1	10-Apr-09	HB-2405806-1	PB003	23-Mar-11
R02011	Week 6	368	ng/mL	1	04-Jun-09	HB-2405807-1	PB003	23-Mar-11
R02011	Week 16	221	ng/mL	1	13-Aug-09	HB-2405808-1	PB003	23-Mar-11
R02011	Week 28	321	ng/mL	1	05-Nov-09	HB-2405809-1	PB003	23-Mar-11
R02012	Screening	330	ng/mL	1	15-Apr-09	HB-2405865-1	PB003	23-Mar-11
R02012	Week 6	188	ng/mL	1	10-Jun-09	HB-2405866-1	PB003	23-Mar-11
R02012	Week 16	196	ng/mL	1	18-Aug-09	HB-2405867-1	PB003	23-Mar-11
R02012	Week 28	210	ng/mL	1	09-Nov-09	HB-2405868-1	PB003	23-Mar-11
R02013	Screening	328	ng/mL	1	15-Apr-09	HB-2405895-1	PB003	23-Mar-11
R02013	Week 6	225	ng/mL	1	10-Jun-09	HB-2405896-1	PB003	23-Mar-11
R02013	Week 16	309	ng/mL	1	18-Aug-09	HB-2405897-1	PB003	23-Mar-11
R02013	Week 28	294	ng/mL	1	10-Nov-09	HB-2405898-1	PB003	23-Mar-11
R02014	Screening	322	ng/mL	1	24-Apr-09	HB-2405877-1	PB003	23-Mar-11
R02014	Week 6	232	ng/mL	1	15-Jun-09	HB-2405878-1	PB003	23-Mar-11
R02014	Week 16	302	ng/mL	1	24-Aug-09	HB-2405879-1	PB003	23-Mar-11
R02014	Week 28	301	ng/mL	1	16-Nov-09	HB-2405880-1	PB003	23-Mar-11
R02015	Screening	551	ng/mL	5	24-Apr-09	HB-2405891-1	PB013	06-Apr-11
R02015	Week 6	309	ng/mL	1	16-Jun-09	HB-2405892-1	PB003	23-Mar-11
R02015	Week 16	343	ng/mL	1	25-Aug-09	HB-2405893-1	PB003	23-Mar-11
R02015	Week 28	484	ng/mL	1	17-Nov-09	HB-2405894-1	PB003	23-Mar-11

R02016	Screening	149	ng/mL	1	24-Apr-09	HB-2405824-1	PB003	23-Mar-11
R02016	Week 6	12.2	ng/mL	1	19-Jun-09	HB-2405825-1	PB003	23-Mar-11
R02016	Week 16	97.2	ng/mL	1	01-Sep-09	HB-2405826-1	PB003	23-Mar-11
R02016	Week 28	80.3	ng/mL	1	20-Nov-09	HB-2405827-1	PB003	23-Mar-11
R02017	Screening	186	ng/mL	1	27-Apr-09	HB-2405814-1	PB003	23-Mar-11
R02017	Week 6	25.1	ng/mL	1	19-Jun-09	HB-2405815-1	PB003	23-Mar-11
R02017	Week 16	274	ng/mL	1	24-Aug-09	HB-2405816-1	PB003	23-Mar-11
R02017	Week 28	280	ng/mL	1	20-Nov-09	HB-2405817-1	PB003	23-Mar-11
R02018	Screening	184	ng/mL	1	07-May-09	HB-2405882-1	PB003	23-Mar-11
R02018	Week 6	118	ng/mL	1	02-Jul-09	HB-2405883-1	PB003	23-Mar-11
R02018	Early Term	177	ng/mL	1	07-Jul-09	HB-2405884-1	PB003	23-Mar-11
R02019	Screening	165	ng/mL	1	12-May-09	HB-2405853-1	PB003	23-Mar-11
R02019	Week 6	130	ng/mL	1	06-Jul-09	HB-2405854-1	PB003	23-Mar-11
R02019	Week 16	176	ng/mL	1	18-Sep-09	HB-2405855-1	PB003	23-Mar-11
R02019	Week 28	205	ng/mL	1	08-Dec-09	HB-2405856-1	PB003	23-Mar-11
R02020	Screening	278	ng/mL	1	14-May-09	HB-2405875-1	PB003	23-Mar-11
R02020	Week 6	117	ng/mL	1	09-Jul-09	HB-2405876-1	PB003	23-Mar-11
R02021	Screening	179	ng/mL	1	27-May-09	HB-2405821-1	PB003	23-Mar-11
R02021	Week 16	< 0.500	ng/mL	1	25-Sep-09	HB-2405822-1	PB003	23-Mar-11
R02021	Week 28	153	ng/mL	1	11-Dec-09	HB-2405823-1	PB003	23-Mar-11
R02022	Screening	191	ng/mL	1	18-Jun-09	HB-2405885-1	PB003	23-Mar-11
R02022	Week 6	120	ng/mL	1	14-Aug-09	HB-2405886-1	PB003	23-Mar-11
R02022	Week 16	164	ng/mL	1	20-Nov-09	HB-2405887-1	PB003	23-Mar-11
R02022	Week 28	231	ng/mL	1	11-Feb-10	HB-2405888-1	PB003	23-Mar-11
R02023	Screening	107	ng/mL	1	18-Jun-09	HB-2405818-1	PB003	23-Mar-11
R02023	Week 6	93.6	ng/mL	1	14-Aug-09	HB-2405819-1	PB003	23-Mar-11
R02023	Week 16	23.6	ng/mL	1	22-Oct-09	HB-2405820-1	PB003	23-Mar-11

R02024	Screening	58.6	ng/mL	1	26-Jun-09	HB-2405906-1	PB003	23-Mar-11
R02024	Week 6	10.8	ng/mL	1	21-Aug-09	HB-2405907-1	PB003	23-Mar-11
R02024	Week 16	< 0.500	ng/mL	1	13-Nov-09	HB-2405908-1	PB003	23-Mar-11
R02024	Week 28	2.08	ng/mL	1	29-Jan-10	HB-2405909-1	PB003	23-Mar-11
R02025	Screening	186	ng/mL	1	29-Jun-09	HB-2405904-1	PB003	23-Mar-11
R02025	Week 6	112	ng/mL	1	25-Aug-09	HB-2405905-1	PB003	23-Mar-11
R02026	Screening	197	ng/mL	1	30-Jun-09	HB-2405837-1	PB004	24-Mar-11
R02026	Week 6	182	ng/mL	1	26-Aug-09	HB-2405838-1	PB004	24-Mar-11
R02026	Week 16	217	ng/mL	1	04-Nov-09	HB-2405839-1	PB004	24-Mar-11
R02026	Week 28	551	ng/mL	5	27-Jan-10	HB-2405840-1	PB013	06-Apr-11
R02027	Screening	304	ng/mL	1	01-Jul-09	HB-2405828-1	PB004	24-Mar-11
R02027	Week 6	37.4	ng/mL	1	26-Aug-09	HB-2405829-1	PB004	24-Mar-11
R02027	Week 16	354	ng/mL	1	04-Nov-09	HB-2405830-1	PB004	24-Mar-11
R02027	Week 28	365	ng/mL	1	27-Jan-10	HB-2405831-1	PB004	24-Mar-11
R02028	Screening	200	ng/mL	1	08-Jul-09	HB-2405900-1	PB004	24-Mar-11
R02028	Week 6	198	ng/mL	1	02-Sep-09	HB-2405901-1	PB004	24-Mar-11
R02028	Week 16	158	ng/mL	1	11-Nov-09	HB-2405902-1	PB004	24-Mar-11
R02028	Week 28	193	ng/mL	1	03-Feb-10	HB-2405903-1	PB004	24-Mar-11
R02029	Screening	405	ng/mL	1	09-Jul-09	HB-2405869-1	PB004	24-Mar-11
R02029	Week 6	77.5	ng/mL	1	04-Sep-09	HB-2405870-1	PB004	24-Mar-11
R02029	Week 16	537	ng/mL	5	12-Nov-09	HB-2405871-1	PB013	06-Apr-11
R02029	Week 28	602	ng/mL	5	04-Feb-10	HB-2405872-1	PB013	06-Apr-11
R02030	Screening	246	ng/mL	1	16-Jul-09	HB-2405889-1	PB004	24-Mar-11
R02030	Early Term	247	ng/mL	1	09-Sep-09	HB-2405890-1	PB004	24-Mar-11
R02031	Screening	205	ng/mL	1	20-Jul-09	HB-2405857-1	PB004	24-Mar-11
R02031	Week 6	16.0	ng/mL	1	10-Sep-09	HB-2405858-1	PB004	24-Mar-11
R02031	Week 16	6.04	ng/mL	1	19-Nov-09	HB-2405859-1	PB004	24-Mar-11

R02031	Week 28	100	ng/mL	1	11-Feb-10	HB-2405860-1	PB004	24-Mar-11
R02032	Screening	121	ng/mL	1	21-Jul-09	HB-2405873-1	PB004	24-Mar-11
R02032	Week 6	12.3	ng/mL	1	16-Sep-09	HB-2405874-1	PB004	24-Mar-11
R03001	Screening	28.6	ng/mL	1	18-Feb-09	HB-2405988-1	PB004	24-Mar-11
R03001	Week 6	19.5	ng/mL	1	10-Apr-09	HB-2405989-1	PB004	24-Mar-11
R03001	Week 16	22.0	ng/mL	1	22-Jun-09	HB-2405990-1	PB004	24-Mar-11
R03001	Week 28	70.3	ng/mL	1	14-Sep-09	HB-2405991-1	PB004	24-Mar-11
R03002	Screening	400	ng/mL	1	23-Feb-09	HB-2405919-1	PB004	24-Mar-11
R03002	Week 6	< 0.500	ng/mL	1	13-Apr-09	HB-2405920-1	PB004	24-Mar-11
R03002	Week 16	< 0.500	ng/mL	1	22-Jun-09	HB-2405921-1	PB004	24-Mar-11
R03002	Week 28	< 0.500	ng/mL	1	14-Sep-09	HB-2405922-1	PB004	24-Mar-11
R03003	Screening	344	ng/mL	1	23-Feb-09	HB-2405984-1	PB004	24-Mar-11
R03003	Week 6	357	ng/mL	1	13-Apr-09	HB-2405985-1	PB004	24-Mar-11
R03003	Week 16	210	ng/mL	1	22-Jun-09	HB-2405986-1	PB004	24-Mar-11
R03003	Week 28	289	ng/mL	1	15-Sep-09	HB-2405987-1	PB004	24-Mar-11
R03004	Screening	251	ng/mL	1	18-Feb-09	HB-2405980-1	PB004	24-Mar-11
R03004	Week 6	176	ng/mL	1	13-Apr-09	HB-2405981-1	PB004	24-Mar-11
R03004	Week 16	296	ng/mL	1	23-Jun-09	HB-2405982-1	PB004	24-Mar-11
R03004	Week 28	140	ng/mL	1	14-Sep-09	HB-2405983-1	PB004	24-Mar-11
R03005	Screening	294	ng/mL	1	25-Feb-09	HB-2405962-1	PB004	24-Mar-11
R03005	Week 6	309	ng/mL	1	14-Apr-09	HB-2405963-1	PB004	24-Mar-11
R03005	Early Term	463	ng/mL	1	11-Jun-09	HB-2405964-1	PB004	24-Mar-11
R03006	Screening	125	ng/mL	1	25-Feb-09	HB-2405929-1	PB004	24-Mar-11
R03006	Week 6	111	ng/mL	1	13-Apr-09	HB-2405930-1	PB004	24-Mar-11
R03006	Week 16	33.1	ng/mL	1	23-Jun-09	HB-2405931-1	PB004	24-Mar-11
R03006	Week 28	64.7	ng/mL	1	16-Sep-09	HB-2405932-1	PB004	24-Mar-11
R03007	Screening	336	ng/mL	1	25-Feb-09	HB-2405967-1	PB004	24-Mar-11

R03007	Week 6	10.2	ng/mL	1		15-Apr-09	HB-2405968-1	PB004	24-Mar-11
R03007	Week 16	256	ng/mL	1		25-Jun-09	HB-2405969-1	PB004	24-Mar-11
R03007	Week 28	408	ng/mL	1		16-Sep-09	HB-2405970-1	PB004	24-Mar-11
R03008	Screening	189	ng/mL	1		18-Feb-09	HB-2405972-1	PB004	24-Mar-11
R03008	Week 6	7.32	ng/mL	1		14-Apr-09	HB-2405973-1	PB004	24-Mar-11
R03008	Week 16	< 0.500	ng/mL	1		23-Jun-09	HB-2405974-1	PB004	24-Mar-11
R03008	Week 28	< 0.500	ng/mL	1		15-Sep-09	HB-2405975-1	PB004	24-Mar-11
R03009	Screening	375	ng/mL	1		25-Feb-09	HB-2405916-1	PB004	24-Mar-11
R03009	Week 6	52.7	ng/mL	1		21-Apr-09	HB-2405917-1	PB004	24-Mar-11
R03009	Early Term	166	ng/mL	1		06-May-09	HB-2405918-1	PB004	24-Mar-11
R03010	Screening	36.8	ng/mL	1		05-Mar-09	HB-2405999-1	PB004	24-Mar-11
R03010	Week 6	< 0.500	ng/mL	1		22-Apr-09	HB-2406000-1	PB004	24-Mar-11
R03010	Week 16	< 0.500	ng/mL	1		07-Jul-09	HB-2406001-1	PB004	24-Mar-11
R03010	Week 28	< 0.500	ng/mL	1		22-Sep-09	HB-2406002-1	PB004	24-Mar-11
R03011	Screening	58.8	ng/mL	1		12-Mar-09	HB-2405938-1	PB004	24-Mar-11
R03011	Week 6	88.8	ng/mL	1		05-May-09	HB-2405939-1	PB004	24-Mar-11
R03011	Week 16	45.2	ng/mL	1		15-Jul-09	HB-2405940-1	PB004	24-Mar-11
R03011	Week 28	90.9	ng/mL	1		05-Oct-09	HB-2405941-1	PB004	24-Mar-11
R03012	Screening	306	ng/mL	1		26-Mar-09	HB-2405965-1	PB004	24-Mar-11
R03012	Week 16	193	ng/mL	1	Occasion changed at CCLS request	22-Apr-09	HB-2405966-1	PB004	24-Mar-11
R03013	Screening	223	ng/mL	1		26-Mar-09	HB-2405910-1	PB005	24-Mar-11
R03013	Week 6	136	ng/mL	1		20-May-09	HB-2405911-1	PB005	24-Mar-11
R03013	Week 16	231	ng/mL	1		03-Aug-09	HB-2405912-1	PB005	24-Mar-11
R03013	Week 28	144	ng/mL	1		19-Oct-09	HB-2405913-1	PB005	24-Mar-11
R03014	Screening	741	ng/mL	5		26-Mar-09	HB-2405942-1	PB013	06-Apr-11
R03014	Week 6	778	ng/mL	5		21-May-09	HB-2405943-1	PB013	06-Apr-11
R03014	Early Term	598	ng/mL	5		17-Jul-09	HB-2405944-1	PB013	06-Apr-11

R03015	Screening	75.3	ng/mL	1	30-Mar-09	HB-2405923-1	PB005	24-Mar-11
R03015	Early Term	161	ng/mL	1	04-Jun-09	HB-2405924-1	PB005	24-Mar-11
R03016	Screening	286	ng/mL	1	31-Mar-09	HB-2405959-1	PB005	24-Mar-11
R03016	Week 6	290	ng/mL	1	26-May-09	HB-2405958-1	PB005	24-Mar-11
R03016	Week 16	267	ng/mL	1	11-Aug-09	HB-2405960-1	PB005	24-Mar-11
R03016	Week 28	159	ng/mL	1	27-Oct-09	HB-2405961-1	PB005	24-Mar-11
R03017	Screening	0.810	ng/mL	1	08-Apr-09	HB-2406007-1	PB005	24-Mar-11
R03017	Early Term	1.15	ng/mL	1	26-May-09	HB-2406008-1	PB005	24-Mar-11
R03018	Screening	133	ng/mL	1	08-Apr-09	HB-2405925-1	PB005	24-Mar-11
R03018	Week 6	10.4	ng/mL	1	01-Jun-09	HB-2405926-1	PB005	24-Mar-11
R03018	Week 16	6.42	ng/mL	1	25-Aug-09	HB-2405927-1	PB005	24-Mar-11
R03019	Screening	276	ng/mL	1	16-Apr-09	HB-2405995-1	PB005	24-Mar-11
R03019	Week 6	173	ng/mL	1	08-Jun-09	HB-2405996-1	PB005	24-Mar-11
R03019	Week 16	238	ng/mL	1	20-Aug-09	HB-2405997-1	PB005	24-Mar-11
R03019	Week 28	217	ng/mL	1	10-Nov-09	HB-2405998-1	PB005	24-Mar-11
R03020	Screening	81.7	ng/mL	1	23-Apr-09	HB-2405950-1	PB005	24-Mar-11
R03020	Week 6	98.1	ng/mL	1	10-Jun-09	HB-2405951-1	PB005	24-Mar-11
R03020	Week 16	36.3	ng/mL	1	24-Aug-09	HB-2405952-1	PB005	24-Mar-11
R03020	Week 28	138	ng/mL	1	10-Nov-09	HB-2405953-1	PB005	24-Mar-11
R03021	Screening	305	ng/mL	1	23-Apr-09	HB-2405933-1	PB011	01-Apr-11
R03022	Screening	182	ng/mL	1	30-Apr-09	HB-2405945-1	PB005	24-Mar-11
R03022	Week 6	172	ng/mL	1	16-Jun-09	HB-2405946-1	PB005	24-Mar-11
R03022	Week 16	136	ng/mL	1	25-Aug-09	HB-2405948-1	PB005	24-Mar-11
R03022	Week 28	160	ng/mL	1	16-Nov-09	HB-2405949-1	PB005	24-Mar-11
R03023	Screening	167	ng/mL	1	30-Apr-09	HB-2405976-1	PB005	24-Mar-11
R03023	Early Term	112	ng/mL	1	17-Jun-09	HB-2405977-1	PB005	24-Mar-11
R03024	Screening	93.7	ng/mL	1	29-Apr-09	HB-2405978-1	PB005	24-Mar-11

R03024	Early Term	35.1	ng/mL	1	08-Jun-09	HB-2405979-1	PB005	24-Mar-11
R03025	Screening	207	ng/mL	1	06-May-09	HB-2405992-1	PB005	24-Mar-11
R03025	Week 6	139	ng/mL	1	24-Jun-09	HB-2405993-1	PB005	24-Mar-11
R03025	Early Term	247	ng/mL	1	04-Aug-09	HB-2405994-1	PB005	24-Mar-11
R03026	Screening	360	ng/mL	1	07-May-09	HB-2405934-1	PB005	24-Mar-11
R03026	Week 6	537	ng/mL	5	23-Jun-09	HB-2405935-1	PB013	06-Apr-11
R03026	Week 16	283	ng/mL	1	01-Sep-09	HB-2405936-1	PB005	24-Mar-11
R03026	Week 28	475	ng/mL	1	18-Nov-09	HB-2405937-1	PB005	24-Mar-11
R03027	Screening	216	ng/mL	1	06-May-09	HB-2405914-1	PB005	24-Mar-11
R03027	Week 6	225	ng/mL	1	24-Jun-09	HB-2405915-1	PB005	24-Mar-11
R03028	Screening	135	ng/mL	1	07-May-09	HB-2406003-1	PB005	24-Mar-11
R03028	Week 6	90.3	ng/mL	1	30-Jun-09	HB-2406004-1	PB005	24-Mar-11
R03028	Week 16	126	ng/mL	1	08-Sep-09	HB-2406005-1	PB005	24-Mar-11
R03028	Week 28	125	ng/mL	1	23-Nov-09	HB-2406006-1	PB005	24-Mar-11
R03029	Screening	218	ng/mL	1	06-May-09	HB-2405956-1	PB005	24-Mar-11
R03029	Week 6	123	ng/mL	1	30-Jun-09	HB-2405957-1	PB005	24-Mar-11
R03030	Screening	307	ng/mL	1	07-May-09	HB-2405928-1	PB011	01-Apr-11
R03031	Screening	149	ng/mL	1	06-May-09	HB-2405954-1	PB005	24-Mar-11
R03031	Week 6	218	ng/mL	1	16-Jul-09	HB-2405955-1	PB005	24-Mar-11
R03032	Screening	188	ng/mL	1	11-May-09	HB-2405971-1	PB011	01-Apr-11
R04001	Screening	322	ng/mL	1	20-Feb-09	HB-2406280-1	PB005	24-Mar-11
R04001	Week 6	248	ng/mL	1	14-Apr-09	HB-2406281-1	PB005	24-Mar-11
R04001	Week 16	254	ng/mL	1	22-Jun-09	HB-2406282-1	PB005	24-Mar-11
R04002	Screening	216	ng/mL	1	20-Feb-09	HB-2406212-1	PB005	24-Mar-11
R04002	Week 6	241	ng/mL	1	14-Apr-09	HB-2406213-1	PB005	24-Mar-11
R04002	Week 16	223	ng/mL	1	22-Jun-09	HB-2406214-1	PB005	24-Mar-11
R04002	Early Term	303	ng/mL	1	14-Sep-09	HB-2406215-1	PB005	24-Mar-11

R04003	Screening	296	ng/mL	1		20-Feb-09	HB-2406054-1	PB005	24-Mar-11
R04003	Week 6	40.0	ng/mL	1		14-Apr-09	HB-2406055-1	PB005	24-Mar-11
R04003	Week 16	255	ng/mL	1		22-Jun-09	HB-2406056-1	PB005	24-Mar-11
R04003	Early Term	292	ng/mL	1		15-Sep-09	HB-2406057-1	PB005	24-Mar-11
R04004	Screening	278	IP ng/mL	1		25-Feb-09	HB-2406098-1	PB013	06-Apr-11
R04004	Early Term	266	IP ng/mL	1		14-Apr-09	HB-2406099-1	PB013	06-Apr-11
R04005	Screening	314	ng/mL	1		25-Feb-09	HB-2406021-1	PB005	24-Mar-11
R04005	Week 6	NS	ng/mL	1	NS	15-Apr-09	HB-2806494-1		
R04005	Week 16	278	ng/mL	1		24-Jun-09	HB-2406022-1	PB005	24-Mar-11
R04005	Early Term	332	ng/mL	1	collection date changed at CCLS request	15-Sep-09	HB-2406023-1	PB005	24-Mar-11
R04006	Screening	235	ng/mL	1		08-Mar-09	HB-2406287-1	PB005	24-Mar-11
R04006	Early Term	196	ng/mL	1		13-Apr-09	HB-2406288-1	PB005	24-Mar-11
R04007	Screening	276	ng/mL	1		03-Mar-09	HB-2406242-1	PB006	26-Mar-11
R04007	Week 6	375	ng/mL	1		22-Apr-09	HB-2406243-1	PB006	26-Mar-11
R04007	Week 16	338	ng/mL	1		07-Jul-09	HB-2406244-1	PB006	26-Mar-11
R04007	Week 28	381	ng/mL	1		29-Sep-09	HB-2406245-1	PB006	26-Mar-11
R04008	Screening	438	ng/mL	1		26-Feb-09	HB-2406307-1	PB006	26-Mar-11
R04008	Week 6	119	ng/mL	1		22-Apr-09	HB-2406308-1	PB006	26-Mar-11
R04008	Week 16	298	ng/mL	1		02-Jul-09	HB-2406309-1	PB006	26-Mar-11
R04008	Week 28	318	ng/mL	1		23-Sep-09	HB-2406310-1	PB006	26-Mar-11
R04009	Screening	160	ng/mL	1		26-Feb-09	HB-2406109-1	PB006	26-Mar-11
R04009	Week 6	141	ng/mL	1		24-Apr-09	HB-2406110-1	PB006	26-Mar-11
R04009	Early Term	152	ng/mL	1		23-Jul-09	HB-2406111-1	PB006	26-Mar-11
R04010	Screening	373	ng/mL	1		26-Feb-09	HB-2406060-1	PB006	26-Mar-11
R04010	Week 6	128	ng/mL	1		22-Apr-09	HB-2406061-1	PB006	26-Mar-11
R04010	Week 16	239	ng/mL	1		07-Jul-09	HB-2406062-1	PB006	26-Mar-11
R04010	Week 28	312	ng/mL	1		23-Sep-09	HB-2406063-1	PB006	26-Mar-11

R04011	Screening	151	ng/mL	1	04-Mar-09	HB-2406372-1	PB006	26-Mar-11
R04011	Week 6	79.9	ng/mL	1	22-Apr-09	HB-2406373-1	PB006	26-Mar-11
R04011	Week 16	177	ng/mL	1	29-Jul-09	HB-2406374-1	PB006	26-Mar-11
R04011	Week 28	94.4	ng/mL	1	23-Sep-09	HB-2406375-1	PB006	26-Mar-11
R04012	Screening	336	ng/mL	1	04-Mar-09	HB-2406216-1	PB006	26-Mar-11
R04012	Week 6	103	ng/mL	1	22-Apr-09	HB-2406217-1	PB006	26-Mar-11
R04012	Week 16	54.2	ng/mL	1	01-Jul-09	HB-2406218-1	PB006	26-Mar-11
R04012	Week 28	114	ng/mL	1	23-Sep-09	HB-2406219-1	PB006	26-Mar-11
R04013	Screening	360	ng/mL	1	04-Mar-09	HB-2406198-1	PB006	26-Mar-11
R04013	Early Term	318	ng/mL	1	20-May-09	HB-2406199-1	PB006	26-Mar-11
R04014	Screening	289	ng/mL	1	04-Mar-09	HB-2406129-1	PB006	26-Mar-11
R04014	Week 6	333	ng/mL	1	22-Apr-09	HB-2406130-1	PB006	26-Mar-11
R04014	Week 16	169	ng/mL	1	06-Jul-09	HB-2406131-1	PB006	26-Mar-11
R04015	Screening	435	ng/mL	1	04-Mar-09	HB-2406220-1	PB006	26-Mar-11
R04015	Week 6	217	ng/mL	1	22-Apr-09	HB-2406221-1	PB006	26-Mar-11
R04015	Week 16	473	ng/mL	1	01-Jul-09	HB-2406222-1	PB006	26-Mar-11
R04015	Week 28	292	ng/mL	1	23-Sep-09	HB-2406223-1	PB006	26-Mar-11
R04016	Screening	280	ng/mL	1	12-Mar-09	HB-2406026-1	PB006	26-Mar-11
R04016	Week 6	161	ng/mL	1	24-Apr-09	HB-2406027-1	PB006	26-Mar-11
R04016	Week 16	86.4	ng/mL	1	02-Jul-09	HB-2406028-1	PB006	26-Mar-11
R04016	Week 28	292	ng/mL	1	25-Sep-09	HB-2406029-1	PB006	26-Mar-11
R04017	Screening	232	ng/mL	1	08-Mar-09	HB-2406082-1	PB006	26-Mar-11
R04017	Week 6	136	ng/mL	1	24-Apr-09	HB-2406083-1	PB006	26-Mar-11
R04017	Week 16	214	ng/mL	1	02-Jul-09	HB-2406084-1	PB006	26-Mar-11
R04017	Week 28	214	ng/mL	1	25-Sep-09	HB-2406085-1	PB006	26-Mar-11
R04018	Screening	323	ng/mL	1	10-Mar-09	HB-2406186-1	PB006	26-Mar-11
R04018	Week 6	254	ng/mL	1	24-Apr-09	HB-2406187-1	PB006	26-Mar-11

R04018	Week 16	288	ng/mL	1	01-Jul-09	HB-2406188-1	PB006	26-Mar-11
R04018	Week 28	202	ng/mL	1	25-Sep-09	HB-2406189-1	PB006	26-Mar-11
R04019	Screening	370	ng/mL	1	20-Mar-09	HB-2406349-1	PB006	26-Mar-11
R04019	Week 6	< 0.500	ng/mL	1	13-May-09	HB-2406350-1	PB006	26-Mar-11
R04019	Week 16	109	ng/mL	1	11-Aug-09	HB-2406351-1	PB006	26-Mar-11
R04019	Week 28	244	ng/mL	1	12-Oct-09	HB-2406352-1	PB006	26-Mar-11
R04020	Screening	327	ng/mL	1	20-Mar-09	HB-2406166-1	PB006	26-Mar-11
R04020	Week 6	117	ng/mL	1	11-May-09	HB-2406167-1	PB006	26-Mar-11
R04020	Week 16	114	ng/mL	1	20-Jul-09	HB-2406168-1	PB006	26-Mar-11
R04020	Week 28	115	ng/mL	1	12-Oct-09	HB-2406169-1	PB006	26-Mar-11
R04021	Screening	186	ng/mL	1	20-Mar-09	HB-2406263-1	PB006	26-Mar-11
R04021	Week 6	274	ng/mL	1	11-May-09	HB-2406264-1	PB006	26-Mar-11
R04021	Early Term	243	ng/mL	1	31-Jul-09	HB-2406265-1	PB006	26-Mar-11
R04022	Screening	134	ng/mL	1	26-Mar-09	HB-2406030-1	PB006	26-Mar-11
R04022	Week 6	75.0	ng/mL	1	15-May-09	HB-2406031-1	PB006	26-Mar-11
R04022	Week 16	90.9	ng/mL	1	18-Aug-09	HB-2406032-1	PB006	26-Mar-11
R04022	Week 28	130	ng/mL	1	09-Oct-09	HB-2406033-1	PB006	26-Mar-11
R04023	Screening	228	ng/mL	1	26-Mar-09	HB-2406311-1	PB006	26-Mar-11
R04023	Week 6	1.45	ng/mL	1	11-May-09	HB-2406312-1	PB006	26-Mar-11
R04023	Week 16	< 0.500	ng/mL	1	20-Jul-09	HB-2406313-1	PB006	26-Mar-11
R04023	Week 28	92.5	ng/mL	1	12-Oct-09	HB-2406314-1	PB006	26-Mar-11
R04024	Screening	141	ng/mL	1	26-Mar-09	HB-2406178-1	PB006	26-Mar-11
R04024	Early Term	211	ng/mL	1	13-May-09	HB-2406179-1	PB006	26-Mar-11
R04025	Screening	261	ng/mL	1	20-Mar-09	HB-2406283-1	PB006	26-Mar-11
R04025	Early Term	293	ng/mL	1	15-May-09	HB-2406284-1	PB006	26-Mar-11
R04026	Screening	578	ng/mL	5	09-Apr-09	HB-2406064-1	PB013	06-Apr-11
R04026	Week 6	170	ng/mL	1	22-May-09	HB-2406065-1	PB006	26-Mar-11

R04026	Week 16	259	ng/mL	1	31-Jul-09	HB-2406066-1	PB006	26-Mar-11
R04026	Week 28	320	ng/mL	1	22-Oct-09	HB-2406067-1	PB006	26-Mar-11
R04027	Screening	97.4	ng/mL	1	13-Apr-09	HB-2406337-1	PB014	16-Apr-11
R04027	Week 6	83.4	ng/mL	1	27-May-09	HB-2406338-1	PB014	16-Apr-11
R04027	Week 16	68.3	ng/mL	1	05-Aug-09	HB-2406339-1	PB014	16-Apr-11
R04027	Week 28	87.7	ng/mL	1	28-Oct-09	HB-2406340-1	PB014	16-Apr-11
R04028	Screening	820	ng/mL	5	16-Apr-09	HB-2406046-1	PB015	18-Apr-11
R04028	Week 6	496	ng/mL	1	04-Jun-09	HB-2406047-1	PB014	16-Apr-11
R04028	Week 16	746	ng/mL	5	13-Aug-09	HB-2406048-1	PB015	18-Apr-11
R04028	Week 28	581	ng/mL	5	05-Nov-09	HB-2406049-1	PB015	18-Apr-11
R04029	Screening	299	ng/mL	1	16-Apr-09	HB-2406094-1	PB014	16-Apr-11
R04029	Week 6	174	ng/mL	1	04-Jun-09	HB-2406095-1	PB014	16-Apr-11
R04029	Week 16	150	ng/mL	1	13-Aug-09	HB-2406096-1	PB014	16-Apr-11
R04029	Week 28	151	ng/mL	1	12-Nov-09	HB-2406097-1	PB014	16-Apr-11
R04030	Screening	316	ng/mL	1	15-Apr-09	HB-2406156-1	PB014	16-Apr-11
R04030	Week 6	310	ng/mL	1	04-Jun-09	HB-2406157-1	PB014	16-Apr-11
R04030	Early Term	327	ng/mL	1	07-Jul-09	HB-2406158-1	PB014	16-Apr-11
R04031	Screening	172	ng/mL	1	20-Apr-09	HB-2406353-1	PB014	16-Apr-11
R04031	Early Term	241	ng/mL	1	29-May-09	HB-2406354-1	PB014	16-Apr-11
R04032	Screening	62.4	ng/mL	1	15-Apr-09	HB-2406038-1	PB014	16-Apr-11
R04032	Week 6	93.8	ng/mL	1	04-Jun-09	HB-2406039-1	PB014	16-Apr-11
R04032	Week 16	20.7	ng/mL	1	18-Aug-09	HB-2406040-1	PB014	16-Apr-11
R04032	Week 28	20.6	ng/mL	1	05-Nov-09	HB-2406041-1	PB014	16-Apr-11
R04033	Screening	455	ng/mL	1	15-Apr-09	HB-2406078-1	PB014	16-Apr-11
R04033	Week 6	675	ng/mL	5	16-Jun-09	HB-2406079-1	PB015	18-Apr-11
R04033	Week 16	563	ng/mL	5	20-Aug-09	HB-2406080-1	PB015	18-Apr-11
R04033	Week 28	788	ng/mL	5	09-Nov-09	HB-2406081-1	PB015	18-Apr-11

R04034	Screening	289	ng/mL	1	15-Apr-09	HB-2406132-1	PB014	16-Apr-11
R04034	Early Term	394	ng/mL	1	05-Aug-09	HB-2406133-1	PB014	16-Apr-11
R04035	Screening	180	ng/mL	1	29-Apr-09	HB-2406272-1	PB014	16-Apr-11
R04035	Week 6	308	ng/mL	1	15-Jun-09	HB-2406273-1	PB014	16-Apr-11
R04035	Week 16	204	ng/mL	1	24-Aug-09	HB-2406274-1	PB014	16-Apr-11
R04035	Week 28	240	ng/mL	1	17-Nov-09	HB-2406275-1	PB014	16-Apr-11
R04036	Screening	210	ng/mL	1	27-Apr-09	HB-2406162-1	PB014	16-Apr-11
R04036	Week 6	65.3	ng/mL	1	16-Jun-09	HB-2406163-1	PB014	16-Apr-11
R04036	Week 16	211	ng/mL	1	01-Sep-09	HB-2406164-1	PB014	16-Apr-11
R04036	Week 28	124	ng/mL	1	25-Nov-09	HB-2406165-1	PB014	16-Apr-11
R04037	Screening	494	ng/mL	5	28-Apr-09	HB-2406301-1	PB015	18-Apr-11
R04037	Week 6	378	ng/mL	1	16-Jun-09	HB-2406302-1	PB014	16-Apr-11
R04037	Week 16	552	ng/mL	5	25-Aug-09	HB-2406303-1	PB015	18-Apr-11
R04037	Week 28	418	ng/mL	1	17-Nov-09	HB-2406304-1	PB014	16-Apr-11
R04038	Screening	304	ng/mL	1	29-Apr-09	HB-2406234-1	PB014	16-Apr-11
R04038	Week 6	272	ng/mL	1	16-Jun-09	HB-2406235-1	PB014	16-Apr-11
R04038	Week 16	237	ng/mL	1	25-Aug-09	HB-2406236-1	PB014	16-Apr-11
R04038	Week 28	266	ng/mL	1	17-Nov-09	HB-2406237-1	PB014	16-Apr-11
R04039	Screening	362	ng/mL	1	29-Apr-09	HB-2406297-1	PB014	16-Apr-11
R04039	Week 6	365	ng/mL	1	16-Jun-09	HB-2406298-1	PB014	16-Apr-11
R04039	Week 16	442	ng/mL	1	25-Aug-09	HB-2406299-1	PB014	16-Apr-11
R04039	Week 28	393	ng/mL	1	17-Nov-09	HB-2406300-1	PB014	16-Apr-11
R04040	Screening	294	ng/mL	1	29-Apr-09	HB-2406379-1	PB014	16-Apr-11
R04040	Week 6	135	ng/mL	1	16-Jun-09	HB-2406380-1	PB014	16-Apr-11
R04040	Week 16	108	ng/mL	1	25-Aug-09	HB-2406381-1	PB014	16-Apr-11
R04040	Week 28	105	ng/mL	1	17-Nov-09	HB-2406382-1	PB014	16-Apr-11
R04041	Screening	267	ng/mL	1	27-Apr-09	HB-2406323-1	PB014	16-Apr-11

R04041	Week 6	225	ng/mL	1	18-Jun-09	HB-2406324-1	PB014	16-Apr-11
R04041	Week 16	233	ng/mL	1	25-Aug-09	HB-2406325-1	PB014	16-Apr-11
R04041	Week 28	213	ng/mL	1	17-Nov-09	HB-2406326-1	PB014	16-Apr-11
R04042	Screening	460	ng/mL	1	29-Apr-09	HB-2406276-1	PB014	16-Apr-11
R04042	Week 6	381	ng/mL	1	16-Jun-09	HB-2406277-1	PB014	16-Apr-11
R04042	Early Term	462	ng/mL	1	18-Nov-09	HB-2406278-1	PB014	16-Apr-11
R04043	Screening	145	ng/mL	1	29-Apr-09	HB-2406142-1	PB014	16-Apr-11
R04043	Early Term	255	ng/mL	1	12-Aug-09	HB-2406144-1	PB014	16-Apr-11
R04044	Screening	232	ng/mL	1	29-Apr-09	HB-2406332-1	PB014	16-Apr-11
R04044	Week 6	259	ng/mL	1	19-Jun-09	HB-2406333-1	PB014	16-Apr-11
R04044	Early Term	405	ng/mL	1	15-Jul-09	HB-2406334-1	PB014	16-Apr-11
R04045	Screening	221	ng/mL	1	28-Apr-09	HB-2406050-1	PB014	16-Apr-11
R04045	Week 6	88.4	ng/mL	1	16-Jun-09	HB-2406051-1	PB014	16-Apr-11
R04045	Week 16	250	ng/mL	1	25-Aug-09	HB-2406052-1	PB014	16-Apr-11
R04045	Week 28	382	ng/mL	1	17-Nov-09	HB-2406053-1	PB014	16-Apr-11
R04046	Screening	444	ng/mL	1	29-Apr-09	HB-2406141-1	PB014	16-Apr-11
R04046	Week 6	175	ng/mL	1	18-Jun-09	HB-2406143-1	PB014	16-Apr-11
R04046	Early Term	371	ng/mL	1	06-Oct-09	HB-2406145-1	PB014	16-Apr-11
R04047	Screening	461	ng/mL	1	21-Apr-09	HB-2406230-1	PB007i	29-Mar-11
R04047	Week 6	329	ng/mL	1	25-Jun-09	HB-2406231-1	PB007i	29-Mar-11
R04047	Week 16	274	ng/mL	1	02-Sep-09	HB-2406232-1	PB007i	29-Mar-11
R04047	Week 28	278	ng/mL	1	01-Dec-09	HB-2406233-1	PB007i	29-Mar-11
R04048	Screening	222	ng/mL	1	28-Apr-09	HB-2406058-1	PB007i	29-Mar-11
R04048	Early Term	270	ng/mL	1	30-Jun-09	HB-2406059-1	PB007i	29-Mar-11
R04049	Screening	208	ng/mL	1	29-Apr-09	HB-2406173-1	PB007i	29-Mar-11
R04049	Week 6	171	ng/mL	1	02-Jul-09	HB-2406174-1	PB007i	29-Mar-11
R04049	Week 16	214	ng/mL	1	11-Sep-09	HB-2406175-1	PB007i	29-Mar-11

R04049	Week 28	316	ng/mL	1		02-Dec-09	HB-2406176-1	PB007i	29-Mar-11
R04050	Week 6	234	ng/mL	1		14-Jul-09	HB-2406318-1	PB007i	29-Mar-11
R04050	Week 16	202	ng/mL	1		25-Sep-09	HB-2406319-1	PB007i	29-Mar-11
R04050	Week 28	329	ng/mL	1		15-Dec-09	HB-2406320-1	PB007i	29-Mar-11
R04051	Screening	174	ng/mL	1		02-Jun-09	HB-2406289-1	PB007i	29-Mar-11
R04051	Week 6	200	ng/mL	1		14-Jul-09	HB-2406290-1	PB007i	29-Mar-11
R04051	Week 16	251	ng/mL	1		22-Sep-09	HB-2406291-1	PB007i	29-Mar-11
R04051	Week 28	219	ng/mL	1		15-Dec-09	HB-2406292-1	PB007i	29-Mar-11
R04052	Screening	204	ng/mL	1		02-Jun-09	HB-2406255-1	PB007i	29-Mar-11
R04052	Week 6	215	ng/mL	1		14-Jul-09	HB-2406256-1	PB007i	29-Mar-11
R04052	Week 16	224	ng/mL	1		21-Sep-09	HB-2406257-1	PB007i	29-Mar-11
R04052	Week 28	227	ng/mL	1		14-Dec-09	HB-2406258-1	PB007i	29-Mar-11
R04053	Screening	422	ng/mL	1	Visit changed at CCLS request	02-Jun-09	HB-2406043-1	PB007i	29-Mar-11
R04053	Week 6	307	ng/mL	1		30-Jul-09	HB-2406044-1	PB007i	29-Mar-11
R04053	Week 28	251	ng/mL	1		31-Aug-09	HB-2406045-1	PB007i	29-Mar-11
R04054	Screening	126	ng/mL	1		26-May-09	HB-2406126-1	PB007i	29-Mar-11
R04054	Week 6	207	ng/mL	1		03-Aug-09	HB-2406127-1	PB007i	29-Mar-11
R04054	Early Term	130	ng/mL	1		02-Oct-09	HB-2406128-1	PB007i	29-Mar-11
R04055	Screening	223	ng/mL	1		28-May-09	HB-2406120-1	PB007i	29-Mar-11
R04055	Week 6	43.8	ng/mL	1		16-Jul-09	HB-2406121-1	PB007i	29-Mar-11
R04055	Week 16	121	ng/mL	1		24-Sep-09	HB-2406122-1	PB007i	29-Mar-11
R04055	Week 28	149	ng/mL	1		17-Dec-09	HB-2406123-1	PB007i	29-Mar-11
R04056	Screening	278	ng/mL	1		29-May-09	HB-2406327-1	PB007i	29-Mar-11
R04056	Week 6	221	ng/mL	1		20-Jul-09	HB-2406328-1	PB007i	29-Mar-11
R04056	Early Term	274	ng/mL	1		28-Sep-09	HB-2406329-1	PB007i	29-Mar-11
R04057	Screening	160	ng/mL	1		27-May-09	HB-2406383-1	PB007i	29-Mar-11
R04057	Week 6	246	ng/mL	1		31-Jul-09	HB-2406384-1	PB007i	29-Mar-11

R04057	Week 16	237	ng/mL	1	09-Oct-09	HB-2406385-1	PB007i	29-Mar-11
R04057	Week 28	330	ng/mL	1	21-Jan-10	HB-2406386-1	PB007i	29-Mar-11
R04058	Screening	190	ng/mL	1	29-May-09	HB-2406387-1	PB007i	29-Mar-11
R04058	Week 6	118	ng/mL	1	23-Jul-09	HB-2406388-1	PB007i	29-Mar-11
R04058	Week 16	172	ng/mL	1	01-Oct-09	HB-2406389-1	PB007i	29-Mar-11
R04058	Week 28	270	ng/mL	1	23-Dec-09	HB-2406390-1	PB007i	29-Mar-11
R04059	Screening	632	ng/mL	5	29-May-09	HB-2406100-1	PB013	06-Apr-11
R04059	Week 6	547	ng/mL	5	12-Aug-09	HB-2406101-1	PB013	06-Apr-11
R04059	Week 16	472	ng/mL	1	02-Oct-09	HB-2406102-1	PB007i	29-Mar-11
R04059	Week 28	316	ng/mL	1	23-Dec-09	HB-2406103-1	PB007i	29-Mar-11
R04060	Screening	246	ng/mL	1	28-May-09	HB-2406148-1	PB007i	29-Mar-11
R04060	Week 6	245	ng/mL	1	31-Jul-09	HB-2406149-1	PB007i	29-Mar-11
R04060	Week 16	258	ng/mL	1	01-Oct-09	HB-2406150-1	PB007i	29-Mar-11
R04060	Week 28	344	ng/mL	1	23-Dec-09	HB-2406151-1	PB007i	29-Mar-11
R04061	Screening	236	ng/mL	1	10-Jun-09	HB-2406285-1	PB007i	29-Mar-11
R04061	Early Term	199	ng/mL	1	18-Aug-09	HB-2406286-1	PB007i	29-Mar-11
R04062	Screening	224	ng/mL	1	10-Jun-09	HB-2406014-1	PB007i	29-Mar-11
R04062	Week 6	162	ng/mL	1	30-Jul-09	HB-2406015-1	PB007i	29-Mar-11
R04062	Week 16	251	ng/mL	1	08-Oct-09	HB-2406016-1	PB007i	29-Mar-11
R04062	Week 28	302	ng/mL	1	30-Dec-09	HB-2406017-1	PB007i	29-Mar-11
R04063	Screening	137	ng/mL	1	10-Jun-09	HB-2406069-1	PB007i	29-Mar-11
R04063	Week 6	68.5	ng/mL	1	13-Aug-09	HB-2406070-1	PB007i	29-Mar-11
R04063	Week 16	48.5	ng/mL	1	08-Oct-09	HB-2406071-1	PB007i	29-Mar-11
R04063	Week 28	65.8	ng/mL	1	30-Dec-09	HB-2406072-1	PB007i	29-Mar-11
R04064	Screening	269	ng/mL	1	08-Jun-09	HB-2406074-1	PB007i	29-Mar-11
R04064	Week 6	372	ng/mL	1	03-Aug-09	HB-2406075-1	PB007i	29-Mar-11
R04064	Week 16	450	ng/mL	1	28-Oct-09	HB-2406076-1	PB007i	29-Mar-11

R04064	Week 28	151	ng/mL	1	30-Dec-09	HB-2406077-1	PB007i	29-Mar-11
R04065	Screening	360	ng/mL	1	10-Jun-09	HB-2406251-1	PB007i	29-Mar-11
R04065	Week 6	334	ng/mL	1	03-Aug-09	HB-2406252-1	PB007i	29-Mar-11
R04065	Week 16	289	ng/mL	1	30-Nov-09	HB-2406253-1	PB007i	29-Mar-11
R04065	Week 28	242	ng/mL	1	30-Dec-09	HB-2406254-1	PB007i	29-Mar-11
R04066	Screening	131	ng/mL	1	08-Jun-09	HB-2406170-1	PB008	29-Mar-11
R04066	Week 6	74.7	ng/mL	1	04-Aug-09	HB-2406171-1	PB008	29-Mar-11
R04066	Early Term	214	ng/mL	1	18-Sep-09	HB-2406172-1	PB008	29-Mar-11
R04067	Screening	262	ng/mL	1	08-Jun-09	HB-2406013-1	PB011	01-Apr-11
R04068	Screening	347	ng/mL	1	08-Jun-09	HB-2406391-1	PB008	29-Mar-11
R04068	Week 16	232	ng/mL	1	16-Oct-09	HB-2406394-1	PB008	29-Mar-11
R04068	Week 28	369	ng/mL	1	08-Jan-10	HB-2406395-1	PB008	29-Mar-11
R04069	Screening	224	ng/mL	1	10-Jun-09	HB-2406180-1	PB008	29-Mar-11
R04069	Week 6	227	ng/mL	1	06-Aug-09	HB-2406181-1	PB008	29-Mar-11
R04069	Week 16	225	ng/mL	1	16-Oct-09	HB-2406182-1	PB008	29-Mar-11
R04069	Week 28	122	ng/mL	1	06-Jan-10	HB-2406183-1	PB008	29-Mar-11
R04070	Screening	328	ng/mL	1	12-Jun-09	HB-2406137-1	PB008	29-Mar-11
R04070	Week 6	184	ng/mL	1	12-Aug-09	HB-2406138-1	PB008	29-Mar-11
R04070	Week 16	384	ng/mL	1	15-Oct-09	HB-2406139-1	PB008	29-Mar-11
R04070	Week 28	241	ng/mL	1	18-Feb-10	HB-2406140-1	PB008	29-Mar-11
R04071	Screening	394	ng/mL	1	12-Jun-09	HB-2406035-1	PB008	29-Mar-11
R04071	Week 6	578	ng/mL	5	07-Aug-09	HB-2406036-1	PB013	06-Apr-11
R04071	Week 16	463	ng/mL	5	15-Oct-09	HB-2406037-1	PB013	06-Apr-11
R04071	Week 28	12.3	ng/mL	1	08-Jan-10	HB-2406034-1	PB008	29-Mar-11
R04072	Screening	402	ng/mL	1	12-Jun-09	HB-2406266-1	PB008	29-Mar-11
R04072	Week 6	331	ng/mL	1	07-Aug-09	HB-2406267-1	PB008	29-Mar-11
R04072	Week 16	419	ng/mL	1	22-Oct-09	HB-2406268-1	PB008	29-Mar-11

R04072	Week 28	509	ng/mL	5	08-Jan-10	HB-2406269-1	PB013	06-Apr-11
R04073	Screening	176	ng/mL	1	22-Jun-09	HB-2406315-1	PB011	01-Apr-11
R04074	Screening	124	ng/mL	1	22-Jun-09	HB-2406024-1	PB008	29-Mar-11
R04074	Early Term	86.1	ng/mL	1	26-Aug-09	HB-2406025-1	PB008	29-Mar-11
R04075	Screening	421	ng/mL	1	22-Jun-09	HB-2406376-1	PB008	29-Mar-11
R04075	Week 6	391	ng/mL	1	14-Aug-09	HB-2406377-1	PB008	29-Mar-11
R04075	Early Term	547	ng/mL	5	28-Oct-09	HB-2406378-1	PB013	06-Apr-11
R04076	Screening	456	ng/mL	1	22-Jun-09	HB-2406195-1	PB008	29-Mar-11
R04076	Week 6	430	ng/mL	1	18-Aug-09	HB-2406196-1	PB008	29-Mar-11
R04076	Early Term	371	ng/mL	5	28-Sep-09	HB-2406197-1	PB013	06-Apr-11
R04077	Screening	411	ng/mL	1	22-Jun-09	HB-2406116-1	PB008	29-Mar-11
R04077	Week 6	289	ng/mL	1	10-Aug-09	HB-2406117-1	PB008	29-Mar-11
R04077	Early Term	273	ng/mL	1	19-Oct-09	HB-2406118-1	PB008	29-Mar-11
R04078	Screening	233	ng/mL	1	23-Jun-09	HB-2406248-1	PB008	29-Mar-11
R04078	Week 6	239	ng/mL	1	10-Aug-09	HB-2406249-1	PB008	29-Mar-11
R04078	Early Term	200	ng/mL	1	14-Sep-09	HB-2406250-1	PB008	29-Mar-11
R04079	Screening	140	ng/mL	1	22-Jun-09	HB-2406134-1	PB008	29-Mar-11
R04079	Week 6	191	ng/mL	1	12-Aug-09	HB-2406135-1	PB008	29-Mar-11
R04079	Week 16	150	ng/mL	1	04-Nov-09	HB-2406136-1	PB008	29-Mar-11
R04080	Screening	243	ng/mL	1	22-Jun-09	HB-2406367-1	PB011	01-Apr-11
R04081	Screening	221	ng/mL	1	22-Jun-09	HB-2406160-1	PB008	29-Mar-11
R04081	Early Term	261	ng/mL	1	10-Aug-09	HB-2406161-1	PB008	29-Mar-11
R04082	Screening	200	ng/mL	1	22-Jun-09	HB-2406270-1	PB008	29-Mar-11
R04082	Early Term	279	ng/mL	1	28-Sep-09	HB-2406271-1	PB008	29-Mar-11
R04083	Screening	413	ng/mL	1	19-Jun-09	HB-2406259-1	PB008	29-Mar-11
R04083	Week 6	688	ng/mL	10	10-Aug-09	HB-2406260-1	PB013	06-Apr-11
R04083	Week 16	376	ng/mL	1	19-Oct-09	HB-2406261-1	PB008	29-Mar-11

R04083	Week 28	291	ng/mL	1	11-Jan-10	HB-2406262-1	PB008	29-Mar-11
R04084	Screening	222	ng/mL	1	12-Jun-09	HB-2406335-1	PB008	29-Mar-11
R04084	Early Term	212	ng/mL	1	17-Aug-09	HB-2406336-1	PB008	29-Mar-11
R04085	Screening	118	ng/mL	1	08-Jun-09	HB-2406073-1	PB011	01-Apr-11
R04086	Screening	334	ng/mL	1	24-Jun-09	HB-2406224-1	PB008	29-Mar-11
R04086	Early Term	151	ng/mL	1	13-Aug-09	HB-2406225-1	PB008	29-Mar-11
R04087	Screening	151	ng/mL	1	24-Jun-09	HB-2406018-1	PB008	29-Mar-11
R04087	Week 6	152	ng/mL	1	24-Aug-09	HB-2406019-1	PB008	29-Mar-11
R04087	Early Term	179	ng/mL	1	22-Oct-09	HB-2406020-1	PB008	29-Mar-11
R04088	Screening	395	ng/mL	1	24-Jun-09	HB-2406124-1	PB008	29-Mar-11
R04088	Early Term	493	ng/mL	5	11-Aug-09	HB-2406125-1	PB013	06-Apr-11
R04089	Screening	157	ng/mL	1	24-Jun-09	HB-2406106-1	PB008	29-Mar-11
R04089	Week 6	176	ng/mL	1	10-Sep-09	HB-2406107-1	PB008	29-Mar-11
R04089	Early Term	131	ng/mL	1	22-Oct-09	HB-2406108-1	PB008	29-Mar-11
R04090	Screening	< 0.500	ng/mL	1	24-Jun-09	HB-2406226-1	PB008	29-Mar-11
R04090	Week 6	0.602	ng/mL	1	13-Aug-09	HB-2406227-1	PB008	29-Mar-11
R04090	Week 16	11.4	ng/mL	1	22-Oct-09	HB-2406228-1	PB008	29-Mar-11
R04090	Week 28	< 0.500	ng/mL	1	14-Jan-10	HB-2406229-1	PB008	29-Mar-11
R04091	Screening	94.4	ng/mL	1	22-Jun-09	HB-2406355-1	PB008	29-Mar-11
R04091	Week 6	141	ng/mL	1	13-Aug-09	HB-2406356-1	PB008	29-Mar-11
R04091	Week 16	39.8	ng/mL	1	22-Oct-09	HB-2406357-1	PB008	29-Mar-11
R04091	Week 28	107	ng/mL	1	04-Feb-10	HB-2406358-1	PB008	29-Mar-11
R04092	Screening	258	ng/mL	1	22-Jun-09	HB-2406089-1	PB009	31-Mar-11
R04092	Week 6	343	ng/mL	1	18-Aug-09	HB-2406090-1	PB009	31-Mar-11
R04092	Week 16	239	ng/mL	1	28-Dec-09	HB-2406091-1	PB009	31-Mar-11
R04092	Week 28	354	ng/mL	1	20-Jan-10	HB-2406092-1	PB009	31-Mar-11
R04093	Screening	248	ng/mL	1	26-May-09	HB-2406293-1	PB009	31-Mar-11

R04093	Week 6	302	ng/mL	1		19-Aug-09	HB-2406294-1	PB009	31-Mar-11
R04093	Week 16	190	ng/mL	1		28-Oct-09	HB-2406295-1	PB009	31-Mar-11
R04093	Week 28	326	ng/mL	1		28-Jan-10	HB-2406296-1	PB009	31-Mar-11
R04094	Screening	48.0	ng/mL	1		26-Jun-09	HB-2406104-1	PB009	31-Mar-11
R04094	Week 6	NS	ng/mL	1	NS	19-Aug-09	HB-2806495-1		
R04094	Week 16	41.5	ng/mL	1		28-Oct-09	HB-2406105-1	PB009	31-Mar-11
R04095	Screening	283	ng/mL	1		26-Jun-09	HB-2406194-1	PB011	01-Apr-11
R04096	Screening	98.2	ng/mL	1		26-Jun-09	HB-2406238-1	PB009	31-Mar-11
R04096	Week 6	110	ng/mL	1		19-Aug-09	HB-2406239-1	PB009	31-Mar-11
R04096	Week 16	111	ng/mL	1		28-Oct-09	HB-2406240-1	PB009	31-Mar-11
R04096	Week 28	170	ng/mL	1		23-Feb-10	HB-2406241-1	PB009	31-Mar-11
R04097	Screening	231	ng/mL	1		26-Jun-09	HB-2406009-1	PB009	31-Mar-11
R04097	Week 6	312	ng/mL	1		19-Aug-09	HB-2406010-1	PB009	31-Mar-11
R04097	Week 16	236	ng/mL	1		30-Oct-09	HB-2406011-1	PB009	31-Mar-11
R04097	Week 28	254	ng/mL	1		20-Jan-10	HB-2406012-1	PB009	31-Mar-11
R04098	Screening	122	ng/mL	1		26-Jun-09	HB-2406330-1	PB009	31-Mar-11
R04098	Early Term	303	ng/mL	1		12-Oct-09	HB-2406331-1	PB009	31-Mar-11
R04099	Screening	93.6	ng/mL	1		26-Jun-09	HB-2406152-1	PB009	31-Mar-11
R04099	Week 6	62.1	ng/mL	1		19-Aug-09	HB-2406153-1	PB009	31-Mar-11
R04099	Week 16	< 0.500	ng/mL	1		30-Oct-09	HB-2406154-1	PB009	31-Mar-11
R04099	Week 28	< 0.500	ng/mL	1		02-Feb-10	HB-2406155-1	PB009	31-Mar-11
R04100	Screening	188	ng/mL	1		26-Jun-09	HB-2406345-1	PB009	31-Mar-11
R04100	Week 6	161	ng/mL	1		20-Aug-09	HB-2406346-1	PB009	31-Mar-11
R04100	Week 16	0.693	ng/mL	1		28-Oct-09	HB-2406347-1	PB009	31-Mar-11
R04100	Week 28	< 0.500	ng/mL	1		20-Jan-10	HB-2406348-1	PB009	31-Mar-11
R04101	Screening	151	ng/mL	1		26-Jun-09	HB-2406177-1	PB011	01-Apr-11
R04102	Screening	170	ng/mL	1		26-Jun-09	HB-2406208-1	PB009	31-Mar-11

R04102	Week 6	45.3	ng/mL	1		02-Sep-09	HB-2406209-1	PB009	31-Mar-11
R04102	Week 16	11.3	ng/mL	1		30-Oct-09	HB-2406210-1	PB009	31-Mar-11
R04102	Week 28	345	ng/mL	1		20-Jan-10	HB-2406211-1	PB009	31-Mar-11
R04103	Screening	218	ng/mL	1		26-Jun-09	HB-2406246-1	PB009	31-Mar-11
R04103	Week 6	234	ng/mL	1		24-Aug-09	HB-2406247-1	PB009	31-Mar-11
R04105	Screening	246	ng/mL	1		20-Jul-09	HB-2406112-1	PB009	31-Mar-11
R04105	Week 6	199	ng/mL	1		03-Sep-09	HB-2406113-1	PB009	31-Mar-11
R04105	Week 16	91.5	ng/mL	1		12-Nov-09	HB-2406114-1	PB009	31-Mar-11
R04105	Week 28	< 0.500	ng/mL	1		04-Feb-10	HB-2406115-1	PB009	31-Mar-11
R04106	Screening	272	ng/mL	1		20-Jul-09	HB-2406305-1	PB009	31-Mar-11
R04106	Week 6	261	ng/mL	1		03-Sep-09	HB-2406306-1	PB009	31-Mar-11
R04107	Screening	233	ng/mL	1		20-Jul-09	HB-2406191-1	PB009	31-Mar-11
R04107	Week 6	172	ng/mL	1		03-Sep-09	HB-2406192-1	PB009	31-Mar-11
R04107	Week 16	185	ng/mL	1		23-Nov-09	HB-2406193-1	PB009	31-Mar-11
R04107	Week 28	166	ng/mL	1		04-Feb-10	HB-2406190-1	PB009	31-Mar-11
R04108	Screening	201	ng/mL	1		10-Jul-09	HB-2406119-1	PB011	01-Apr-11
R04109	Screening	386	ng/mL	1		17-Jul-09	HB-2406068-1	PB011	01-Apr-11
R04110	Screening	282	ng/mL	1		10-Jul-09	HB-2406321-1	PB009	31-Mar-11
R04110	Week 16	262	ng/mL	1	Occasion changed at CCLS request	28-Aug-09	HB-2406322-1	PB009	31-Mar-11
R04111	Screening	423	ng/mL	1		20-Jul-09	HB-2406279-1	PB011	01-Apr-11
R04112	Screening	194	ng/mL	1		17-Jul-09	HB-2406184-1	PB009	31-Mar-11
R04112	Week 16	204	ng/mL	1	Occasion changed at CCLS request	23-Sep-09	HB-2406185-1	PB009	31-Mar-11
R04113	Screening	203	ng/mL	1		20-Jul-09	HB-2406359-1	PB009	31-Mar-11
R04113	Week 6	224	ng/mL	1		03-Sep-09	HB-2406360-1	PB009	31-Mar-11
R04113	Week 16	251	ng/mL	1		20-Nov-09	HB-2406361-1	PB009	31-Mar-11
R04113	Week 28	124	ng/mL	1		04-Feb-10	HB-2406362-1	PB009	31-Mar-11
R04114	Screening	181	ng/mL	1		20-Jul-09	HB-2406204-1	PB009	31-Mar-11

R04114	Week 6	< 0.500	ng/mL	1	31-Aug-09	HB-2406205-1	PB009	31-Mar-11
R04114	Week 16	1.13	ng/mL	1	12-Nov-09	HB-2406206-1	PB009	31-Mar-11
R04114	Week 28	< 0.500	ng/mL	1	04-Feb-10	HB-2406207-1	PB009	31-Mar-11
R04115	Screening	302	ng/mL	1	20-Jul-09	HB-2406146-1	PB009	31-Mar-11
R04115	Week 6	318	ng/mL	1	09-Sep-09	HB-2406147-1	PB009	31-Mar-11
R04116	Screening	200	ng/mL	1	20-Jul-09	HB-2406341-1	PB009	31-Mar-11
R04116	Week 6	19.6	ng/mL	1	03-Sep-09	HB-2406342-1	PB009	31-Mar-11
R04116	Week 16	75.4	ng/mL	1	12-Nov-09	HB-2406343-1	PB009	31-Mar-11
R04116	Week 28	< 0.500	ng/mL	1	04-Feb-10	HB-2406344-1	PB009	31-Mar-11
R04117	Screening	419	ng/mL	1	17-Jul-09	HB-2406363-1	PB009	31-Mar-11
R04117	Week 6	431	ng/mL	1	03-Sep-09	HB-2406364-1	PB009	31-Mar-11
R04117	Week 16	460	ng/mL	5	12-Nov-09	HB-2406365-1	PB013	06-Apr-11
R04117	Week 28	439	ng/mL	1	04-Feb-10	HB-2406366-1	PB009	31-Mar-11
R04118	Screening	100	ng/mL	1	20-Jul-09	HB-2406368-1	PB009	31-Mar-11
R04118	Week 6	48.4	ng/mL	1	03-Sep-09	HB-2406369-1	PB009	31-Mar-11
R04118	Week 16	60.7	ng/mL	1	12-Nov-09	HB-2406370-1	PB009	31-Mar-11
R04118	Week 28	85.6	ng/mL	1	04-Feb-10	HB-2406371-1	PB009	31-Mar-11
R04119	Screening	478	ng/mL	1	20-Jul-09	HB-2406086-1	PB010	01-Apr-11
R04119	Week 6	354	ng/mL	1	03-Sep-09	HB-2406087-1	PB010	01-Apr-11
R04119	Early Term	342	ng/mL	1	16-Feb-10	HB-2406088-1	PB010	01-Apr-11
R04120	Screening	248	ng/mL	1	20-Jul-09	HB-2406200-1	PB010	01-Apr-11
R04120	Week 6	99.7	ng/mL	1	02-Sep-09	HB-2406201-1	PB010	01-Apr-11
R04120	Week 16	231	ng/mL	1	20-Nov-09	HB-2406202-1	PB010	01-Apr-11
R04120	Week 28	189	ng/mL	1	05-Feb-10	HB-2406203-1	PB010	01-Apr-11
R04121	Screening	266	ng/mL	1	20-Jul-09	HB-2406093-1	PB011	01-Apr-11
R05001	Screening	197	ng/mL	1	16-Jun-09	HB-2406433-1	PB010	01-Apr-11
R05001	Week 6	210	ng/mL	1	10-Aug-09	HB-2406434-1	PB010	01-Apr-11

R05001	Week 16	160	ng/mL	1	19-Oct-09	HB-2406435-1	PB010	01-Apr-11
R05001	Week 28	226	ng/mL	1	11-Jan-10	HB-2406436-1	PB010	01-Apr-11
R05002	Screening	252	ng/mL	1	16-Jun-09	HB-2406410-1	PB010	01-Apr-11
R05002	Week 6	8.02	ng/mL	1	10-Aug-09	HB-2406411-1	PB010	01-Apr-11
R05002	Week 16	233	ng/mL	1	19-Oct-09	HB-2406412-1	PB010	01-Apr-11
R05002	Week 28	317	ng/mL	1	11-Jan-10	HB-2406413-1	PB010	01-Apr-11
R05003	Screening	426	ng/mL	1	16-Jun-09	HB-2406406-1	PB010	01-Apr-11
R05003	Week 6	232	ng/mL	1	10-Aug-09	HB-2406407-1	PB010	01-Apr-11
R05003	Week 16	250	ng/mL	1	19-Oct-09	HB-2406408-1	PB010	01-Apr-11
R05003	Week 28	379	ng/mL	1	11-Jan-10	HB-2406409-1	PB010	01-Apr-11
R05004	Screening	150	ng/mL	1	22-Jun-09	HB-2406477-1	PB010	01-Apr-11
R05004	Week 6	96.6	ng/mL	1	17-Aug-09	HB-2406478-1	PB010	01-Apr-11
R05004	Week 16	117	ng/mL	1	26-Oct-09	HB-2406479-1	PB010	01-Apr-11
R05004	Week 28	134	ng/mL	1	18-Jan-10	HB-2406480-1	PB010	01-Apr-11
R05005	Screening	128	ng/mL	1	23-Jun-09	HB-2406484-1	PB010	01-Apr-11
R05005	Week 6	166	ng/mL	1	17-Aug-09	HB-2406485-1	PB010	01-Apr-11
R05006	Screening	233	ng/mL	1	22-Jun-09	HB-2406396-1	PB010	01-Apr-11
R05006	Week 6	292	ng/mL	1	17-Aug-09	HB-2406397-1	PB010	01-Apr-11
R05006	Week 16	361	ng/mL	1	26-Oct-09	HB-2406398-1	PB010	01-Apr-11
R05006	Week 28	445	ng/mL	1	18-Jan-10	HB-2406399-1	PB010	01-Apr-11
R05007	Screening	161	ng/mL	1	22-Jun-09	HB-2406475-1	PB011	01-Apr-11
R05008	Screening	140	ng/mL	1	30-Jun-09	HB-2406454-1	PB010	01-Apr-11
R05008	Week 6	126	ng/mL	1	18-Aug-09	HB-2406455-1	PB010	01-Apr-11
R05008	Week 16	108	ng/mL	1	26-Oct-09	HB-2406456-1	PB010	01-Apr-11
R05008	Week 28	114	ng/mL	1	18-Jan-10	HB-2406457-1	PB010	01-Apr-11
R05009	Screening	0.640	ng/mL	1	29-Jun-09	HB-2406418-1	PB010	01-Apr-11
R05009	Early Term	9.35	ng/mL	1	03-Aug-09	HB-2406419-1	PB010	01-Apr-11

R05010	Screening	176	ng/mL	1	29-Jun-09	HB-2406448-1	PB010	01-Apr-11
R05010	Early Term	208	ng/mL	1	08-Sep-09	HB-2406449-1	PB010	01-Apr-11
R05011	Screening	250	ng/mL	1	23-Jun-09	HB-2406429-1	PB010	01-Apr-11
R05011	Week 6	0.875	ng/mL	1	17-Aug-09	HB-2406430-1	PB010	01-Apr-11
R05011	Week 16	< 0.500	ng/mL	1	26-Oct-09	HB-2406431-1	PB010	01-Apr-11
R05011	Week 28	< 0.500	ng/mL	1	18-Jan-10	HB-2406432-1	PB010	01-Apr-11
R05012	Screening	239	ng/mL	1	06-Jul-09	HB-2406443-1	PB010	01-Apr-11
R05012	Early Term	289	ng/mL	1	11-Nov-09	HB-2406444-1	PB010	01-Apr-11
R05013	Screening	297	ng/mL	1	06-Jul-09	HB-2406421-1	PB010	01-Apr-11
R05013	Week 6	11.3	ng/mL	1	24-Aug-09	HB-2406422-1	PB010	01-Apr-11
R05013	Week 16	37.5	ng/mL	1	02-Nov-09	HB-2406423-1	PB010	01-Apr-11
R05013	Week 28	258	ng/mL	1	27-Jan-10	HB-2406424-1	PB010	01-Apr-11
R05014	Screening	127	ng/mL	1	07-Jul-09	HB-2406481-1	PB010	01-Apr-11
R05014	Week 6	162	ng/mL	1	25-Aug-09	HB-2406482-1	PB010	01-Apr-11
R05014	Early Term	165	ng/mL	1	13-Nov-09	HB-2406483-1	PB010	01-Apr-11
R05015	Screening	147	ng/mL	1	06-Jul-09	HB-2406450-1	PB010	01-Apr-11
R05015	Week 6	259	ng/mL	1	24-Aug-09	HB-2406451-1	PB010	01-Apr-11
R05015	Week 16	233	ng/mL	1	02-Nov-09	HB-2406452-1	PB010	01-Apr-11
R05015	Week 28	209	ng/mL	1	25-Jan-10	HB-2406453-1	PB010	01-Apr-11
R05016	Screening	259	ng/mL	1	13-Jul-09	HB-2406437-1	PB010	01-Apr-11
R05016	Early Term	188	ng/mL	1	09-Nov-09	HB-2406438-1	PB010	01-Apr-11
R05017	Screening	493	ng/mL	1	13-Jul-09	HB-2406404-1	PB010	01-Apr-11
R05017	Early Term	471	ng/mL	5	21-Dec-09	HB-2406405-1	PB013	06-Apr-11
R05018	Screening	294	ng/mL	1	13-Jul-09	HB-2406463-1	PB010	01-Apr-11
R05018	Week 6	295	ng/mL	1	31-Aug-09	HB-2406464-1	PB010	01-Apr-11
R05018	Week 16	269	ng/mL	1	10-Nov-09	HB-2406465-1	PB010	01-Apr-11
R05018	Week 28	279	ng/mL	1	01-Feb-10	HB-2406466-1	PB010	01-Apr-11

R05019	Screening	262	ng/mL	1	14-Jul-09	HB-2406467-1	PB010	01-Apr-11
R05019	Week 6	342	ng/mL	1	31-Aug-09	HB-2406468-1	PB010	01-Apr-11
R05019	Week 16	347	ng/mL	1	10-Nov-09	HB-2406469-1	PB010	01-Apr-11
R05019	Week 28	324	ng/mL	1	01-Feb-10	HB-2406470-1	PB010	01-Apr-11
R05020	Screening	288	ng/mL	1	14-Jul-09	HB-2406471-1	PB010	01-Apr-11
R05020	Week 6	254	ng/mL	1	31-Aug-09	HB-2406472-1	PB010	01-Apr-11
R05020	Week 16	192	ng/mL	1	09-Nov-09	HB-2406473-1	PB010	01-Apr-11
R05020	Week 28	267	ng/mL	1	01-Feb-10	HB-2406474-1	PB010	01-Apr-11
R05021	Screening	158	ng/mL	1	13-Jul-09	HB-2406414-1	PB011	01-Apr-11
R05021	Week 6	5.97	ng/mL	1	31-Aug-09	HB-2406415-1	PB011	01-Apr-11
R05021	Week 16	80.4	ng/mL	1	09-Nov-09	HB-2406416-1	PB011	01-Apr-11
R05021	Week 28	80.4	ng/mL	1	02-Feb-10	HB-2406417-1	PB011	01-Apr-11
R05022	Screening	488	ng/mL	5	20-Jul-09	HB-2406400-1	PB013	06-Apr-11
R05022	Week 6	327	ng/mL	1	08-Sep-09	HB-2406401-1	PB011	01-Apr-11
R05022	Week 16	314	ng/mL	1	16-Nov-09	HB-2406402-1	PB011	01-Apr-11
R05022	Week 28	242	ng/mL	1	08-Feb-10	HB-2406403-1	PB011	01-Apr-11
R05023	Screening	111	ng/mL	1	14-Jul-09	HB-2406458-1	PB011	01-Apr-11
R05023	Week 6	25.0	ng/mL	1	05-Oct-09	HB-2406459-1	PB011	01-Apr-11
R05023	Week 16	21.5	ng/mL	1	16-Nov-09	HB-2406460-1	PB011	01-Apr-11
R05024	Screening	168	ng/mL	1	14-Jul-09	HB-2406476-1	PB011	01-Apr-11
R05025	Screening	283	ng/mL	1	21-Jul-09	HB-2406425-1	PB011	01-Apr-11
R05025	Week 6	321	ng/mL	1	09-Sep-09	HB-2406426-1	PB011	01-Apr-11
R05025	Week 16	276	ng/mL	1	18-Nov-09	HB-2406427-1	PB011	01-Apr-11
R05025	Week 28	40.2	ng/mL	1	08-Feb-10	HB-2406428-1	PB011	01-Apr-11
R05026	Screening	540	ng/mL	5	07-Jul-09	HB-2406420-1	PB013	06-Apr-11
R05027	Screening	139	ng/mL	1	21-Jul-09	HB-2406439-1	PB011	01-Apr-11
R05027	Week 6	< 0.500	ng/mL	1	08-Sep-09	HB-2406440-1	PB011	01-Apr-11

---

R05027	Week 16	20.1	ng/mL	1		16-Nov-09	HB-2406441-1	PB011	01-Apr-11
R05027	Week 28	259	ng/mL	1		19-Feb-10	HB-2406442-1	PB011	01-Apr-11
R05028	Screening	307	ng/mL	1		14-Jul-09	HB-2406445-1	PB011	01-Apr-11
R05028	Week 6	199	ng/mL	1		07-Oct-09	HB-2406446-1	PB011	01-Apr-11
R05028	Week 16	181	ng/mL	1		18-Nov-09	HB-2406447-1	PB011	01-Apr-11
S02051	Screening	556	ng/mL	5	No Randomisation number, so screening number added as subject	20-Jul-09	HB-2405881-1	PB013	06-Apr-11
S02053	Screening	153	ng/mL	1	No Randomisation number, so screening number added as subject	22-Jul-09	HB-2405899-1	PB011	01-Apr-11

---

IP Interference peak

NS No sample

**Table 5**  
**Determination of Cotinine in Human Plasma:**  
**Incurred Sample Reproducibility**

Original Batch	Sample ID	Original Dilution	Analyte	Original Result 'A' (ng/mL)	Annotations	Repeat Dilution	Repeat Batch	Repeat Result 'B' (ng/mL)	Annotations	% Difference B-A/A+B x200
PB001	SR01001 PWeek 6 XD346034-4	1	Cotinine	247		1	PB012i	237		-4.1
PB001	SR01001 PWeek 16 XD752533-4	1	Cotinine	33.2		1	PB012i	37.6		12.4
PB001	SR01002 PWeek 6 XD346045-4	1	Cotinine	42.4		1	PB012i	46.1		8.4
PB001	SR01002 PWeek 16 XD752523-4	1	Cotinine	154		1	PB012i	176		13.3
PB001	SR01004 PWeek 6 XD346025-4	1	Cotinine	181		1	PB012i	244		29.6
PB001	SR01004 PWeek 16 XD752531-4	1	Cotinine	247		1	PB012i	303		20.4
PB001	SR01005 PWeek 6 XD346032-4	1	Cotinine	170		1	PB012i	185		8.5
PB001	SR01005 PWeek 16 XE439925-4	1	Cotinine	147		1	PB012i	170		14.5
PB001	SR01006 PWeek 6 XD338784-4	1	Cotinine	422		1	PB012i	506	AL	18.1
PB001	SR01006 PWeek 16 XD752515-4	1	Cotinine	290		1	PB012i	319		9.5
PB001	SR01007 PWeek 6 XD340754-4	1	Cotinine	466		10	PB012i	313		-39.3
PB001	SR01007 PWeek 16 XD752511-4	1	Cotinine	186		1	PB012i	240		25.4
PB001	SR01008 PWeek 6 XD353891-4	1	Cotinine	256		1	PB012i	332		25.9
PB001	SR01008 PEarly Term XD752521-4	1	Cotinine	244		1	PB012i	320		27.0
PB001	SR01009 PWeek 6 XD353454-4	1	Cotinine	35.2		1	PB012i	37.2		5.5

Original Batch	Sample ID	Original Dilution	Analyte	Original Result 'A' (ng/mL)	Annotations	Repeat Dilution	Repeat Batch	Repeat Result 'B' (ng/mL)	Annotations	% Difference B-A/A+B x200
PB001	SR01009 PWeek 16 XD752524-4	1	Cotinine	121		1	PB012i	138		13.1
PB001	SR01011 PWeek 6 XD753224-4	1	Cotinine	134		1	PB012i	165		20.7
PB001	SR01011 PWeek 16 XD752581-4	1	Cotinine	151		1	PB012i	173		13.6
PB001	SR01012 PWeek 6 XD753222-4	1	Cotinine	229		1	PB012i	282		20.7
PB001	SR01012 PWeek 16 XD752564-4	1	Cotinine	311		1	PB012i	382		20.5
PB001	SR01013 PWeek 6 XD753231-4	1	Cotinine	122		1	PB012i	151		21.2
PB001	SR01013 PWeek 16 XD752573-4	1	Cotinine	29.7		1	PB012i	38.9		26.8
PB002	SR01021 PWeek 6 XX807212-4	1	Cotinine	248		1	PB012i	177		-33.4
PB002	SR01021 PWeek 16 XG658373-4	1	Cotinine	183		1	PB012i	155		-16.6

AL = Above limit of quantification

## **8 APPENDICES**

**Appendix 1**  
**Certificates of Analysis**

**Cotinine**

Certificate Of Analysis


Page 1 of 1

Certificate of Analysis

SIGMA-ALDRICH

Product Name (-)-Cotinine,  
-98%  
Product Number C5923  
Product Brand SIGMA  
CAS Number 486-56-6  
Molecular Formula  $C_{17}H_{17}N_2O$   
Molecular Weight 176.22

TEST	SPECIFICATION	LOT 120M4046V RESULTS
APPEARANCE	WHITE TO YELLOW SOLID TO VISCIOUS LIQUID	YELLOW VISCIOUS LIQUID
SOLUBILITY	CLEAR TO SLIGHTLY HAZY COLORLESS TO YELLOW SOLUTION AT 50MG/ML IN ETHANOL	VERY SLIGHTLY HAZY FAINT YELLOW
IDENTITY	CONSISTENT WITH STRUCTURE BY IR OR NMR	CONFORMS BY H-NMR
SPECIFIC ROTATION	ALPHA D = -23 TO -19, AT C=1 IN ETOH	ALPHA D = -21.2 AT C=1 IN ETOH
WATER BY KARL FISCHER	REPORT RESULT	2.00%
CARBON *	66.8 TO 69.5%	68.09%
NITROGEN *	15.6 TO 16.2%	15.97%
PURITY BY THIN LAYER CHROMATOGRAPHY	APPROX. 98%	99.0%
PRODUCT CROSS REFERENCE INFORMATION	* ANHYDROUS BASIS	REPLACEMENT FOR ALDRICH #284718
QC RELEASE DATE		NOV 2010
RECOMMENDED RETEST	3 YEARS	NOV 2013



Rodney Burbach, Manager  
Quality Control  
St. Louis, Missouri USA

## Cotinine-d3

Certificate Of Analysis

Page 1 of 1

# Certificate of Analysis

SIGMA-ALDRICH

<b>Product Name</b>	(±)-Cotinine-methyl-d <sub>3</sub> 99 atom % D
<b>Product Number</b>	488976
<b>Product Brand</b>	ALDRICH
<b>CAS Number</b>	110952-70-0
<b>Molecular Formula</b>	C <sub>10</sub> D <sub>3</sub> H <sub>9</sub> N <sub>2</sub> O
<b>Molecular Weight</b>	179.23

TEST	LOT IS1107 RESULTS
<b>GC: Minimum 99% chemical purity</b>	99.4%
<b>1H-NMR (FT): Structure and purity verification</b>	Meets requirement
<b>Isotopic Enrich.: Minimum 99 atom% D based upon labeled precursor</b>	99.8 atom% D
<b>% Water: &lt; = 0.5%</b>	0.24%
<b>D-NMR: Structure and purity verification</b>	Meets requirement
<b>Appearance: Yellow solid</b>	Yellow solid
<b>13C-NMR: Structure and purity verification</b>	Meets requirement
<b>Release Date:</b>	2004/08/17

Dr. John Kuo, Senior Scientist  
Analytical / Quality Control  
Miamisburg, Ohio USA

<http://www.sigmaaldrich.com/catalog/CertOfAnalysisPage.do?symbol=488976&Lot...> 10-Jun-2009

# Nicotine

Certificate Of Analysis

Page 1 of 1

## Certificate of Analysis

SIGMA-ALDRICH

<b>Product Name</b>	(-)-Nicotine hydrogen tartrate salt, ≥98% (TLC), powder	
<b>Product Number</b>	N5260	
<b>Product Brand</b>	SIGMA	
<b>CAS Number</b>	65-31-6	
<b>Molecular Formula</b>	$C_{10}H_{14}N_2 \cdot 2C_4H_6O_6$	
<b>Molecular Weight</b>	462.41	
<b>TEST</b>	<b>SPECIFICATION</b>	<b>LOT 129K0021 RESULTS</b>
<b>Appearance (Form)</b>	Powder	Powder
<b>Solubility (Color)</b>	Colorless to Faint Yellow 50 mg/ml in water	Colorless
<b>Solubility (Turbidity)</b>	Clear to Very Slightly Hazy	Clear
<b>Water (by Karl Fischer)</b>	≤10 %	7 %
<b>Carbon (anhydrous)</b>	45.4 - 47.7 %	47.0 %
<b>Nitrogen (anhydrous)</b>	5.8 - 6.4 %	6.0 %
<b>Purity (TLC)</b>	≥98 %	100 %
<b>Specification Date:</b>		MAR 2010
<b>Date of QC Release:</b>		MAR 2010
<b>Print Date:</b>		MAR 25 2010



Rodney Burbach, Manager  
Quality Control  
St. Louis, Missouri USA

## Nicotine-d3


Certificate Of Analysis

Page 1 of 1

# Certificate of Analysis

SIGMA-ALDRICH

<b>Product Name</b>	(±)-Nicotine-d <sub>3</sub> salicylate salt, 98 atom % D
<b>Product Number</b>	N5768
<b>Product Brand</b>	FLUKA
<b>Molecular Formula</b>	C <sub>11</sub> H <sub>11</sub> D <sub>3</sub> N <sub>2</sub> O <sub>3</sub>
<b>Molecular Weight</b>	303.37
<b>TEST</b>	LOT 048K4040 RESULTS
<b>APPEARANCE</b>	WHITE WITH A YELLOW CAST POWDER
<b>SOLUBILITY</b>	CLEAR COLORLESS SOLUTION AT 10 MG PLUS 1.0 ML OF WATER
<b>PROTON NMR SPECTRUM</b>	CONSISTENT WITH STRUCTURE
<b>ELEMENTAL ANALYSIS</b>	67.71% CARBON 9.03% NITROGEN
<b>PURITY BY THIN LAYER CHROMATOGRAPHY</b>	99.5%
<b>QC RELEASE DATE</b>	MAY 2008




Rodney Burbach, Manager  
Quality Control  
St. Louis, Missouri USA

## **Appendix 2**


### **Representative Chromatograms**

Reagent Blank - Batch PB001 (observed internal standard peak <10% of utilised internal standard peak area)

BLK-RB (2610332)-1-1-C - Cotinine (Blank) 177.100/80.000 Da - sample ...  
(peak not found)





BLK-RB (2610332)-1-1-C - Cotinine-d3(IS) (Blank) 180.100/80.000 Da - sample 4 o  
Area: 245.1503939396 counts Height: 108.5581843141 cps RT: 0.8372884468 .



**Matrix Blank - Batch PB001 (observed internal standard peak <10% of utilised internal standard peak area)**

■ **BLK-MB (2610333)-1-1-C - Cotinine (Blank) 177.100/80.000 Da - sample ...**  
**(peak not found)**



■ BLK-MB (2610333)-1-1-C - Cotinine-d3(1S)(Blank) 180.100/80.000 Da - sample 5 ..  
Area: 650.1016750855 counts Height: 226.7110325648 cps RT: 0.8479605166 .



Matrix Blank containing Internal Standard - Batch PB001(Observed Cotinine peak  $\leq 20\%$  of utilised LLOQ)


BLK-MB+IS (2610334)-1-1-C - Cotinine (Blank) 177.100/80.000 Da - sam...  
Area: 516.7810396778 counts Height: 209.6610147051 cps RT: 0.811193...

BLK-MB+IS (2610334)-1-1-C - Cotinine-d3(IS)(Blank) 180.100/80.000 Da - sample  
Area: 27169.5912743276 counts Height: 8904.6284099634 cps RT: 0.8108508...




**Matrix Blank (Carryover assessment) - Batch PB001 (observed internal standard peak <10% of utilised internal standard peak area)**

■ **BLK-CARRYOVER (2610344)-1-1-C - Cotinine (Blank) 177.100/80.000 Da...**  
**(peak not found)**




■ **BLK-CARRYOVER (2610344)-1-1-C - Cotinine-d3(IS)(Blank) 180.100/80.000 Da - .**  
Area: 699.7833518705 counts Height: 356.0375890832 cps RT: 0.8443993601 .




Calibration Standard 0.5 ng/mL - Batch PB001

**CAL-1.5/0.5 (2610365)-1-1-C - Cotinine (Standard) 177.100/80.000 Da - s...**  
**Area: 7024.0945658749 counts Height: 2562.9286254123 cps RT: 0.8119...**





**CAL-1.5/0.5 (2610365)-1-1-C - Cotinine-d3(IS) (Standard) 180.100/80.000 Da - sa..**  
**Area: 31695.8171759567 counts Height: 10563.0117708660 cps RT: 0.810525..**



Calibration Standard 500 ng/mL - Batch PB001


**CAL-500/500 (2610357)-1-1-C - Cotinine (Standard) 177.100/80.000 Da - ...**  
**Area: 6615211.5152970357 counts Height: 2146408.5095576523 cps RT:...**

**CAL-500/500 (2610357)-1-1-C - Cotinine-d3(1S) (Standard) 180.100/80.000 Da - sa**  
**Area: 40049.0561428831 counts Height: 13765.8191197450 cps RT: 0.810613..**




QC Sample 15 ng/mL - Batch PB001

■ QC-30/15 (2610371)-1-1-C - Cotinine (QC) 177.100/80.000 Da - sample 26...  
Area: 221788.3749445961 counts Height: 74755.5322813687 cps RT: 0.8...





■ QC-30/15 (2610371)-1-1-C - Cotinine-d3(IS)(QC) 180.100/80.000 Da - sample 26...  
Area: 33914.1111184905 counts Height: 10864.7278623619 cps RT: 0.811352...



Subject R01001, Pre-screening –Batch PB001

**HB-2405671-1-2-C - Cotinine (Unknown) 177.100/80.000 Da - sample 11 o...**  
**Area: 3269435.7679062616 counts Height: 1105415.2973200607 cps RT:...**



**HB-2405671-1-2-C - Cotinine-d3(1S)(Unknown) 180.100/80.000 Da - sample 11 of ..**  
**Area: 36335.4919609084 counts Height: 11966.4941553771 cps RT: 0.811665..**



Subject R01001, Week 6 Batch PB001


**HB-2405672-1-2-C - Cotinine (Unknown) 177.100/80.000 Da - sample 12 o...**  
**Area: 4285307.3859558273 counts Height: 1504569.2919916681 cps RT:...**

**HB-2405672-1-2-C - Cotinine-d3(1S) (Unknown) 180.100/80.000 Da - sample 12 of ..**  
**Area: 45416.2583314112 counts Height: 15431.6475480286 cps RT: 0.806605..**




Subject R01001, Week 16 Batch PB001

HB-2405673-1-2-C - Cotinine (Unknown) 177.100/80.000 Da - sample 13 o...  
Area: 656234.1276586086 counts Height: 232491.2511895146 cps RT: 0...





HB-2405673-1-2-C - Cotinine-d3(1S) (Unknown) 180.100/80.000 Da - sample 13 of ..  
Area: 45841.0122940578 counts Height: 15674.0360295957 cps RT: 0.807660..



Subject R01010, Pre-screening Batch PB001

■ **HB-2405762-1-2-C - Cotinine (Unknown) 177.100/80.000 Da - sample 47 o...**  
**Area: 4860388.9281050982 counts Height: 1605186.3898407619 cps RT:...**



■ **HB-2405762-1-2-C - Cotinine-d3(1S) (Unknown) 180.100/80.000 Da - sample 47 of ..**  
**Area: 33969.2003791659 counts Height: 11144.6048826372 cps RT: 0.813289..**



Subject R01010, Week 28 Batch PB001


■ **HB-2405765-1-2-C - Cotinine (Unknown) 177.100/80.000 Da - sample 50 o...**  
**Area: 5374728.1603466002 counts Height: 1856867.8514010909 cps RT:...**

■ **HB-2405765-1-2-C - Cotinine-d3(1S) (Unknown) 180.100/80.000 Da - sample 50 of ..**  
**Area: 49864.8011094891 counts Height: 17233.7167583051 cps RT: 0.806895..**




Subject R01016, Pre-screening Batch PB001

HB-2405794-1-2-C - Cotinine (Unknown) 177.100/80.000 Da - sample 70 o...  
Area: 1292142.3198194201 counts Height: 426429.2479851952 cps RT: ...




HB-2405794-1-2-C - Cotinine-d3(1S)(Unknown) 180.100/80.000 Da - sample 70 of ..  
Area: 29688.5580669604 counts Height: 9524.5851418992 cps RT: 0.8151112..




Subject R01016, Week 6 Batch PB001

■ **HB-2405795-1-2-C - Cotinine (Unknown) 177.100/80.000 Da - sample 71 o...**  
**Area: 2134953.9047966246 counts Height: 749910.8762562415 cps RT: ...**




■ **HB-2405795-1-2-C - Cotinine-d3(1S) (Unknown) 180.100/80.000 Da - sample 71 of ..**  
**Area: 46837.0428448385 counts Height: 16550.4765732209 cps RT: 0.807745..**




Subject R01016, Week 16 Batch PB001

■ **HB-2405796-1-2-C - Cotinine (Unknown) 177.100/80.000 Da - sample 72 o...**  
**Area: 1492899.3748732053 counts Height: 525712.8257821875 cps RT: ...**





■ **HB-2405796-1-2-C - Cotinine-d3(1S) (Unknown) 180.100/80.000 Da - sample 72 of ..**  
**Area: 44426.8834529553 counts Height: 15400.7159517842 cps RT: 0.807752..**



Subject R02007, Pre-screening Batch PB003

HB-2405843-1-2-C - Cotinine (Unknown) 177.100/80.000 Da - sample 14 o...  
Area: 3311139.0517230355 counts Height: 1175875.6543358152 cps RT:...



HB-2405843-1-2-C - Cotinine-d3(1S) (Unknown) 180.100/80.000 Da - sample 14 of ..  
Area: 33238.9101319080 counts Height: 11336.6169901384 cps RT: 0.808551..



Subject R02007, Week 6 Batch PB003

■ **HB-2405844-1-2-C - Cotinine (Unknown) 177.100/80.000 Da - sample 15 o...**  
**Area: 2494364.9939587014 counts Height: 897214.3600462893 cps RT: ...**



■ **HB-2405844-1-2-C - Cotinine-d3(1S)(Unknown) 180.100/80.000 Da - sample 15 of ..**  
**Area: 33576.9233187862 counts Height: 11362.4776234898 cps RT: 0.810451..**



Subject R02015, Week 6 Batch PB003


■ **HB-2405892-1-2-C - Cotinine (Unknown) 177.100/80.000 Da - sample 49 o...**  
**Area: 4216780.2366162352 counts Height: 1511341.3332083067 cps RT:...**

■ **HB-2405892-1-2-C - Cotinine-d3(1S)(Unknown) 180.100/80.000 Da - sample 49 of ..**  
**Area: 37233.9552349868 counts Height: 13033.2866943666 cps RT: 0.808020..**




Subject R02015, Week 28 Batch PB003

HB-2405894-1-2-C - Cotinine (Unknown) 177.100/80.000 Da - sample 51 o...  
Area: 6212538.9144801032 counts Height: 2202430.8414405566 cps RT:...



HB-2405894-1-2-C - Cotinine-d3(IS)(Unknown) 180.100/80.000 Da - sample 51 of ..  
Area: 38977.8628104876 counts Height: 13553.2659876264 cps RT: 0.808344..



**Appendix 3**  
**Repeat Analysis Summary**

### Analytical Reassay Summary

Original Batch	Sample ID	Original Dilution	Analyte	Original Result (ng/mL)	Reason for Repeat	Repeat Dilution	Repeat Batch	Repeat Result (ng/mL)	Repeat Result Annotations	Final Result Used (ng/mL)
PB001	SR01010 PWeek 16 XE439921-4	1	Cotinine	549	AL/HI	5	PB013	584		584
PB002	SR01028 PScreening XD755043-4	1	Cotinine	501	AL	5	PB013	436		436
PB002	SR01028 PWeek 28 XS412501-4	1	Cotinine	603	AL	5	PB013	499		499
PB002	SR01034 PScreening XE439945-4	1	Cotinine	593	AL	5	PB013	439		439
PB002	SR01037 PWeek 28 XH516234-4	1	Cotinine	534	AL	5	PB013	402		402
PB003	SR02015 PScreening XD472913-4	1	Cotinine	547	AL/HI	5	PB013	551		551
PB004	SR02026 PWeek 28 XD472851-4	1	Cotinine	700	AL/HI	5	PB013	551		551
PB004	SR02029 PWeek 16 XT486252-4	1	Cotinine	599	AL	5	PB013	537		537
PB004	SR02029 PWeek 28 XD755414-4	1	Cotinine	648	AL	5	PB013	602		602
PB005	SR03014 PScreening XD000245-4	1	Cotinine	558	AL/HI	5	PB013	741		741
PB005	SR03014 PWeek 6 XD480163-4	1	Cotinine	532	AL/HI	5	PB013	778		778
PB005	SR03014 PWeek 6 XH516543-4	1	Cotinine	440	HI	5	PB013	598		598
PB005	SR04004 PScreening XG514953-4	1	Cotinine	185	PC/HI	1	PB013	278	IP	278 IP
PB005	SR04004 PWeek 6 XO638552-4	1	Cotinine	221	PC	1	PB013	266	IP	266 IP
PB005	SR03026 PWeek 6 XC679021-4	1	Cotinine	548	AL	5	PB013	537		537
PB006	SR04026 PScreening XT527002-4	1	Cotinine	583	AL	5	PB013	578		578

Original Batch	Sample ID	Original Dilution	Analyte	Original Result (ng/mL)	Reason for Repeat	Repeat Dilution	Repeat Batch	Repeat Result (ng/mL)	Repeat Result Annotations	Final Result Used (ng/mL)
PB007i	SR04059 PScreening XH924805-4	1	Cotinine	506	AL	5	PB013	632		632
PB007i	SR04059 PWeek 6 XV396224-4	1	Cotinine	509	AL	5	PB013	547		547
PB008	SR04071 PWeek 6 XV396132-4	1	Cotinine	552	AL	5	PB013	578		578
PB008	SR04071 PWeek 16 XV419723-4	1	Cotinine	549	AL	5	PB013	463		463
PB008	SR04072 PWeek 28 XV419841-4	1	Cotinine	558	AL	5	PB013	509		509
PB008	SR04075 PWeek 28 XE970049-4	1	Cotinine	529	AL	5	PB013	547		547
PB008	SR04076 PWeek 28 XV419831-4	1	Cotinine	523	AL	5	PB013	371		371
PB008	SR04083 PWeek 6 XV396212-4	1	Cotinine	>500	AL	10	PB013	688		688
PB008	SR04088 PWeek 28 XV419803-4	1	Cotinine	606	AL	5	PB013	493		493
PB009	SR04117 PWeek 16 XE969497-4	1	Cotinine	515	AL	5	PB013	460		460
PB010	SR05017 PWeek 28 XB426776-4	1	Cotinine	519	AL	5	PB013	471		471
PB011	SR05022 PScreening XE487452-4	1	Cotinine	522	AL	5	PB013	488		488
PB011	SS02051 PScreening XE353494-4	1	Cotinine	620	AL	5	PB013	556		556
PB011	SR05026 PScreening XE487421-4	1	Cotinine	548	AL	5	PB013	540		540
PB014	SR04028 PScreening XT527001-4	1	Cotinine	707	AL	5	PB015	820		820
PB014	SR04028 PWeek 16 XT526890-4	1	Cotinine	721	AL	5	PB015	746		746
PB014	SR04028 PWeek 28 XU629470-4	1	Cotinine	587	AL	5	PB015	581		581

Original Batch	Sample ID	Original Dilution	Analyte	Original Result (ng/mL)	Reason for Repeat	Repeat Dilution	Repeat Batch	Repeat Result (ng/mL)	Repeat Result Annotations	Final Result Used (ng/mL)
PB014	SR04033 PWeek 6 XT526703-4	1	Cotinine	993	AL	5	PB015	675		675
PB014	SR04033 PWeek 16 XT526870-4	1	Cotinine	688	AL	5	PB015	563		563
PB014	SR04033 PWeek 28 XU786701-4	1	Cotinine	757	AL	5	PB015	788		788
PB014	SR04037 PScreening XG514903-4	1	Cotinine	532	AL	5	PB015	494		494
PB014	SR04037 PWeek 16 XT526852-4	1	Cotinine	621	AL	5	PB015	552		552

AL = Above limit of quantification

HI = High internal standard

IP = Interference peak

PC = Poor chromatography

**Appendix 4**  
**Batch Analysis Summary**

Date of Extraction	Date of Injection	Batch Names	Batch Contents	LLOQ (ng/mL)	Analyte	Batch Status
21-Mar-2011	21-Mar-2011	PB001	Study samples	0.500	Cotinine	Data Reported
21-Mar-2011	23-Mar-2011	PB002	Study samples	0.500	Cotinine	Data Reported
23-Mar-2001	23-Mar-2011	PB003	Study samples	0.500	Cotinine	Data Reported
23-Mar-2011	24-Mar-2011	PB004	Study samples	0.500	Cotinine	Data Reported
24-Mar-2011	24-Mar-2011	PB005	Study samples	0.500	Cotinine	Data Reported
25-Mar-2011	26-Mar-2011	PB006	Study samples	0.500	Cotinine	Data Reported
28-Mar-2011	28-Mar-2011	PB007	Study samples	N/A	Cotinine	Data Not Reported
28-Mar-2011	29-Mar-2011	PB007i	Re-injection of PB007	0.500	Cotinine	Data Reported
28-Mar-2011	29-Mar-2011	PB012	Incurred Sample Reproducibility	N/A	Cotinine	Data Not Reported
28-Mar-2011	29-Mar-2011	PB012i	Re-injection of PB012	0.500	Cotinine	Data Reported
29-Mar-2011	29-Mar-2011	PB008	Study samples	0.500	Cotinine	Data Reported
29-Mar-2011	31-Mar-2011	PB009	Study samples	0.500	Cotinine	Data Reported
31-Mar-2011	01-Apr-2011	PB010	Study samples	0.500	Cotinine	Data Reported
31-Mar-2011	01-Apr-2011	PB011	Study samples	0.500	Cotinine	Data Reported
06-Apr-2011	06-Apr-2011	PB013	Re-assays	0.500	Cotinine	Data Reported
14-Apr-2011	16-Apr-2011	PB014	Study samples	1.00	Cotinine	Data Reported
18-Apr-2011	18-Apr-2011	PB015	Re-assays	1.00	Cotinine	Data Reported

**Appendix 5**  
**Deviations from Protocol and Analytical Procedure**

## **Protocol**

The following deviations were noted during the course of the study, none of which affected the integrity of the study data:

- In batch PB005, an interferent peak was noted at the retention window of Cotinine in the MB (carryover) injected after the top calibration point (>20% of the utilised LLOQ). However all other blanks within this batch had no peaks >20% of the utilised LLOQ (RB = 8.4%, MB = 1.0%, MB + IS = 6.3%, 2nd MB (Carryover) = 7.2% of cal 0.5). This interference does not appear to be the result of carryover, but may have been contaminated during the extraction procedure. The interferent peak did not appear to affect the accuracy of the calibration standards and quality control samples in this batch, as they are all within the acceptance criteria. Because of these factors, the LLOQ was not raised in the batch
- Some subjects did not complete the duration of the study. Therefore four samples were not taken. In addition an early termination sample was taken for some subjects
- All samples received at Covance Harrogate were analysed as no randomisation list was provided
- Gender was not included in the data tables generated as the gender of the samples was not provided in the shipment lists provided to Covance Harrogate. In addition the following information was included in the data tables: dilution factor, comment, collection date and parent aliquot name
- The incurred sample reproducibility acceptance criteria documented in the protocol was not met
- The study title of the protocol omits in error the word 'Placebo' prior to 'Controlled'

## **Analytical Procedure**

The following deviation was noted in the analytical procedure during the course of the study. This did not affect the integrity of the study data:

- Batches PB007 and PB012 were injected on to the LC-MS/MS with the incorrect reagent. The reagent was re-prepared and batches successfully re-injected as PB007i and PB012i respectively

**Appendix 6**  
**Protocol Observations**

### **Protocol Observations**

The following observations were noted during the course of the study, none of which affected the integrity of the study data:

- On page 7, section 4.8 and 4.9 (second paragraph in both sections), definitive protocol states ' $\leq 20\%$  of the mean utilised LLOQ' this is incorrect as only a single calibration line was utilised and should be ' $\leq 20\%$  of the utilised LLOQ'
- On page 7, section 4.8, third paragraph, fourth sentence, the acceptance criteria was incorrect. It states 'peak area  $\leq 5\%$ ' this is a typographical error and should be ' $\leq 10\%$ ' in agreement with section 4.9 of the same protocol

## 9 ANNEX

The Annex consists of 59 pages, including this one, and includes:

- [Analytical Procedure HB-10-082-V3](#) (41 pages)
- [Study Protocol](#) (17 pages)

**ANALYTICAL PROCEDURE - SECTION A**

Covance HB-10-082-V3


Determination of Nicotine and Cotinine in Human Plasma (EDTA)


using Protein Precipitation and


Ultra High Performance Liquid Chromatography (UHPLC)

with Tandem Mass-Spectrometric Detection

**Original author** Jayne Spink  
**Title:** Method Development Specialist

**Version written/  
updated by**  **Date** 14 JULY 2011  
**Name:** Heather Wilshaw  
**Title:** Experimental Officer

**Reviewed by**  **Date** 14 July 11  
**Name:** Barry Hawthorne  
**Title:** Method Development Specialist

**Authorised by**  **Date** 18<sup>th</sup> July 2011  
**Name:** Sarah Fenton  
**Title:** Study Director

## 1 INTRODUCTION

### 1.1 Method notes

#### Validation summary

Maximum acceptable batch size during validation:	96
Maximum number of freeze/thaw cycles in matrix:	4
Maximum storage at room temperature in matrix:	25 hours
Maximum storage at nominal -80°C in matrix:	91 days
Extract viability refrigerated:	3 days
Sample collection (blood) stability at room temperature:	2 hours
Haemolysed plasma sample assessment:	Data Acceptable
Stock Solution A (Nicotine only) Stability at nominal -20 °C: (1000 µg/mL in water: methanol (50:50 v/v))	55 days
Stock Solution A (Cotinine only) Stability at nominal -20 °C: (1000 µg/mL in water: methanol (50:50 v/v))	55 days
Working Standard Solution D (Nicotine only) Stability at nominal -20°C: (10000 ng/mL in water: methanol (50:50 v/v))	55 days (from prep of A stock)
Working Standard Solution E (Cotinine only) Stability at nominal -20°C: (10000 ng/mL in water: methanol (50:50 v/v))	55 days (from prep of A stock)
Mixed Working Standard Solution F Stability at nominal -20°C: (Nicotine and Cotinine 10000 ng/mL in water: methanol (50:50 v/v))	55 days (from prep of A stock)
Mixed Working Standard Solution N Stability at nominal -20°C: (Nicotine 30ng/mL and Cotinine 10 ng/mL in water: methanol (50:50 v/v))	55 days (from prep of A stock)

Analytical Procedure: Covance HB-10-082-V3

Analyte: Nicotine and Cotinine in Human Plasma (EDTA)

Stock Solution A (Nicotine only) Stability at room temperature: (1000 µg/mL in water: methanol (50:50 v/v))	6 hrs
Stock Solution A* (Cotinine only) Stability at room temperature: (1000 µg/mL in water: methanol (50:50 v/v))	6 hrs
Working Standard Solution D (Nicotine only) Stability at room temperature: (10000 ng/mL in water: methanol (50:50 v/v))	6 hrs
Working Standard Solution E (Cotinine only) Stability at room temperature: (10000 ng/mL in water: methanol (50:50 v/v))	6 hrs
Mixed Working Standard Solution F Stability at room temperature: (Nicotine and Cotinine 10000 ng/mL in water: methanol (50:50 v/v))	6 hrs
Mixed Working Standard Solution N Stability at room temperature: (Nicotine 30ng/mL and Cotinine 10 ng/mL in water: methanol (50:50 v/v))	6 hrs

Analytical Procedure: Covance HB-10-082-V3

Analyte: Nicotine and Cotinine in Human Plasma (EDTA)

Internal standard stock solution stability at room temperature (Cotinine-d3): (1000 µg/mL in water: methanol (50:50 v/v))	6 hours
Internal standard precision (% RSD): Nicotine-d3 and Cotinine-d3	<i>Stable label ≤20%</i>
Nicotine calibration range:	1.5 to 500 ng/mL
Cotinine calibration range:	0.5 to 500 ng/mL
Maximum validated dilution factor:	10-fold

The above data were generated in Covance Study number 8235697.

Incurred sample reproducibility (ISR) was assessed in the following Covance study number(s) and the samples assessed passed the acceptance criteria.

Covance Study Number	Study Type
8233095	Determination of Cotinine in Human Plasma Samples from a Multicenter, Randomised, Double-Blind Controlled Trial of the Ability of a Traditional Swedish Smokeless Tobacco Product (“Snus”) to Increase the Quit Rate Among Cigarette Smokers Who Wish to Stop Smoking (Sponsor Reference number SM 08-01)

#### Data processing

Height/area:	Area
Regression fit:	Nicotine – Linear Cotinine – Quadratic
Weighting factor:	Nicotine – 1/x Cotinine – 1/x <sup>2</sup>
Data system:	Analyst (current version) using Classic algorithm
Smoothing:	5

Data presentation:	Three significant figures
Ions monitored:	163.3 → 130.1 ( $\pm 0.5$ Da) (Nicotine)
	166.3 → 130.1 ( $\pm 0.5$ Da) (Nicotine-d3)
	177.1 → 80.0 ( $\pm 0.5$ Da) (Cotinine)
	180.1 → 80.0 ( $\pm 0.5$ Da) (Cotinine-d3)
Nautilus LIMS naming convention:	Nicotine Nicotine-d3 Cotinine Cotinine-d3
Approximate Retention times:	Nicotine 2.1 minutes Nicotine-d3 2.2 minutes Cotinine 0.8 minutes Cotinine-d3 0.8 minutes

The following points that may affect the behaviour of this assay have been observed:

**NICOTINE AND COTININE MAY BE PRESENT IN THE ENVIRONMENT THEREFORE CARE SHOULD BE TAKEN TO AVOID CONTAMINATION.**

**To minimise possible exposure to sources of contamination the following points should be observed:**

**Pre-wash all glassware and any other non-disposable items with methanol prior to use.**

**Use different fume cupboards for spiking and extraction where possible.**

**Use un-opened bottles of solvents where possible.**


**Keep bottles of solvents or reagents carefully sealed during storage.**

**Change lab coats and gloves frequently.**

Analytical Procedure: Covance HB-10-082-V3


Analyte: Nicotine and Cotinine in Human Plasma (EDTA)

The structure of Nicotine is:




Supplied as (-) – Nicotine hydrogen tartrate salt ( $C_{10}H_{14}N_2 \cdot 2C_4H_6O_6$ ) Mwt = 462.4

The structure of Cotinine is:




Supplied as (-) – Cotinine ( $C_{10}H_{12}N_2O$ ) Mwt = 176.2

The structure of Nicotine-d3 (Nicotine internal standard) is:



Supplied as ( $\pm$ ) – Nicotine-d3 salicylate ( $C_{17}H_{17}D_3N_2O_3$ ) Mwt = 303.4

The structure of Cotinine-d3 (cotinine internal standard) is:



Supplied as ( $\pm$ ) – Cotinine methyl-d3 ( $C_{10}H_9D_3N_2O$ ) Mwt = 179.2

**Analytical Procedure:** Covance HB-10-082-V3

**Analyte:** Nicotine and Cotinine in Human Plasma (EDTA)

The differences between validated versions (Vx) of the analytical procedure, at the time of issue and the previous version are listed in Attachment 1. This is not applicable to V1 and draft (Dx) documents, where x = version number.

## **2 SAFETY AND HANDLING**

The test articles used in this method have been subjected to COSHH assessments. Based on these assessments all procedures in this method have been assigned general handling and emergency codes, which are explained in the company health and safety manual CLEHS023. In general, all laboratory procedures carried out during the study will be subject to COSHH general handling categories 1a/1b, 2a and 3a (disposable latex or nitrile gloves, laboratory coat and safety glasses) and emergency categories A3 and B1 (contain/isolate spillage using same protective equipment as in the general handling categories and warn all relevant personnel in the area). Additional categories will be assigned appropriately within this document. All biological samples will be considered biohazardous and handled appropriately (see SOP BIO 3).

### 3 SAMPLE PREPARATION PROCEDURE

#### Manual solid phase extraction of Nicotine and Cotinine from human plasma

	PROCEDURE	Additional Handling COSHH CODES	Additional Emergency COSHH CODES
1	Thaw frozen quality control samples, control matrix and matrix study samples at room temperature.	4a	C6, D1
2	Vortex mix samples (ca. 10 seconds).	4a	C6, D1
3	Spike calibration standards appropriately (see <a href="#">section 5.3</a> ).	4b	C6, D1
4	Aliquot calibration standards, QCs, study samples and blanks (50 $\mu$ L)* into a 2 mL 96 deep well plate, using a 10 -50 $\mu$ L pipette.	4b	C6, D1
5	Return unused portion of samples to freezer.	4a	C6, D1
6	Add internal standard solution (25 $\mu$ L, 40/20 ng/mL) using a Handystep pipette, to all wells except blanks, which receive 25 $\mu$ L of 0.2% acetic acid (aq).	4b	C6, D1
7	Vortex mix plate (ca. 60 seconds).	4b	C6, D1
8	Add acetonitrile (200 $\mu$ L) using a Handystep pipette, to all wells.	4b	C6, D1
9	Vortex mix plate (ca. 60 seconds).	4b	C6, D1
10	Centrifuge (ca. 5 minutes, ca. 2000g, nominal 4°C).	4a	C6, D1
11#	Transfer 100 $\mu$ L (Variable X in Flexus method) of the supernatant to a 1.2 mL 96 deep well plate.	4b	C6, D1
12	Add 10 mM ammonium acetate (50 $\mu$ L) using a Handystep pipette to all wells.	4b	C6, D1
13	Cap plate and vortex mix (ca 60 seconds).	4a	C2, D1
14	Centrifuge (ca. 5 minutes, ca. 2000g, nominal 4°C).	4a	C2, D1
15	Submit for analysis.	4a	C2, D1

\* samples (including QC samples) which require dilution: dilute pro rata with control matrix eg ten-fold dilution is made by adding 20  $\mu$ L of sample/QC to 180  $\mu$ L of control matrix in to a 1.5 mL Eppendorf tube. Vortex mix (ca. 5 seconds) and take 50  $\mu$ L for analysis.

Reagent blank consists of 50  $\mu$ L of water in place of matrix.

# steps performed on Flexus, using method Bio 10 (attachment 2)

## 4 MATERIALS, APPARATUS, REAGENTS AND SOLUTIONS

### 4.1 Control matrices

The control matrix for this study is human plasma with EDTA anticoagulant. The plasma must be obtained from nicotine free (non smoker) subjects. This control matrix should be subaliquotted into appropriate volumes prior to use.

For whole blood stability assessment, human whole blood with EDTA anticoagulant will be used and will be stored refrigerated prior to use.

Haemolysed plasma is prepared by adding 20  $\mu\text{L}$  of lysed blood per 980  $\mu\text{L}$  of plasma. Lysed blood is prepared by freezing whole blood ( $-20^{\circ}\text{C}$ ), thawing and centrifuging at room temperature (2000 g for 15 minutes). The supernatant is lysed blood.

### 4.2 Study specific disposable and non disposable equipment

For standard laboratory procedures, disposable equipment is sourced from appropriate suppliers and will be considered suitable for purpose.

### 4.3 Chemicals, solvents and analytical standards

The chemicals, solvents and analytical standards used in this method are presented in the following table. Unless stated otherwise elsewhere, any equivalent chemicals and solvents may be substituted, provided they meet, or are considered to be equivalent to the minimum specifications stated in the table.

Name	Minimum specification
Nicotine (Supplied by Sigma as (-) – Nicotine hydrogen tartrate salt)	See C of A for specification
Cotinine (Supplied by Sigma as (-) – Cotinine)	See C of A for specification
Nicotine-d3 (Supplied by Sigma as (±) – Nicotine-d3 salicylate)	See C of A for specification
Cotinine-d3 (Supplied by Sigma as (±) – Cotinine methyl-d3)	See C of A for specification
Acetic acid (ca. 100%)	AnalaR®
Acetonitrile	HPLC
Ammonium acetate	AnalaR® or HPLC grade
Ammonia solution (specific gravity ca. 0.88)	GPR™
Formic acid	AnalaR® or HPLC grade
Methanol	HPLC
2-Propanol (IPA)	HPLC
THF (Tetrahydrofuran)	HPLC
Water	Super-Q

#### 4.4 Preparation of solutions, solvents and reagents

*Quantities may be scaled up or down as required for the specific needs of the study. All reagents are to be prepared in glass bottles and stored at room temperature for a maximum of one month unless stated otherwise. Mix all reagents thoroughly after preparation. For use of bulk reagents refer to bulk reagent preparation record for preparation and storage details. Additional COSHH for all reagents: 4b/d, C1, D1.*

##### 4.4.1 Water: methanol (50:50 v/v)

Add 500 mL of methanol to 500 mL of water. Mix thoroughly.

##### 4.4.2 0.2% acetic acid (aq)

Add 2 mL of acetic acid to 1 L of water. Mix thoroughly.

##### 4.4.3 Ammonium acetate (10 mM)

Weigh 1.54 g of ammonium acetate (Fwt 77.08) and dissolve in 2 L of water. Mix thoroughly.

##### 4.4.4 Mobile phase A, auto-sampler 'weak' wash solvent & slave pump solvent Ammonium acetate (10 mM) : acetonitrile 50:50 v/v)

Weigh 1.93 g ammonium acetate (Fwt 77.08) and dissolve in 2500 mL of water. Add 2500 mL of acetonitrile. Mix thoroughly. Expiry = 2 weeks

##### 4.4.5 Mobile phase B

##### Ammonium acetate (100 mM) : acetonitrile 20:80 v/v)

Weigh 7.71 g ammonium acetate (Fwt 77.08) and dissolve in 1000 mL of water. Add 4000 mL of acetonitrile. Mix thoroughly. Expiry = 2 weeks

##### 4.4.6 Auto-sampler 'strong' wash solvent

##### (Water: methanol: IPA: THF: ammonia, 25:25:25:25:0.5 v/v/v/v/v)

Add 20 mL of ammonia to 1000 mL of water, 1000 mL of methanol, 1000 mL of IPA and 1000 mL of THF.

## 5 NICOTINE, COTININE, NICOTINE-D3 AND COTININE-D3 STANDARD SOLUTIONS

*If air displacement or positive displacement pipettes are used for any of the work detailed in this section then these must be calibrated on the day of use. All quantities may be scaled up or down as required for the specific needs of the study, provided that the final concentrations are as indicated in this document.*

*Additional COSHH considerations:*

*Weighing compound for A-stocks: 4c, 5a (dust), C3/C8, D1/D2/D3.*

*Preparing working solutions: 4a/b, C8, D1*

*Preparing matrix samples: 4b, C6/C8, D1*

### 5.1 Nicotine and Cotinine stock solutions

Accurately weigh Nicotine (approximately 30 mg) and Cotinine (approximately 10 mg) into separate containers.

Dissolve in **water: methanol (50:50 v/v)** (approximately 10 mL for each compound, after application of correction factor, accurately measured) to achieve a concentration of 1000 µg/mL (Calibration standard stock solutions A (Nicotine) and A\* (Cotinine)).

Correct for water content, salt, purity, etc (use form 1978) as appropriate.

Prepare second stock Nicotine and Cotinine standard solutions in the same manner (Quality control standard stock solution A and A\* respectively).

<b>Preparation container:</b>	Foil wrapped plastic scintillation vial
<b>Storage temperature:</b>	Nominal -20°C
<b>Storage container:</b>	Foil wrapped plastic scintillation vial
<b>Shelf life:</b>	55 days
<b>Other requirements:</b>	Protected from light

## 5.2 Correlation of calibration and quality control solutions

Dilute calibration and quality control stock solutions A as described in the following table.

Preparation of correlation solutions				
Solution	Standard/solution used and volume ( $\mu\text{L}$ )	Reagent/solvent volume (mL)	Final volume (mL)	Final concentration ( $\mu\text{g}/\text{mL}$ )
CORR1	A 100	9900	10	10
CORR2	A* 100	9900	10	10
CORR3+	CORR1 (100) & CORR2 (100)	19780	20	0.05

CORR1 & CORR2 solutions prepared in methanol.

CORR3 solutions prepared in mobile phase A.

+ working solution also contains 10  $\mu\text{L}$  of internal standard solution A & A\*

Perform a minimum of triplicate injections of each working solution CORR3 using the chromatographic system described in Section B. Calculate the mean peak area ratios for each solution and the percentage difference of the means.

Alternatively, perform triplicate absorbance readings at 256 nm for each working solution CORR1 and CORR2, using an ultraviolet spectrophotometer. Calculate the mean absorbance for each solution and the percentage difference of the means.

### 5.3 Calibration standards

Prepare calibration standard solutions as detailed in the table below

Preparation of diluted working standards from calibration standard stocks solution A and A*						
TA working std	TA std Used and vol ( $\mu\text{L}$ )	Reagent/solvent volume (mL)	Final volume (mL)	Final Conc Nicotine (ng/mL)	Final Conc Cotinine (ng/mL)	Storage Nominal temp ( $^{\circ}\text{C}$ )
B	A 1000	9.000	10	100000	N/A	
C	A* 1000	9.000	10	N/A	100000	
D	B 1000	9.000	10	10000	N/A	
E	C 1000	9.000	10	N/A	10000	
F	B 1000 and C 1000	8.000	10	10000	10000	
G	B 900 and C 900	8.200	10	9000	9000	
H	B 600 and C 400	9.000	10	6000	4000	
I	B 200 and C 100	9.700	10	2000	1000	-20
J	B 100 and C 20	9.880	10	1000	200	
K	D 200 and E 100	9.700	10	200	100	
L	D 100 and E 50	9.850	10	100	50	
M	D 60 and E 20	9.920	10	60	20	
N	D 45 and E 15	14.940	15	30	10	

**Expiry: 55 days (from prep of A stock)**

Working standards prepared in water: **methanol (50:50 v/v)** in foil wrapped, plastic scintillation vials. The working standards may be divided into 100  $\mu\text{L}$  and stored in amber 0.5 mL Eppendorf tubes if required.

Solutions are stored at nominal  $-20^{\circ}\text{C}$ .

Analytical Procedure: Covance HB-10-082-V3

Analyte: Nicotine and Cotinine in Human Plasma (EDTA)

Preparation of calibration standards				
Nominal Conc Nicotine (ng/mL)	Nominal Conc Cotinine (ng/mL)	Working std used & vol ( $\mu$ L)	Matrix volume ( $\mu$ L)	Final volume ( $\mu$ L)
500	500	F 30	570	600
450	450	G 15	285	300
300	200	H 15	285	300
100	50	I 15	285	300
50	10	J 15	285	300
10	5	K 15	285	300
5	2.5	L 15	285	300
3	1	M 15	285	300
1.5	0.5	N 30	570	600

Calibration standards prepared in human plasma (non smokers) in 1.5 mL amber Eppendorf tubes. These standards are prepared fresh on the day of analysis. They are not stored.

#### 5.4 Quality control samples

Prepare quality control samples solutions as detailed in the following tables.

Preparation of diluted working standards from quality control stock solutions A and A*						
TA working std	TA std used and vol (μL)	Reagent/solvent volume (mL)	Final volume (mL)	Final Conc Nicotine (ng/mL)	Final Conc Cotinine (ng/mL)	Storage Nominal temp (°C)
B	A 1000	9.000	10	100000	N/A	
C	A* 1000	9.000	10	N/A	100000	
D	B 1000	9.000	10	10000	N/A	See comments
E	C 1000	9.000	10	N/A	10000	below
F	B 800 and C 800	8.400	10	8000	8000	
G	D 600 and E 300	9.100	10	600	300	
H	D 90 and E 30	9.880	10	90	30	
I	D 45 and E 15	14.940	15	30	10	
J#	B 800	9.200	10	8000	N/A	
K#	C 800	9.200	10	N/A	8000	

Expiry: 55 days (from prep of A stock)

Working standards prepared in water: methanol (50:50 v/v) in foil wrapped, plastic scintillation vials.

All solutions stored nominal -20°C, excluding J and K which are prepared fresh on the day of analysis and discarded.

# used in validation only.

Analytical Procedure: Covance HB-10-082-V3      Analyte: Nicotine and Cotinine in Human Plasma (EDTA)

Preparation of quality control samples using quality control working standards							
QC Level	Nominal	Nominal	Working std used & vol ( $\mu$ L)	Matrix volume (mL)	Final volume (mL)	Storage	
	Conc Nicotine (ng/mL)	Conc Cotinine (ng/mL)				Nominal Temp ( $^{\circ}$ C)	Expiry
DiQC	2500	2500	B 25 and C 25	0.950	1		
HiQC	400	400	F 500	9.500	10	-80	91 days
MeQC	30	15	G 500	9.500	10		
LoQC	4.5	1.5	H 500	9.500	10		
LLOQ QC#	1.5	0.5	I 100	1.900	2		
Individual LoQC+	4.5	1.5	H 15	0.285	0.3		
Haemolysed LoQC ~	4.5	1.5	H 200	3.800	4		

Quality control samples prepared in human plasma (non smokers) in plastic scintillation vials. 200  $\mu$ L aliquots of each QC level are stored in amber 0.5 mL or 1.5 mL Eppendorf tubes.

# used in validation only.

+ Prepared using documented control matrix from a minimum of six individual subjects.

~ Prepared in haemolysed plasma.

Preparation of quality control samples for effects of Nicotine and Cotinine on the quantification of each other							
Nominal Conc (Nicotine) (ng/mL)	Nominal Conc (Cotinine) (ng/mL)	Working std used & vol ( $\mu$ L)	Matrix volume ( $\mu$ L)	Final volume (mL)	Storage		
					Nominal Temp ( $^{\circ}$ C)	Aliq vol ( $\mu$ L)	Vessel
400	N/A	J 50	950	1	Prepared fresh on day of analysis		
N/A	400	K 50	950	1			

Quality control samples prepared in human plasma (non smoker) in 1.5 mL Eppendorf tubes

Samples are used in validation only.

### 5.4.1 Sample collection (whole blood) stability assessment (validation only)

Prepare whole blood stability samples as detailed in the following table.

Preparation of whole blood stability samples from quality control solutions					
Whole Blood Stability Solution	Nominal Conc (Nicotine) (ng/mL)	Nominal Conc (Cotinine) (ng/mL)	Working std used & vol ( $\mu$ L)	Matrix volume (mL)	Final volume (mL)
WBS-A#	600	300	QC B (60) & QC C (30)	9.910	10
MeQC Blood+	30	15	WBS-A (2000)	38.000	40

# WBS-A solution is prepared in human plasma (non smokers) in polypropylene tube. This solution is used for spiking purposes only and is prepared fresh on day of analysis, then discarded.

+MeQC Blood is used for the sample collection stability samples. This solution is prepared in warmed (37°C) human whole blood (EDTA) in a polypropylene container.

*For spiking, blood may be removed from incubation but should be spiked as soon as is feasible.*

*Thorough mixing of blood should be performed by gently inverting the tube several times.*

*Do not shake or vortex mix blood as this will disrupt the red blood cells. When transferring blood using a pipette (including a Handystep), aspirate and dispense as slow as possible.*

7 sets of 5 mL aliquots of MeQC Blood are transferred into polypropylene tubes and labelled as  $T_{(0)}$  and  $T_{(0.5)}$ ,  $T_{(1)}$  and  $T_{(2)}$  RT and  $T_{(0.5)}$  and  $T_{(1)}$  and  $T_{(2)}$  WI .

Whole blood stability samples should be spiked fresh on the day of the experiment and divided into aliquots as detailed in the table above. Typically one aliquot ( $T_{(0)}$ ) should be harvested immediately (baseline sample). The remaining aliquots should then be stored at room temperature and on wet ice. At the timepoints detailed in the study protocol, further aliquots should be harvested.

After each timepoint, the harvested plasma should be immediately aliquotted appropriately (200  $\mu$ L in 1.5 mL Eppendorf tubes) and stored as per QC samples prior to analysis.

Plasma should be harvested by centrifuging at 2000 g for 5 min at room temperature.

**Analytical Procedure:** Covance HB-10-082-V3      **Analyte:** Nicotine and Cotinine in Human Plasma (EDTA)

### 5.5 Internal standard solution

Accurately weigh Nicotine-d3 (approximately 2 mg) and Cotinine-d3 (approximately 2 mg of each compound) into separate vessels.

Dissolve in **water: methanol (50:50 v/v)** (approximately 10 mL for each compound, accurately measured) to achieve a concentration of 200 µg/mL (internal standard stock solutions A (Nicotine-d3) and A\* (Cotinine-d3)).

Correct for water content, salt, purity, etc (use form 1978) as appropriate.

**Preparation container:** Foil wrapped plastic scintillation vial  
**Storage temperature:** Nominal -20°C  
**Storage container:** Foil wrapped plastic scintillation vial  
**Shelf life:** Assessed on a batch by batch basis  
**Other requirements:** None

Prepare working internal standard solutions as detailed in the following table.

Preparation of diluted working standards from calibration standard stock solution A						
IS Working std	IS std used and vol (µL)	Reagent/solvent volume (mL)	Final volume (mL)	Final Conc Nicotine (ng/mL)	Final Conc Cotinine (ng/mL)	Storage Nominal temp (°C)
B	A 200 and A* 25	39.775	40	1000	125	-20
C	B 400	9.600	10	40	5	Prep fresh on day of analysis

Solution B prepared in **water: methanol (50:50 v/v)** in foil wrapped plastic scintillation vial.

Solution C prepared in **0.2% acetic acid (aq)** in foil wrapped plastic scintillation vial.

Expiry: Assessed on a batch per batch basis

The performance of the internal standard working solution(s) will be monitored during the study.

## 6 RECOVERY AND MATRIX EFFECTS - VALIDATION ONLY

### 6.1 Preparation of recovery and matrix effect samples

For recovery assessment extract nine matrix blanks and post-spike three extracts at the LoQC, MeQC and HiQC concentrations as detailed in section 6.3. For matrix effect assessment extract six matrix blanks from different individuals and three water blanks and post-spike each to the LoQC concentration as detailed in section 6.3.

### 6.2 Preparation of pure standards using quality control working solutions

Pure standard	QC solution used and vol (μL)	ISTD used and vol (μL)	Reagent/solvent volume (mL)	Final volume (mL)	Final conc. Nicotine (ng/mL)	Final conc. Cotinine (ng/mL)
RecHi	F 181.8	B 72.6	9745.6	10	145.4	145.4
RecMe	G 181.8	B 72.6	9745.6	10	10.91	5.45
RecLo	H 181.8	B 72.6	9745.6	10	1.64	0.55

Pure standards prepared in 10mM ammonium acetate in polypropylene containers

### 6.3 Post spiking procedure for preparing reference standards

Refer to section 6.1 for details of recovery and matrix effect samples. Add 50 μL of the appropriate pure standard solution as described below into the 100 μL of acetonitrile in the well (post spike step takes place after step 12 in section 3).

For LoQC post-spiking use pure standard RecLo

For MeQC post-spiking use pure standard RecMe

For HiQC post-spiking use pure standard RecHi

## **7 ROOM TEMPERATURE AND REFRIGERATED/FROZEN STABILITY OF SOLUTIONS - FOR VALIDATION ONLY**

### **7.1 Preparation of samples to assess nicotine, cotinine, nicotine-d3 and cotinine-d3 room temperature stability**

Sub-aliquots of Nicotine QC A, Cotinine QC A\*, Nicotine-d3 IS A, Cotinine-d3 IS A\* solutions, plus working solutions CAL D, E, F and N will be transferred into appropriate sealed polypropylene vials. The sub-aliquots will be stored frozen prior to the determination of stability of the stock solutions at room temperature. Aliquots will be prepared as follows.

Record information on form 1953.

- Nicotine (B) - baseline frozen.
- Cotinine (B) - baseline frozen
- Nicotine-d3 (B) - baseline frozen.
- Cotinine-d3 (B) - baseline frozen
- CAL D (B)- baseline frozen.
- CAL E (B) - baseline frozen.
- CAL F (B) – baseline frozen
- CAL N (B) – baseline frozen
- Nicotine (S) - stored at room temperature.

**Analytical Procedure:** Covance HB-10-082-V3      **Analyte:** Nicotine and Cotinine in Human Plasma (EDTA)

- Cotinine (S) - stored at room temperature
- Nicotine-d3 (S) - stored at room temperature.
- Cotinine-d3 (S) - stored at room temperature
- CAL D (S) - stored at room temperature.
- CAL E (S) – stored at room temperature.
- CAL F (S) - stored at room temperature.
- CAL N (S) - stored at room temperature

## **7.2 Room temperature stability solutions**

To perform the room temperature stability, the “S” aliquots described in section 7.1 should be removed from storage and placed at room temperature for a minimum of six hours. After a minimum of six hours the aliquots of stock solutions will be assessed for stability in accordance with Section 7.3 or returned to storage.

Record information on form 1953.

### 7.3 Preparation of working solutions for stability assessment

Sample	TA solution & volume used ( $\mu\text{L}$ )	ISTD solution & volume used ( $\mu\text{L}$ )	Additional solvent used* ( $\mu\text{L}$ )
Solution W	Nicotine QC A (B) (50) & Cotinine QC A* (B) (50)	N/A	9900
Solution X	N/A	Nicotine-d3 IS A (B) (50) & Cotinine-d3 IS A* (B) (50)	9900
Solution Y	Nicotine QC A (S) (50) & Cotinine QC A* (S) (50)	N/A	9900
Solution Z	N/A	Nicotine-d3 IS A (S) (50) & Cotinine-d3 IS A* (S) (50)	9900
Baseline	Solution W (100)	Solution X (100)	9800
Nicotine and cotinine stability	Solution Y (100)	Solution X (100)	9800
Nicotine-d3 and cotinine-d3 stability	Solution W (100)	Solution Z (100)	9800
CAL D baseline (Nicotine only)	CAL D (B) (50)	Solution X (100)	9850
CAL D stability (Nicotine only)	CAL D (S) (50)	Solution X (100)	9850
CAL E baseline (Cotinine only)	CAL E (B) (50)	Solution X (100)	9850
CAL E stability (Cotinine only)	CAL E (S) (50)	Solution X (100)	9850
CAL F baseline (Nicotine and Cotinine)	CAL F (B) (50)	Solution X (100)	9850
CAL F stability (Nicotine and Cotinine)	CAL F (S) (50)	Solution X (100)	9850
CAL N baseline (Nicotine and Cotinine)	CAL N (B) (200)	Solution X (100)	9700
CAL N stability (Nicotine and Cotinine)	CAL N (S) (200)	Solution X (100)	9700

\* Mobile phase A.

Similar dilutions can be prepared for assessment of frozen longer term stock solution stability.

Inject 6 replicates of each solution on the LC-MS/MS.

## ATTACHMENT 1

### Changes from Version V1 to Version V2

#### Section A

- 1.1 - Method notes updated with stability and ISR information
- 5.4 – Storage temperature of samples amended

### Changes from Version V2 to Version V3


#### Section A

- 1.1 – Method notes updated with stability information
- 5.1 – Expiry date of A stock solutions updated to 55 days
- 5.3 & 5.4 – Expiry date of working standards updated to 55 days
- 5.3 & 5.4 – Storage temperature of working standards amended
- 5.4 – Expiry date of QC samples added (91 days)
- 5.4 – Removal of ‘#’
- Attachment 1 – Spelling corrected

The wording in some sections may have been changed to reflect current practices or due to process improvements, but these changes do not affect the way in which the method is executed.

## ATTACHMENT 2

### Flexus Method Bio 10



NAME	LAYOUT	SEQ	DILUENT	SOURCERACK	DESTRACK	SOURCE FIRSTPOS	SOURCE LASTPOS
Bio 10	dt_covance	100	SYSTEM			RA0	RA0
Bio 10	dt_covance	200	SYSTEM			RA0	RA0
Bio 10	dt_covance	300	SYSTEM	DWP2mlSQ_001		RA0	RA0
Bio 10	dt_covance	400	SYSTEM	MDWP1.2ml_001		RA0	RA0
Bio 10	dt_covance	500	SYSTEM	DWP2mlSQ_001	MDWP1.2ml_001	_FirPos	_LasPos
Bio 10	dt_covance	800	SYSTEM	MDWP1.2ml_001		RA0	RA0
Bio 10	dt_covance	900	SYSTEM	DWP2mlSQ_001		RA0	RA0
Bio 10	dt_covance	1000	SYSTEM			RA0	RA0

DEST FIRSTPOS	DEST LASTPOS	DEST VOL	DIL VOL	DIL DILRACK	DIL POS	LIQPARA	ACTION	REMARK
RA0	RA0						Init	
RA0	RA0						Flush	Cycles=2
RA0	RA0						MoveR	Carrier=MTPPIP3_001;Slot=1
RA0	RA0						MoveR	Carrier=MTPPIP3_001;Slot=2
_FirPos	_LasPos	_XVol1	0	SYSTEM		DTSamTransLLD		
RA0	RA0						MoveR	Carrier=Matrix_DWP_Stkx_001;Slot=4
RA0	RA0						MoveR	Carrier=DWP_Stack_3x_001;Slot=12
RA0	RA0						Init	

**ANALYTICAL PROCEDURE - SECTION B**

Covance HB-10-082-V3


Determination of Nicotine and Cotinine in Human Plasma


using Protein Precipitation and


Ultra High Performance Liquid Chromatography (UHPLC)

with Tandem Mass-Spectrometric Detection

**Original author** Jayne Spink  
**Title:** Method Development Specialist

**Version written/  
updated by**  **Date** 14 JULY 2011  
**Name:** Heather Wilshaw  
**Title:** Experimental Officer

**Reviewed by**  **Date** 14 July 11  
**Name:** Barry Hawthorne  
**Title:** Method Development Specialist

**Authorised by**  **Date** 18<sup>th</sup> July 2011  
**Name:** Sarah Fenton  
**Title:** Study Director

Analytical Procedure: Covance HB-10-082-V3     Analyte: Nicotine and Cotinine in Human Plasma (EDTA)

## 1     LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY (LC-MS/MS) *API 5000*

Final extract solutions are submitted for LC-MS/MS analysis under the following conditions.

### LC Conditions

Analytical column#	BioBasic SCX 50 x 3 mm, 5 µm Supplier: Thermo Part n/o 73205-053030		
Column oven temperature#	Nominal 35°C		
Auto-sampler temperature	Nominal 4°C		
Mobile phase A#	10 mM ammonium acetate: acetonitrile (50:50 v/v)		
Mobile phase B#	100 mM ammonium acetate: acetonitrile (20:80 v/v)		
Flow rate#	See table below		
Gradient settings:	See table below		
Time (minutes)	Flow rate (mL/min)	A (%)	B (%)
Initial	0.4	100	0
1.0	0.4	100	0
2.0	0.4	0	100
3.0	0.4	0	100
3.1	0.5	0	100
4.0	0.5	0	100
4.1	0.5	100	0
5.0	0.5	100	0
5.1	0.4	100	0
5.5	0.4	100	0
Switching Valve times	0.6 – 3.5 mins – To MS 3.5 – 5.5 mins – To waste		
Slave pump solvent	10 mM ammonium acetate: acetonitrile (50:50 v/v)		
Slave pump flow rate	0.4 mL/min		

Analytical Procedure: Covance HB-10-082-V3     Analyte: Nicotine and Cotinine in Human Plasma (EDTA)

Wash solvent 1#	10 mM ammonium acetate: acetonitrile (50:50 v/v)
Weak Wash (Acquity)	
Wash solvent 2#	Water: methanol: IPA: THF: ammonia
Strong Wash (Acquity)	(25:25:25:25:0.5 v/v/v/v/v)
Injection mode (Acquity)	Partial loop with needle over-fill
Injection loop volume (Acquity)	50 $\mu$ L
Needle placement	1.0 mm from bottom
Injection volume (Recommended)	20 $\mu$ L (this may vary depending on instrument performance)

# no alternative to be used

#### Waters Acquity

Weak Wash Volume ( $\mu$ L)	5000 (Range 4990 to 5010)
Strong Wash Volume ( $\mu$ L)	5000 (Range 4990 to 5010)

#### Mass Spectrometer Parameters API 5000

Mode of operation#	Turbo IonSpray (positive ion) (MS/MS)
Collision gas setting (CAD)	6 [Where a setting of 12 is approximately equal to $3.0 \times 10^{-5}$ Torr for a API 5000 instrument]
Curtain gas setting (CUR)	20 psi
Ion source gas 1 (GS1)	50 psi
Ion source gas 2 (GS2)	70 psi
Temperature (TEM)	550°C
Q1 Resolution	Unit
Q3 Resolution	Unit
Interface Heater Status	On
Analysis time	4 minutes

**Analytical Procedure:** Covance HB-10-082-V3    **Analyte:** Nicotine and Cotinine in Human Plasma (EDTA)

Compound name	Ions monitored ( $\pm 0.5$ Da)	Dwell time (ms)	Declustering Potential (DP) Volts	Collision Energy (CE) Volts	Collision Cell Exit Potential (CXP) Volts
Nicotine	163.3 $\rightarrow$ 130.1	75	60	29	15
Nicotine-d3	166.3 $\rightarrow$ 130.1	75	60	29	15
Cotinine	177.1 $\rightarrow$ 80.0	75	90	35	14
Cotinine-d3	180.1 $\rightarrow$ 80.0	75	90	35	14

Mass spectrometry parameters may change with instrument optimisation.

Entrance Potential (EP)	10 V
Pause time#	5 ms
Collision gas#	Nitrogen

# no alternative to be used

**Analytical Procedure:** Covance HB-10-082-V3      **Analyte:** Nicotine and Cotinine in Human Plasma (EDTA)

## 2      **STUDY SPECIFIC INSTRUMENTATION**

Unless specifically prohibited, equivalent instrumentation may be substituted, provided it meets the specifications stipulated in the appropriate catalogue or manufacturer's product information.

<b>Name</b>	<b>Specification (Model, Brand etc)</b>	<b>Supplier/Manufacturer</b>
Analytical pump	Acquity – UPB	Waters
Slave pump	LC-10ADV Series 200	Shimadzu Perkin Elmer
Auto-sampler	Acquity – UPS	Waters
Mass Spectrometer	API 5000	AB Sciex
Column oven	Acquity	Waters
Switching Valve	EMMA 10 port- 2 position	VICI
System Controller	SCL-10AVP	Shimadzu

### 3      STANDARDS FOR THE ASSESSMENT OF SYSTEM SUITABILITY

It is vital that some assessment of system suitability is made before running a sample batch.

Injections will be performed to assess as a minimum chromatography and detector response. These will include an extracted high calibration standard (Hi Ref, ULOQ), an extracted low calibration standard (Lo Ref, LLOQ) and a blank sample injected after the Hi Ref to assess carry-over.

**Please note: it may not be possible to eliminate all sources of contamination of Nicotine and Cotinine therefore peaks may be observed in blank samples.**

**System suitability will be assessed on Hi ref and Lo ref samples only.**

Extract viability refrigerated:	3 days
Number of smooths	5

#### **Signal-to-noise ratio (SNR):**

For system suitability purposes the SNR at the LLOQ (lower limit of quantification) should ideally be at least 5:1 as calculated using smoothed data as appropriate. This may be calculated manually by measurement on a chromatogram or conducted electronically using a validated script. A visual comparison should be made to the specimen chromatograms included in Section 4.

If the SNR does not meet the criterion of at least 5:1 then remedial actions could be performed prior to re-assessing the SNR at the LLOQ prior to injection. Under some circumstances the batch may still be injected and a comment made on the batch sheet documenting this (for example, for fast turnaround studies or for where injecting the batch might still generate useful data for trouble shooting purposes).

**Analytical Procedure:** Covance HB-10-082-V3      **Analyte:** Nicotine and Cotinine in Human Plasma (EDTA)

The SNR calculated for system suitability purposes will not be recorded in the raw data, however a statement as to the system suitability will be made on the Analyst Batch Front Sheet (Form 3706).

**Peak retention times:**

Peak retention times Nicotine, Cotinine, Nicotine-d3 and Cotinine-d3 should be within  $\pm 10\%$  (to be assessed after validation) of the peak retention time of the retention times stated in the analytical procedure. Should this criterion not be met then remedial actions might be performed. Under some circumstances the batch might still be injected and a comment made on the batch sheet documenting this (for example: for fast turnaround studies; for where injecting the batch might still generate useful data for trouble shooting; where a new lot number of packing material may have been used during manufacture of a replacement column; or for where a different instrument has been used).

#### **4 SPECIMEN CHROMATOGRAPHY**

A chromatogram obtained from the injection of a prepared control matrix sample for Nicotine is found in Attachment 1. A chromatogram obtained from the injection of a prepared control matrix sample for Cotinine is found in Attachment 2.

A specimen chromatogram showing the Nicotine peak at low concentration and the Nicotine-d3 peak (retention times approximately 2.1 and 2.2 minutes, respectively; data collection time 4.0 minutes; total run time 5.5 minutes) is included as Attachment 3. A specimen chromatogram showing the Cotinine peak at low concentration and the Cotinine-d3 peak (retention times approximately 0.8 and 0.8 minutes, respectively; is included as Attachment 4

A specimen chromatogram showing the Nicotine peak at high concentration and the nicotine-d3 peak is found in Attachment 5. A specimen chromatogram showing the Cotinine peak at high concentration and the cotinine-d3 peak is found in Attachment 6.


**Analytical Procedure:** Covance HB-10-082-V3    **Analyte:** Nicotine and Cotinine in Human Plasma (EDTA)

A specimen calibration curve for Nicotine is found in Attachment 7. A specimen calibration curve for Cotinine is found in Attachment 8.

Analytical Procedure: Covance HB-10-082-V3

Analyte: Nicotine and Cotinine in Human Plasma (EDTA)

### ATTACHMENT 1 Specimen Chromatogram – Control Matrix (Nicotine)




Analytical Procedure: Covance HB-10-082-V3

Analyte: Nicotine and Cotinine in Human Plasma (EDTA)


### ATTACHMENT 2

### Specimen Chromatogram – Control Matrix (Cotinine)

120 - Cotinine (Blank) 117.39038.000 Da - sample 7 of 98 from 0235597\_VAL01.wiff  
Area: 553.1 counts Height: 207.3 cps RT: 0.92 min




120 - Cotinine-d3(5) (Blank) 180.30060.000 Da - sample 7 of 99 from 0235597\_VAL01.wiff  
Area: 1110.4 counts Height: 304.9 cps RT: 0.84 min



Analytical Procedure: Covance HB-10-082-V3

Analyte: Nicotine and Cotinine in Human Plasma (EDTA)


**ATTACHMENT 3**  
**Specimen Chromatogram - Spiked Control Matrix,**  
**low Nicotine concentration (1.5 ng/mL)**



Analytical Procedure: Covance HB-10-082-V3

Analyte: Nicotine and Cotinine in Human Plasma (EDTA)


**ATTACHMENT 4**  
**Specimen Chromatogram - Spiked Control Matrix,**  
**low Cotinine concentration (0.5 ng/mL)**



Analytical Procedure: Covance HB-10-082-V3

Analyte: Nicotine and Cotinine in Human Plasma (EDTA)

**ATTACHMENT 5**  
**Specimen Chromatogram - Spiked Control Matrix,**  
**high Nicotine concentration (500 ng/mL)**




Analytical Procedure: Covance HB-10-082-V3


Analyte: Nicotine and Cotinine in Human Plasma (EDTA)

### ATTACHMENT 6


#### Specimen Chromatogram - Spiked Control Matrix, high Cotinine concentration (500 ng/mL)



### ATTACHMENT 7 Specimen Calibration Curve for Nicotine



### ATTACHMENT 8 Specimen Calibration Curve for Cotinine



# Definitive Protocol

Study Title	Determination of Cotinine in Human Plasma Samples from a Multicenter, Randomised, Double-Blind Controlled Trial of the Ability of a Traditional Swedish Smokeless Tobacco Product (“Snus”) to Increase the Quit Rate Among Cigarette Smokers Who Wish to Stop Smoking (Sponsor Reference number SM 08-01) using Ultra High Performance Liquid Chromatography with Tandem Mass Spectrometric Detection (LC-MS/MS)
Study Director	S Fenton
Sponsor	Swedish Match AB Rosenlundsgatan 36 SE-118 85 Stockholm SWEDEN
Analytical Study Monitor	Lars-Erik Rutqvist
Test Facility	Covance Laboratories Limited Otley Road, Harrogate North Yorkshire, HG3 1PY ENGLAND
Covance Study Number	8233095
Covance Client Identifier	1000025
Sponsor Reference Number	SM 08-01
Page Number	1 of 17

## CONTENTS

CONTENTS .....	2
1 INTRODUCTION.....	3
2 CONTACT DETAILS .....	3
3 EXPERIMENTAL .....	4
3.1 Reference Standards, Internal Standard and Matrix.....	4
4 STUDY SAMPLE ANALYSIS .....	4
4.1 Study Samples.....	4
4.2 Sample Analysis .....	5
4.3 Calculations .....	5
4.4 Computer Systems .....	5
4.5 Calibration Standards.....	5
4.6 Quality Control Samples.....	6
4.7 Sample Acceptance Criteria.....	7
4.8 Blank Assessment .....	7
4.9 Carryover Assessment .....	7
4.10 Injection Order .....	8
4.11 System Suitability .....	8
4.12 Incurred Sample Reproducibility .....	8
5 CRITERIA FOR REPEAT ANALYSIS .....	9
5.1 Analytical.....	9
5.2 Sponsor Request .....	10
6 DATA PRESENTATION AND DATA REPORTING .....	10
7 REPORT .....	10
8 RECORDS TO BE MAINTAINED.....	11
9 REGULATORY COMPLIANCE.....	11
9.1 Protocol Adherence.....	11
9.2 Protocol Amendments.....	11
9.3 Quality Assurance Evaluation.....	12
9.4 Inspection by Regulatory Authorities .....	12
10 REFERENCES .....	12
11 ARCHIVE STATEMENT .....	13
11.1 Proposed Timelines.....	13
11.2 Study Specific Requirements.....	13
12 DISTRIBUTION .....	14
13 APPENDIX 1.....	15
14 APPENDIX 2.....	16
15 APPROVAL .....	17

## 1 INTRODUCTION

The objective of this study is to determine the concentrations of cotinine in human plasma containing K<sub>3</sub>EDTA as an anticoagulant using solid phase extraction for sample preparation and liquid chromatography with tandem mass spectrometric detection (LC-MS/MS).

The method has been validated at Covance Laboratories Limited (Covance Study number 8202356 [1]) for the determination of nicotine and cotinine in human plasma and has a lower limit of quantification (LLOQ) of 1.5 ng/mL for nicotine and 0.5 ng/mL for cotinine using 100 µL of plasma. The method has been initially validated in human plasma containing lithium heparin as an anticoagulant however since the samples have already been taken into tubes containing K<sub>3</sub>EDTA, further validation work was performed to validate for the determination of nicotine and cotinine in human plasma using K<sub>3</sub>EDTA as an anticoagulant (Covance Study number 8235697).

The analytical procedure to be used for this study will be the current version of Covance HB-10-082.

The analytical procedure HB-10-082 has been validated for the determination of nicotine and cotinine. However, only concentrations of cotinine will be determined throughout this study.

This analytical investigation will be conducted in the Department of Bioanalytical Services, Covance Laboratories Limited, Otley Road, Harrogate, North Yorkshire, England, United Kingdom.

## 2 CONTACT DETAILS

Study Director

S Fenton  
Bioanalytical Services  
Covance Laboratories Ltd  
Otley Road, Harrogate HG3 1PY  
United Kingdom  
Phone: +44-1423-848195  
Fax: +44-1423-569595  
Email: sarah.fenton@covance.com

Analytical Study Monitor

Lars Erik Rutqvist  
Swedish Match AB  
Rosenlundsgatan 36  
SE-118 85 Stockholm  
SWEDEN  
Phone: +46-8-6580243  
Fax: +46-8-6583522  
Email: lars-erik.rutqvist@swedishmatch.com

### 3 EXPERIMENTAL

For the duration of the study, all components constituting the test system will be identified and appropriately labelled.

#### 3.1 Reference Standards, Internal Standard and Matrix

Analytical grade nicotine (supplied as (-)-nicotine hydrogen tartrate salt) and cotinine (supplied as (-)-cotinine) will be supplied by Sigma-Aldrich Company Limited. Certificates of Analysis will be provided. The chemical purity and batch number for each compound will be reported.

Analytical grade nicotine-d<sub>3</sub> (supplied as (±)-nicotine-d<sub>3</sub> salicylate salt), the internal standard (ISTD) for nicotine, and cotinine-d<sub>3</sub> (supplied as (±)-cotinine methyl-d<sub>3</sub>), the ISTD for cotinine, will be supplied by Sigma-Aldrich Company Limited. Certificates of Analysis will be provided. The chemical purity and batch number will be reported, if available.

Sigma-Aldrich Company Limited do not specify expiry dates.

All precautions required in the handling, storage and disposal of the reference standards will be evaluated based on data supplied.

The source, lot number and storage conditions of the blank human plasma (K<sub>3</sub>EDTA) will be documented in the raw data.

### 4 STUDY SAMPLE ANALYSIS

#### 4.1 Study Samples

The samples were generated from multiple sites (estimated six sites) in the United States and will be transferred to Covance, Harrogate, UK via Covance Central Laboratory Services, Indianapolis, USA (Sponsor Study number SM 08-01).

Sample identification will be recorded and reported using the information provided on the sample tube label, unless confirmed otherwise by the Sponsor.

The study design according to the clinical protocol is a multi-centre, randomised, double-blind, placebo-controlled, Phase III trial of approximately 250 subjects receiving either snus (a low nitrosamine smokeless tobacco product) or placebo in a 1:1 ratio for 16 weeks. Plasma samples for analysis will be taken from subjects at pre-screening and at weeks 6, 16 and 28. Each subject will generate four samples for analysis

The primary (set 1) study samples will be transported to Covance Laboratories Ltd, Harrogate, from Covance Central Laboratory Services, Indianapolis, USA where the samples will be stored at nominal -80°C prior to analysis. The back-up (set 2) study samples will be retained at Covance Central Laboratory Services (the back-up (set 2)) samples may be requested for analysis if there is limited primary (set 1) sample volume.

The total number of plasma samples expected to be received will be approximately 818. The exact number of samples will be documented in the report.

#### **4.2 Sample Analysis**

All samples from each occasion for each of the subjects will initially be analysed in the same batch. If the information provided with samples is insufficient for clear identification/analysis purposes a discrepancy will be raised with the Sponsor. The analysis of such samples may be delayed until the issue is resolved.

Samples from subjects receiving placebo will not be analysed. The subjects receiving placebo will be identified by the Sponsor.

The total number of plasma samples to be analysed will be approximately 818. The exact number of samples analysed will be documented in the report.

Study samples will be divided into analytical batches consisting of a maximum of approximately 96 plasma samples including the calibration standards and QC samples.

Single analysis will initially be performed on each sample. The result obtained will be the reported value for pharmacokinetic purposes.

#### **4.3 Calculations**

The concentration of cotinine in study samples, calibration standards and QC samples will be determined using a calibration function used in the validation based upon peak area ratios of cotinine to internal standard.

#### **4.4 Computer Systems**

The following computer systems may be used during the conduct of this study. The version number of the systems will be held on file at Covance.

---

System	Use
Nautilus	Laboratory Information Management System (LIMS)
Report Submitter	Data table generation
Analyst	Data collection and processing for all Sciex MS/MS instruments

---

#### **4.5 Calibration Standards**

The calibration standards will be prepared as per the analytical procedure, and will also contain nicotine at the same concentration levels detailed in the analytical procedure.

The calibration standard acceptance criteria will be applied to cotinine only.

Single calibration standards will be spiked in plasma on the day of extraction. In order to maintain the integrity of calibration standards, volumes of standard solutions used for their preparation will not exceed 5% of the final plasma volume.

The calibration standard concentrations will be as follows for cotinine:

0.5, 1, 2.5, 5, 10, 50, 200, 450 and 500 ng/mL

All calibration standards utilised within the regression must have back-calculated values that are within 85-115% (80-120% for the LLOQ) of the theoretical concentration.

No more than 25% of the calibration standard levels may be excluded from the calibration curve and at least seven calibration standard levels must remain in a calibration curve for it to be acceptable.

Calibration standards at the lower or upper limit of quantification may be excluded and a revised calibration range used providing the QC samples are all within the revised calibration range. The reason for exclusion of any calibration standard or changes to the calibration range will be documented in the raw data.

#### **4.6 Quality Control Samples**

The QC samples will be prepared as per the analytical procedure, and will also contain nicotine at the same concentration levels detailed in the analytical procedure.

The QC acceptance criteria will be applied to cotinine only.

The QC samples will be prepared in bulk divided into aliquots and frozen at nominal -80°C prior to analysis. The QC samples will be analysed at the following nominal concentrations for cotinine:

1.5 ng/mL (LoQC), 15 ng/mL (MeQC) (Approximate geometric mean), 400 ng/mL (HiQC) 2500 ng/mL (DiQC)

The DiQC samples will be included in all batches where study samples are diluted. The DiQC sample will be diluted to the highest used dilution factor. The numbers of replicates of the DiQC samples in each batch must be the same as the other QC samples as specified below.

Duplicate QC samples at each of three concentrations (LoQC, MeQC and HiQC) will be analysed. At least four of the six QC samples (LoQC, MeQC and HiQC) must be within  $\pm 15\%$  of their respective nominal values; with a minimum of one QC sample within limit at each concentration.

During sample analysis the validity of stored and injected or re-injected batches is confirmed by the acceptance of the calibration standards and QC samples contained in the batch.

#### **4.7 Sample Acceptance Criteria**

The observed concentration of the diluted QC (DiQC) samples should be within  $\pm 15\%$  of the respective nominal value.

If this criterion is not met for at least one of the diluted QC samples then all samples which have undergone dilution in that batch should be reanalysed.

No extrapolation above the upper limit of quantification (ULOQ) or below the LLOQ is permitted without written authorisation of the Sponsor. If a sample is found to have an observed concentration greater than the ULOQ it should be reanalysed after dilution with blank matrix. Also, if a sample which has undergone dilution has an observed concentration below the LLOQ, it should be reanalysed without dilution where sample volume permits.

#### **4.8 Blank Assessment**

One matrix blank, one matrix blank containing internal standard and one reagent blank will be analysed with each batch of samples.

The blanks detailed above should all demonstrate a lack of significant interference in the chromatographic regions of interest for the analytes, peak area/area ratio, as appropriate,  $\leq 20\%$  of the mean utilised LLOQ calibration standard peak area/area ratio. If this condition is not met for the lowest calibration standard then the next lowest standard, for which this condition applies, should become the LLOQ.

Additionally, extracts of blank matrix should also demonstrate a lack of significant interference in the chromatographic regions of interest for the internal standards, peak area  $\leq 5\%$  of the internal standard peak area for the matrix blank with internal standard.

Raising the batch LLOQ does not invalidate the analytical batch providing that all QC samples are within the acceptable calibration curve range.

#### **4.9 Carryover Assessment**

One matrix blank will be analysed after the two highest calibration standards in each batch of samples. One near the beginning and one near the end of the batch.

The blanks detailed above should all demonstrate a lack of significant interference in the chromatographic regions of interest for the analytes, peak area/area ratio, as appropriate,  $\leq 20\%$  of the mean utilised LLOQ calibration standard peak area/area ratio. If this condition is not met for the lowest calibration standard then the next lowest standard, for which this condition applies, should become the LLOQ.

Additionally, extracts of blank matrix should also demonstrate a lack of significant interference in the chromatographic regions of interest for the internal standards, peak area  $\leq 10\%$  of the internal standard peak area for the matrix blank with internal standard.

Raising the batch LLOQ does not invalidate the analytical batch providing that all QC samples are within the acceptable calibration curve range.

#### **4.10 Injection Order**

Calibration standards and QC samples will be chromatographed with study samples interspersed between them.

#### **4.11 System Suitability**

Prior to the injection of the study batches one or more samples must be evaluated to ensure that the retention times have not significantly changed and that the sensitivity is adequate to quantify the LLOQ. When batches using the same chromatographic conditions are injected consecutively, system suitability will be evaluated on the first injected batch only.

#### **4.12 Incurred Sample Reproducibility**

Following initial analysis, samples will be subjected to repeat analysis as detailed below. The samples selected will be documented in the raw data prior to repeat analysis.

A minimum of 24 samples will be selected from 12 dosed subjects and analysed (singularly). From each subject two samples will be selected from samples taken at Week 6 and Week 16.

The following acceptance criteria will be applied:

The difference between the original and the repeat result should be within  $\pm 20\%$  for two thirds (rounded up) of the samples selected and analysed for ISR assessment.

$$\frac{B - A}{A + B} \times 200 = \text{relative percentage difference* between the two values}$$

Where A is the original and B is the repeat result

\*The  $\pm$  bias is included in the presentation to show any trend of the data.

In addition if the difference between the original and repeat value is  $\geq 50\%$  the data from this sample should be assessed and discussed in the analytical report.

If the above criteria are not met and cannot be explained by performance of the analytical method then the reason for the lack of reproducibility (e.g., analyte instability or inter-conversion) should be investigated, the study placed on hold and its impact on the study assessed. If these criteria are not met, the data will be discussed with the Sponsor this may necessitate the need to establish experiments to determine possible causes. Any additional work will be documented by protocol amendment.

The repeat results will not be used for pharmacokinetic purposes. The second analysis (single analysis) will be used for comparison purposes only. These data will be reported in a separate data table, including the original result and the percentage difference value for “incurred sample reproducibility” in the final report.

## 5 CRITERIA FOR REPEAT ANALYSIS

Repeat analysis may be carried out for analytical reasons or at the request of the Sponsor.

A complete repeat analysis summary will be included in the study report as an appendix.

### 5.1 Analytical

Examples of analytical reasons for reanalysing samples are as follows:

- Instrument malfunction
- Poor chromatography, e.g. poor peak shape, incorrect retention time
- Mis-injection, e.g. low injection volume, needle jam etc.
- Concentration above calibration range or below calibration range (when LLOQ raised or sample diluted)
- Batch rejected due to not meeting the acceptance criteria

Samples selected for analytical reasons will initially be reanalysed once only and the original value ignored although this value should be annotated to indicate the reason why the sample was reanalysed. The new value, if acceptable, would be reported in the final table

- Internal standard peak area less than 10%, (50% for samples which have a concentration below the LLOQ), or greater than 150% of the mean internal standard peak area for the acceptable batch calibration standards and QC samples Refer to the decision tree in [Appendix 1](#) to determine if a sample should be repeated.

Samples selected for low or high internal standard response will initially be reanalysed once only for confirmation purposes.

- If the original result is confirmed (i.e. both results are within  $\leq 30.0\%$  of each other), the original value will be reported (with appropriate annotation if required)
- If the two results are not within  $\leq 30.0\%$  of each other and the repeat result is analytically valid (for example not LI or HI) the repeat result will be reported

If the above criteria do not apply then scientific judgment will be applied in the following order:

- repeat in singlet to confirm data, use the three data values and the decision tree in [Appendix 2](#) to determine the reported result

- report data with the appropriate annotation - for example - LI/HI (as appropriate) with a table footer - confirmed by repeat analysis
- report no result - for example annotate - NR with a table footer Abnormal internal standard response

The reason for the scientific judgment applied must be documented in the raw data and report in all cases.

## **5.2 Sponsor Request**

Samples reanalysed at the request of the Sponsor should, where possible, be reanalysed in duplicate. The selection criteria and reason for repeat analysis should be provided.

## **6 DATA PRESENTATION AND DATA REPORTING**

The reporting (including to whom, how and timeframes) of expedited and clinically significant results and serious breaches is documented in the study records on Form number 4862.

Descriptive statistics (means, standard deviations and RSD%) will be calculated for the back-calculated concentrations of the calibration standards and QC samples. Regression parameters for each calibration curve will also be reported.

Concentration data will be reported to three significant figures  
Only the following information will be included in the data tables

- Subject number
- Visit
- Concentration
- Units
- Gender
- Batch name
- Analysis date

## **7 REPORT**

The report for the analysis of cotinine in human plasma will contain a summary of the methodology and results. Prior to issuing a final report, Covance will prepare one draft version of the report for review and comment by the Study Sponsor. The report will include, but will not necessarily be limited to the following:

- Any deviations from the protocol
- The location of storage of all raw data and the final report
- The dates on which the study was initiated and completed
- A summary and representative chromatograms
- A description and origin of samples
- Study sample data
- Calibration standard and quality control sample data

- Batch analysis summary
- Incurred sample reproducibility data

Sponsor comments should be supplied for inclusion into a final document within six months of receipt of the draft document. In order to facilitate prompt finalisation of study reports, if no Sponsor comments are received within six months of issue, the report will be finalised. Any changes then required will necessitate formal report amendment and may incur additional charges.

## **8 RECORDS TO BE MAINTAINED**

Study records maintained will include, but will not necessarily be limited to, the Protocol (and any amendments); eNotes; study-related correspondence; all laboratory raw data generated.

## **9 REGULATORY COMPLIANCE**

### **9.1 Protocol Adherence**

Covance undertakes to adopt all reasonable measures to record data in accordance with the protocol. Under practical working conditions, however, some minor variations may occur due to circumstances beyond the control of Covance. All such variations will be documented in the study records, together with the reason for their occurrence, and, where appropriate, detailed in the final report. If planned alterations in protocol requirements occur, a protocol amendment will be issued for authorisation by the study Sponsor.

This study is not required to be subject to Good Laboratory Practice Regulation and, consequently, a claim of GLP compliance will not be made. However, the laboratory procedures will satisfy the current requirements of the UK and OECD GLP regulations.

The study will be conducted in accordance with the following regulations and standards:

- UK Statutory Instrument 2004 No. 1031 the Medicines for Human Clinical Use (Clinical Trials) Regulations 2004 plus subsequent amendments
- Good Clinical Practice: Consolidated Guideline ICH Topic E6, adopted by CPMP, July 1996, issued as CPMP/ICH/135/95

All laboratory procedures will also be performed in accordance with Covance Standard Operating Procedures (SOPs).

### **9.2 Protocol Amendments**

Amendments to the authorised protocol whether instigated by Covance or by the Sponsor will be documented by completion of a protocol amendment issued by Covance and authorised by both the Study Director and the Sponsor. No alteration will be made to this protocol without the written permission of the Sponsor.

### **9.3 Quality Assurance Evaluation**

The study described in this protocol will be subject to Quality Assurance evaluation. The form of inspection is described in the QA Standard Operating Procedures, this will include a protocol, data and report audit.

### **9.4 Inspection by Regulatory Authorities**

In the event of any inspection of Covance by an outside authority during the course of the study, the Sponsor will be informed where the inspectors request access to any of the study records.

## **10 REFERENCES**

[1] B V Bailey, Validation of an Analytical Procedure for the Determination of Nicotine and Cotinine in Human Plasma using Solid Phase Extraction and Liquid Chromatography with Tandem Mass Spectrometric Detection (LC-MS/MS) (Covance Study number 8202356)

[2] S Fenton, Validation of an Analytical Procedure for the Determination of Nicotine and Cotinine in Human Plasma (EDTA) using Solid Phase Extraction and Liquid Chromatography with Tandem Mass Spectrometric Detection (LC-MS/MS) (Covance Study Number 8235697)

## 11 ARCHIVE STATEMENT

All primary data (including electronic data), or authenticated copies thereof, protocol and the final report will be retained using appropriate storage media in the Covance Laboratories Limited archives for one year after issue of the final report. At this time the Sponsor will be contacted to determine whether the data should be returned, retained or destroyed on their behalf. Sponsors will be notified of the financial implications of each of these options at that time.

Specimens or samples requiring frozen storage at Covance are specifically excluded from the above. These will be retained for as long as the material permits further evaluation or up to a maximum of three months after issue of the draft report. At this time, the Sponsor will be contacted to determine whether samples should be returned, retained or destroyed on their behalf. Any financial implications of these options will also be notified at this time. Samples will not be destroyed without prior approval of the Study Director.

### 11.1 Proposed Timelines

Experimental start: March 2011

Experimental end: April 2011

Draft report: To be confirmed<sup>#</sup>

<sup>#</sup> The draft report date will depend on the overall duration of the study sample analysis, but this will normally be within four-six weeks of the end of the experimental phase.

### 11.2 Study Specific Requirements

Any deviations or changes to the above will be documented in the raw data and detailed in the report. Planned changes will be detailed in a protocol amendment. The impact of all such occurrences on sample analysis will be evaluated by the Study Director.

## 12 DISTRIBUTION


STUDY MANAGEMENT	NAME
Study Director <sup>1</sup>	S Fenton
Study Co-ordinator <sup>2</sup>	H Woodhouse
OPERATIONAL SUPERVISION	
Laboratory Supervisor <sup>2</sup>	A Ibnouzaki
QUALITY ASSURANCE	
GLP/GCP Operations Manager <sup>2</sup>	L Gillbanks
Resource Management	N/A
Resource Estimation	N/A
Sample Management	AH2

<sup>1</sup> = Any change documented by an Amendment to Protocol

<sup>2</sup> = Any change documented in study records

### 13 APPENDIX 1

Decision tree for stable labelled internal standard (IS), high and low IS repeat analysis selection




14 APPENDIX 2

**Reported Value Decision Tree**

The full scheme applies where initial result warrants repeat assay in duplicate.


A – original result, B – repeat result, z – difference between the two values, Mean – Mean of A and B




## 15 APPROVAL

The Analytical Study Monitor signature below confirms acceptance of this protocol.  
In addition the signature confirms


- A signed Clinical Protocol, approved by the appropriate regulatory and ethical bodies will be in place prior to conducting the analyses specified in this protocol
- Informed consent from all subjects will be in place prior to conducting the analyses specified in this protocol
- Covance will be notified promptly if a subject withdraws their consent to continuing with the clinical trial
- Information in this protocol is accurate and consistent with the clinical trial protocol
- The client and Covance are entering into a formal commitment for Covance to undertake the services detailed in this protocol

  
\_\_\_\_\_  
Lars-Erik Rutqvist MD PhD  
Analytical Study Monitor  
Swedish Match AB

2011-07-14  
Date

  
\_\_\_\_\_  
S Fenton PhD  
Study Director  
Covance Laboratories Limited

9m March 2011  
Date

  
\_\_\_\_\_  
D Bakes BSc  
Associate Director, Bioanalytical Services  
Covance Laboratories Limited

9 March 2011  
Date